UNITED STATES DEPARTMENT OF AGRICULTURE 

ANIMAL AND PLANT HEALTH INSPECTION SERVICE 

 WILDLIFE SERVICES 

ENVIRONMENTAL ASSESSMENT 

FIELD TRIAL OF AN EXPERIMENTAL RABIES VACCINE, 

HUMAN ADENOVIRUS TYPE 5 VECTOR 

IN NEW HAMPSHIRE, NEW YORK, OHIO, VERMONT, AND WEST VIRGINIA

In cooperation with: 

United States Department of Agriculture 

Forest Service 

May 2012 

Prepared by: 

United States Department of Agriculture 

Animal and Plant Health Inspection Service 

Wildlife Services 

4700 River Road, Unit 87 

Riverdale, MD 20737-1234
i

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

TABLE OF CONTENTS 

CHAPTER 1: PURPOSE AND NEED FOR ACTION ........................................................................... 1 

1.1 INTRODUCTION AND BACKGROUND ............................................................................................ 1 

 1.1.1 Public Health Importance of Rabies ....................................................................................... 2 

 1.1.2 Primary Need for Action ......................................................................................................... 2 

 1.1.3 Development of Oral Rabies Vaccine Programs .................................................................... 3 

1.2 PURPOSE OF THE PROPOSED ACTION ........................................................................................... 7 

1.3 NEED FOR ACTION ............................................................................................................................. 8 

1.4 DESCRIPTION OF THE PROPOSED ACTION ................................................................................ 10 

1.5 SCOPE OF THIS ENVIRONMENTAL ASSESSMENT ANALYSIS ............................................... 13 

 1.5.1 Actions Analyzed .................................................................................................................. 13 

 1.5.2 Period for which this EA is Valid ......................................................................................... 13 

 1.5.3 Site Specificity ...................................................................................................................... 13 

 1.5.4 Coordination ......................................................................................................................... 13 

1.6 SUMMARY OF PUBLIC INVOLVEMENT ....................................................................................... 14 

1.7 DECISIONS TO BE MADE................................................................................................................. 14 

1.8 RELATIONSHIP OF THIS EA TO OTHER ENVIRONMENTAL DOCUMENTS .......................... 15 

1.9 AUTHORITIES .................................................................................................................................... 17 

 1.9.1 Federal Authorities ................................................................................................................ 17 

 1.9.2 State and Local Authorities ................................................................................................... 18 

1.10 OTHER RELEVANT LAWS AND REGULATIONS ...................................................................... 19 

CHAPTER 2: ISSUES AND AFFECTED ENVIRONMENT .............................................................. 22 

2.1 ISSUES ................................................................................................................................................. 22 

2.2 OTHER ISSUES CONSIDERED BUT NOT ANALYZED IN DETAIL, WITH RATIONALE ....... 22 

 2.2.1 Potential for Drugs Used in Animal Capture and Handling to Cause Adverse 

 Health Effects in Humans that Hunt and Eat the Species Involved ............................................... 22 

 2.2.2 Potential for Drugs Used in Animal Capture and Handling to Cause Adverse 

 Health Effects in Scavengers or Other Nontarget Animals that may Consume the 

 Species Involved ............................................................................................................................ 23 

 2.2.3 Potential for Adverse Impacts on Wildlife from Aircraft Overflights Conducted 

 in ORV Programs ........................................................................................................................... 24 

 2.2.4 Potential for ORV Bait Distribution to Affect Organic Farming .......................................... 26 

 2.2.5 Potential for ORV to Cause Abortions in Cattle ................................................................... 26 

 2.2.6 Potential Human Health Impacts in the Event of Human Consumption of 

 Vaccinated Wildlife ....................................................................................................................... 27 

 2.2.7 Potential Impacts on Water Resources, including Aquaculture, Fish, Reptiles, 

 and Amphibians ............................................................................................................................. 27 

 2.2.8 Effects on Carnivore Populations in the Absence of Rabies ................................................. 29 

 2.2.9 Effects of Nontarget Species Consumption of ORV Baits on Program 

 Effectiveness .................................................................................................................................. 30 

 2.2.10 Effects of Global Warming, Habitat Loss, and Pollution on Wildlife 

 Populations ..................................................................................................................................... 30 

2.3 AFFECTED ENVIRONMENT ............................................................................................................ 30 

CHAPTER 3: ALTERNATIVES ............................................................................................................ 32 

3.1 ALTERNATIVES CONSIDERED, INCLUDING THE PROPOSED ACTION ................................ 32 

3.2 ALTERNATIVES CONSIDERED BUT NOT ANALYZED IN DETAIL, WITH RATIONALE ..... 32 

 3.2.1 Depopulation of Target Species ............................................................................................ 32 
ii

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

 3.2.2 Population Control through Birth Control ............................................................................ 34

 3.2.3 Employ Other Types of ORV Instead of the ONRAB® Vaccine ......................................... 35 

3.3 SOPs TO MINIMIZE POTENTIAL IMPACTS OF THE RABIES ORV FIELD TRIAL .................. 36 

 3.3.1 Monitoring ............................................................................................................................ 38 

CHAPTER 4: ENVIRONMENTAL CONSEQUENCES ..................................................................... 39 

4.1 ENVIRONMENTAL CONSEQUENCES FOR ISSUES ANALYZED IN DETAIL ......................... 39 

 4.1.1 Potential for Adverse Effects on Target Wildlife ................................................................. 39 

 4.1.1.1 Alternative 1: Current Action (the no action alternative) ..................................... 39 

 4.1.1.2 Alternative 2: Proposed Action (the preferred alternative) ................................... 43 

 4.1.1.3 Alternative 3: No ORV Field Trials ...................................................................... 45 

 4.1.2 Potential for Adverse Effects on Nontarget Wildlife Species, Including 

 Threatened or Endangered Species ................................................................................................ 46 

 4.1.2.1 Alternative 1: Current Action (the no action alternative) ..................................... 46 

 4.1.2.2 Alternative 2: Proposed Action (the preferred alternative) ................................... 52 

 4.1.2.3 Alternative 3: No ORV Field Trials ...................................................................... 57 

 4.1.3 Potential for Adverse Effects on People, Pets, and Livestock that are Exposed to 

 Or Consume the Vaccine Laden Baits ........................................................................................... 57 

 4.1.3.1 Alternative 1: Current Action (the no action alternative) ..................................... 57 

 4.1.3.2 Alternative 2: Proposed Action (the preferred alternative) ................................... 61 

 4.1.3.3 Alternative 3: No ORV Field Trials ...................................................................... 64 

 4.1.4 Potential for the Recombined ONRAB® Virus to “Revert to Virulence” or 

 Recombine with other Viruses and Result in a Virus that Could Cause Disease in Humans 

 or Animals ...................................................................................................................................... 64 

 4.1.4.1 Alternative 1: Current Action (the no action alternative) ..................................... 64 

 4.1.4.2 Alternative 2: Proposed Action (the preferred alternative) ................................... 67 

 4.1.4.3 Alternative 3: No ORV Field Trials ...................................................................... 67 

 4.1.5 Potential for Aerially Dropped Baits to Strike and Injure People, Pets, or Domestic 

 Animals .......................................................................................................................................... 67 

 4.1.5.1 Alternative 1: Current Action (the no action alternative) ..................................... 67 

 4.1.5.2 Alternative 2: Proposed Action (the preferred alternative) ................................... 68 

 4.1.5.3 Alternative 3: No ORV Field Trials ...................................................................... 68 

 4.1.6 Humaneness of Methods Used to Collect Wild Animal Specimens Critical for 

 Timely Program Evaluation ........................................................................................................... 68 

 4.1.6.1 Alternative 1: Current Action (the no action alternative) ..................................... 68 

 4.1.6.2 Alternative 2: Proposed Action (the preferred alternative) ................................... 69 

 4.1.6.3 Alternative 3: No ORV Field Trials ...................................................................... 69 

4.2 CUMULATIVE IMPACTS .................................................................................................................. 69 

4.3 SUMMARY OF IMPACTS OF ALTERNATIVES FOR EACH ISSUE ............................................ 70 

Tables 

Table 2-1 Some Descriptive Statistics of States Proposed for ONRAB® Field Trials ..................... 31 

Table 4-1 Previous Human/V-RG Bait Exposures in the Expanded Field Trial States .................... 61 

Table 4-2 Issues/Impacts/Alternatives – Comparison ....................................................................... 70 

Figures 

Figure 1-1 ONRAB baits utilized during ORV field trial .................................................................... 5 
iii

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

Figure 1-2 Potential areas of the U.S. into which raccoon rabies could spread if not stopped 

 by rabies management programs ........................................................................................ 9 

Figure 1-3 Proposed ONRAB® zones (with bait distribution densities of 75/km2 and 150/km2

) 

 and current V-RG zones ................................................................................................... 11 

Figure 1-4 Proposed northeast NY, VT, NH field trial zones ............................................................ 12 

Figures 1-5, 1-6 Proposed OH and WV field trial zones ............................................................................. 12 

Appendices 

Appendix A LIST OF PREPARERS, REVIEWERS, AND PERSONS/ AGENCIES 

 CONSULTED ................................................................................................................. A-1 

Appendix B LITERATURE CITED ................................................................................................... B-1 

Appendix C SPECIES LISTED AS THREATENED OR ENDANGERED UNDER THE 

 ENDANGERED SPECIES ACT .................................................................................... C-1 

Appendix D SUMMARY OF SPECIES LISTED AS THREATENDED, ENDANGERED, 

OR SPECIAL STATUS UNDER STATE LAW IN THE STATES PROPOSED 

FOR APHIS-WS INVOLVEMENT IN CONTINUED OR EXPANDED ONRAB® 

FIELD TRIALS ............................................................................................................. D-1

Appendix E REGIONAL FORESTER SENSITIVE SPECIES FOR THE MONONGAHELA 

 NATIONAL FOREST .................................................................................................... E-1 

Appendix F ECOREGION DESIGNATIONS WITHIN THE STATES AFFECTED BY 

 APHIS-WS CONTINUED OR EXPANDED INVOLVEMENT IN ONRAB® 

 FIELD TRIALS ............................................................................................................... F-1 

Appendix G STATUES REGARDING RABIES MANAGEMENT ................................................. G-1 

Appendix H ONRAB® FIELD TRIAL STUDY PROTOCOL .......................................................... H-1 

Acronyms 

AdRG1.3 Human Adenovirus Type-5 Rabies Glycoprotein Recombinant Vaccine 

AMS Agricultural Marketing Service 

ANG Air National Guard 

AMDUCA Animal Medical Drug Use Clarification Act 

APHIS Animal and Plant Health Inspection Service 

BIA Bureau of Indian Affairs 

BLM Bureau of Land Management 

BO Biological Opinion 

CDC Centers for Disease Control and Prevention 

CEQ Council on Environmental Quality 

CFIA Canadian Food Inspection Agency 

CVB Center for Veterinary Biologics 

DEA Drug Enforcement Agency 

DOD Department of Defense 

EA Environmental Assessment 
iv

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

EO Executive Order 

ERA Evelyn Rockitinicki Abelseth 

ESA Endangered Species Act 

EIS Environmental Impact Statement 

FAR Federal Aviation Regulation 

FBI Federal Bureau of Investigation 

FDA Food and Drug Administration 

FONSI Finding of no Significant Impact 

FR Federal Register 

FY Fiscal Year 

HAd5 Human Adenovirus Type 5 

OMNR Ontario Ministry of Natural Resources 

ORV Oral Rabies Vaccination 

MIS Management Information System 

MOU Memorandum of Understanding 

NASA National Aeronautics and Space Administration 

NBDOE New Brunswick Department of Environment 

NBDOH New Brunswick Department of Health 

NEPA National Environmental Policy Act 

NHFG New Hampshire Fish and Game Department 

NHPA National Historic Preservation Act 

NFS National Forest System 

NOP National Organic Program 

NPS National Park Service 

NRMP National Rabies Management Program 

NYDEC New York State Department of Environmental Conservation 

ODNR Ohio Department of Natural Resources 

PEP Post-Exposure Prophylaxis 

QMNR Quebec Ministry of Natural Resources 

RFSS Regional Forester Sensitive Species 

RVNA Rabies Virus Neutralizing Antibodies 

SAD Street Alabama Dufferin 

SAG2 Street Alabama Gif2 

SCID Severed Combined Immunodeficient 

SOP Standard Operating Procedure 

T&E Threatened and Endangered 

TDSHS Texas Department of State Health Services 

TVA Tennessee Valley Authority 

TVR Trap Vaccinate Release 

USACE United States Army Corp of Engineers 

USC United States Code 

USCG United States Coast Guard 

USDA United States Department of Agriculture 

USDI United States Department of the Interior 

USFS United States Forest Service 

USFWS United States Fish and Wildlife Service 

VBS Veterinary Biologics Section 

V-RG Vaccinia-Rabies Glycoprotien 

VS Veterinary Services 

VSTA Virus Serum Toxin Act 
v

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

VTFW Vermont Fish and Wildlife Department 

WS Wildlife Services 

WVDA West Virginia Department of Agriculture 

WVDHHR West Virginia Department of Health and Human Resources 

WVDNR West Virginia Department of Natural Resources
1

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

CHAPTER 1: PURPOSE AND NEED FOR ACTION 

1.1 INTRODUCTION AND BACKGROUND 

Rabies is an acute, fatal viral disease of mammals most often transmitted through the bite of a rabid 

animal. The disease can be effectively prevented in humans and many domestic animal species, but 

abundant and widely distributed reservoirs among wild mammals complicate rabies control. Within most 

of the U.S., these reservoirs occur in geographically discrete regions where the virus transmission is 

primarily between members of the same species (Krebs et al. 2000). These species include but are not 

limited to raccoons (Procyon lotor), coyotes (Canis latrans), skunks (primarily striped skunks (Mephitis 

mephitis), gray foxes (Urocyon cinereoargenteus), and red fox (Vulpes vulpes). Species specific variants 

of the virus may be transmitted to other animal species. However, these encounters rarely result in 

sustained virus transmission within that animal species. Once established, virus transmission within a 

specific animal species can persist at epidemic levels for decades, even perhaps for centuries (Krebs et al. 

2000). 

The vast majority of rabies cases reported to the Centers for Disease Control and Prevention (CDC) for 

the United States, including Puerto Rico, each year occur in wildlife (>90% of all cases) as in most 

developed countries. For example in 2010, wildlife accounted for 92% of positive cases while domestic 

animals accounted for 8% (Blanton et al. 2011). A total of 6,155 cases were reported in 2010; broken 

down to 2,246 raccoons (36.5%), 1,448 skunks (23.5%), 1,430 bats (23.2%), 429 foxes (7.0%), 303 cats 

(4.9%), 113 other wildlife (1.8%)1

, 71 cattle (1.2%), 69 dogs (1.1%), 44 other domestic (0.7%)2, and 2 

humans (0.03%) (Blanton et al. 2011). This is very typical of other years, but the number fluctuates from 

year to year and can be influenced greatly by epizootics (epidemics in animals). Epizootic outbreaks can 

occur, increasing the number of reported cases as well as postexposure rabies treatments given to people. 

Two canine rabies epizootics emerged in Texas in 1988, one involving coyotes and dogs in South Texas 

and the other in gray foxes in West/Central Texas. The South Texas epizootic alone has resulted in two 

human deaths and caused over 3,000 people to receive postexposure rabies treatment (TDSHS 2010). 

The following document is an Environmental Assessment (EA) that describes and analyzes the U.S. 

Department of Agriculture (USDA), Animal and Plant Health Inspection Service, Wildlife Services 

(APHIS-WS) proposed involvement in field trials of an experimental rabies vaccine, human adenovirus 

type 5-rabies glycoprotein recombinant vaccine (AdRG1.3), in New Hampshire (NH), New York (NY), 

Ohio (OH), Vermont (VT), and West Virginia (WV). The trade name for this product is ONRAB® 

(Artemis Technologies Inc., Guelph, Ontario, Canada). AdRG1.3 will be referred to as ONRAB® 

throughout this document. This EA analyzes a number of environmental issues or concerns with the oral 

rabies vaccine and with activities associated with Oral Rabies Vaccination (ORV) field trials such as 

capture and handling animals for monitoring and surveillance purposes. The EA also analyzes 

alternatives to the proposed action, including the current action (field trial to occur in WV only) and no 

action alternative (no federal funding or participation by APHIS-WS). 

                                                           

1

 Includes 25 mongooses (Puerto Rico included in report), 29 groundhogs, 22 bobcats, 10 coyotes, 10 deer, 4 otters, 3 opossums, 

2 fishers, 2 javelinas, 1 badger, 1 coati, 1 marmot, 1 muskrat, 1 rabbit, and 1 squirrel. 2

 Includes 37 horses/mules, 6 goats/sheep, and 1 pig. 
2

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

1.1.1 Public Health Importance of Rabies 

Over the last 100 years, rabies in the United States has changed dramatically. About 90 percent or greater 

of all animal cases reported annually to the CDC now occur in wildlife (CDC 2011). Before 1960 the 

majority of cases were reported in domestic animals. The principal rabies hosts today are wild carnivores 

and bats. The number of rabies-related human deaths in the U.S. has declined from more than 100 

annually at the turn of the century to an average of one or two people/year in the 1990s. Modern day 

prophylaxis, which is the series of vaccine injections given to people who have been potentially or 

actually exposed, has proven nearly 100 percent successful in preventing mortality when administered 

promptly (CDC 2011). In the U.S., human fatalities associated with rabies occur in people who fail to 

seek timely medical assistance, usually because they were unaware of their exposure to rabies.

Human rabies deaths are rare, but the estimated public health costs associated with disease detection, 

prevention, and control are high, estimated to exceed $300 to $450 million annually. These costs include 

the vaccination of companion animals, maintenance of rabies laboratories, medical costs, such as those 

incurred for exposure case investigations, rabies post-exposure prophylaxis (PEP), and animal control 

programs (CDC 2011). Accurate estimates of these expenditures are not available. Although the number 

of PEPs given in the U.S. each year is unknown, it is estimated to be about 40,000. When rabies becomes 

epizootic or enzootic (i.e., present in an area over time but with a low case frequency) in a region, the 

number of PEPs in that area increases. Although the cost varies, a course or rabies immune globulin and 

four doses of vaccine given over a four-week period typically exceeds $1000 (CDC 2011) and has been 

reported to be as high as $3,000 or more (Meltzer 1996). The cost per human life saved from rabies 

ranges from approximately $10,000 to $100 million, depending on the nature of the exposure and the 

probability of rabies in a region (CDC 2011). In Massachusetts during 1991-95, the median cost for PEP 

was $2,376 per person (CDC 1999). Also, as epizootics spread in wildlife populations, the risk of “mass” 

human exposures requiring treatment of large numbers of people that contact individual rabid animals 

infected by wild rabid animals increases – one case in Massachusetts involving contact with, or drinking 

milk from, a single rabid cow required PEPs for a total of 71 persons (CDC 1999). The total cost of this 

single incident exceeded $160,000 based on the median cost for PEPs in that state cited above. Perhaps 

the most expensive single mass exposure case on record in the U.S. occurred in 1994 when a kitten from a 

pet store in Concord, NH tested positive for rabies after a brief illness. As a result of potential exposure 

to this kitten or to other potentially rabid animals in the store, at least 665 persons received postexposure 

rabies vaccinations at a total cost of more than $1.1 million (Noah et al. 1995). 

1.1.2 Primary Need for Action 

If rabies virus variant such as those transmitted by raccoons, gray foxes, and coyotes are not prevented 

from spreading to new areas of the U.S., the health threats and costs associated with rabies are expected to 

increase substantially as broader geographic areas of the U.S. are affected. In the area that stretches west 

from the leading edge of the current distribution of raccoon rabies (which stretches from Alabama 

northeast along the Appalachian Mountains through coastal Maine) to the Rocky Mountains, and north 

from the distribution of gray fox and coyote rabies in Texas, there are more than 111 million livestock 

animals, including cattle, horses, mules, swine, goats, and sheep, which are valued at $42 billion (65 FR 

76606-76607, December 7, 2000). If raccoon, gray fox, or coyote rabies were to spread into the above 

described area, increasing numbers of livestock would be at risk to these specific rabies variants. More 
3

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

importantly, human health care concerns would be expected to increase substantially as well if raccoon, 

coyote, and gray fox rabies spread to a much broader geographic area than they currently occupy. 

Allowing these variants of the rabies virus to spread would add to the current high costs of living with 

rabies. The proposed ONRAB® field trial is necessary to further determine if it is safe and immunogenic 

in a variety of meso-carnivores, including raccoons and striped skunks. The vaccine used in the current 

ORV program, vaccinia-rabies glycoprotein (RABORAL V-RG®, Merial, Inc., Athens, GA), has not 

produced sufficient measurable antibody levels in striped skunks where samples in conjunction with 

raccoon sampling have been evaluated. Throughout the remainder of this document, RABORAL V-RG® 

is referred to as “V-RG”. Moreover, higher levels of population immunity are desired in raccoons than 

have been realized through use of V-RG, to move toward effective raccoon rabies elimination strategies. 

Therefore, continuing the ONRAB® field trial in WV as well as expanding trials into OH, NH, NY, and 

VT would allow APHIS-WS implement three key recommendations resulting from the initial 

2011ONRAB® field trial (USDA 2012b). It would allow APHIS-WS to continue to maintain buffered 

ONRAB® and V-RG zones so that critical comparisons can be made between ONRAB® and V-RG 

responses in target species, focus field trial efforts in areas with an elevated risk of raccoon rabies 

spreading to naïve areas, and to bolster efforts to prevent raccoon rabies from spreading beyond the 

northern U.S. border into Quebec. 

1.1.3 Development of Oral Rabies Programs 

Although the concept of ORV to control rabies in free-ranging wildlife populations originated in the U.S. 

(Baer 1988), it has a longer history of implementation in Europe and Canada. The emergence of raccoon 

rabies in the U.S. during the 1970s heightened interest in the application of ORV to raccoons. Due to 

biological and ecological differences among the types of animals that transmit rabies, development of 

specific vaccine and bait combinations was needed. One of the main difficulties was the development of 

a safe and effective vaccine for raccoons. In contrast to red foxes, which were the primary subjects of 

ORV programs in Europe and Canada, raccoons were not readily immunized by the oral route with the 

modified live rabies virus vaccines that worked well in foxes (Rupprecht et al. 1988). Because modified 

“live virus” vaccines pose a small risk of causing vaccine-induced rabies, and have resulted in some cases 

of vaccine-induced rabies in animals (but no cases in humans) during oral baiting programs in Europe and 

Canada (Wandeler 1991), a recombinant vaccine was first chosen for use in the U.S.. Vaccinia-rabies 

glycoprotein (V-RG) vaccine has proven to be orally effective in raccoons, coyotes and foxes. This 

vaccine was extensively evaluated in the laboratory for safety in more than 50 vertebrate species with no 

adverse effects regardless of route or dose. As a consequence of field safety testing in the early 1990s, VRG was conditionally licensed in 1995 and fully licensed in 1997 in the U.S. for vaccination of freeranging raccoons. It remains the only effective vaccine licensed for use in the U.S. and Canada for 

raccoons. V-RG was also recently fully licensed by the USDA in 2002 for vaccination of coyotes in the 

U.S. and Canada. It has been approved for experimental use to vaccinate wild gray foxes in Arizona, New 

Mexico, and Texas. 

However, a higher level of population immunity in raccoons is desired in order to maximize the 

effectiveness of ORV programs. Further, the V-RG vaccine has not produced sufficient levels of 

population immunity in skunks (primarily striped skunks) in the wild at the current dose (Slate et al. 

2005), and V-RG may be less effective in skunks than other species (Tolson et al. 1987). In the U.S., the 
4

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

total geographic area affected by skunk rabies is at least 1.4 million mi2

 (3.5 million km2) or nearly 40% 

of the entire contiguous lower 48 states (Krebs et al. 2000). Unfortunately, the V-RG vaccine is not 

effective by the oral route in skunks (Charlton et al 1992) and at least one modified live rabies virus 

vaccine used for oral vaccination of red foxes, with demonstrated potential for immunization of raccoons 

(Rupprecht et al. 1989), resulted in vaccine-induced rabies in skunks (Rupprecht et al. 1990). Thus, the 

need for new and efficacious vaccines to address rabies in raccoons and skunks as well as other wildlife 

species is apparent. 

Human adenovirus type 5 (HAd5) has been used extensively as a vector for vaccine development mainly 

due to its well-characterized molecular structure, genomic stability, and ability to grow high titers in a 

wide spectrum of cells (Graham and Prevec 1992 in Knowles et al. 2009b). 

One of the most promising vaccines has been a human adenovirus type 5-rabies glycoprotein recombinant 

vaccine (AdRG1.3), the vaccine that is subject of the proposed field trial analyzed in this EA; AdRG1.3 

was modified from the first construct (AdRG1) in the early to mid-1990s at McMaster University, 

Hamilton, Ontario, Canada (Yarosh et al. 1996 in Rosatte et al. 2009). During 1993, Microbix 

Biosystems Inc. (Toronto, Ontario, Canada), was commissioned by the Ontario Ministry of Natural 

Resources (OMNR) to prepare a master seed of virus that OMNR acquired from Microbix in 1999. 

Subsequent laboratory trials were conducted at the Canadian Food Inspection Agency (CFIA), Nepean, 

Ontario, Canada, and production vaccine was developed by Artemis Technologies Inc. (Guelph, Ontario, 

Canada), with assistance from the National Research Council, Biotechnology Research Institute. The 

trade name for this product is ONRAB® (Artemis Technologies Inc., Guelph, Ontario, Canada) (Rosatte 

et al. 2009). The AdRG1.3 vaccine will be referred to as ONRAB® throughout this EA. ONRAB® has 

been aerially distributed in Ontario, Canada since 2006. 

A number of studies have been conducted to determine the best bait formulations and strategies for 

delivery of ORV vaccines to raccoons (Hanlon et al. 1989, Hable et al. 1992, Hadidian et al. 1989, 

Linhart et al. 1991, Linhart et al. 1994), gray fox (Steelman et al. 1998, 2000), and coyotes (Linhart et al. 

1997; Farry et al. 1998a, 1998b). When raccoons, foxes or coyotes eat oral rabies baits and puncture a 

sachet3

 containing the vaccine, the vaccine is swallowed and bathes the lymphatic tissue in the throat area 

and initiates the immunization process. A positive rabies antibody titer in an animal from a baited area is 

most likely due to consumption of a bait and adequate contact with vaccine. However, the lack of a 

detectable antibody response may not be an accurate reflection of immune status. It is possible that the 

animal was successfully immunized, but that the blood sample was taken earlier or later than when 

antibodies could be detected (C. Hanlon, CDC, pers. comm. 2003 as cited in USDA 2004). Antibodies 

induced by a one-time oral vaccination appear to be of relatively short duration. Among a group of 

animals in a baited area, the best time to collect blood samples for detection of antibodies is 4-8 weeks 

after baiting. A successfully immunized animal may have antibodies shortly after vaccination, but then 

the level may decline to undetectable levels. If the animal is then exposed to rabies, it is still likely that 

the animal's "memory" immunity will become activated by the rabies exposure and more antibodies will 

be made very quickly. The successfully immunized animal will most likely survive exposure, even though 

                                                           

3

 A thin plastic packet much like those in which condiments (e.g., catsup, mustard) are provided at fast food restaurants. 
5

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

it did not have measurable antibodies at the time of the exposure (C. Hanlon, CDC, pers. comm. 2003 as 

cited in USDA 2004c). 

Each bait contains 1.8 േ0.1 ml of ONRAB® vaccine (titer of not <109.5 cell culture infectious dose 50% 

[CCID50]/ml) in an elongated plastic blister pack that is coated with an attractant-bait matrix (Figure 1-1). 

The attractant on the vaccine-baits is composed of partially hydrogenated vegetable shortening (34%), 

Microbond® wax (International Wax Ltd., Agincourt, Ontario, Canada) (30%), stearine (12.5%), icingsugar (20%), vegetable oil (1%), artificial marshmallow flavor (1%), artificial sweet flavor (1%), and a 

fat-soluble food dye (0.5%) (khaki green) to camouflage the baits. The bait matrix also contains 100 mg 

of tetracycline hydrochloride as a biomarker to evaluate bait ingestion. Each vaccine-bait weighs 

approximately 4 grams. The body of the blister pack is an elongated oval with dimensions of 1.81x 0.55x 

0.39 in (30x14x10 mm) and a rectangular lip extending to 1.57x 0.79 in (40x20 mm) (Figure 1-1). The 

blister pack contains an identifying label as to the contents of the bait and a toll free phone number where 

people can obtain information about the baits (Rosatte et al. 2009). 

 Figure 1-1. ONRAB baits utilized during ORV field trials 

 (photo: http://www.mnr.gov.on.ca) 

The tetracycline biomarker in the baits binds to calcium, which can be found in the metabolically active 

portions of bones and teeth of animals. Tetracycline deposits can be viewed in the teeth or bones with 

fluorescent light under a microscope. When the tooth or bone sample of an animal is positive for 

tetracycline, it is likely that the animal has eaten at least one bait and possibly multiple baits (C. Hanlon, 

CDC, pers. comm. 2003 as cited in USDA 2004). The presence of tetracycline, however, is not an 

indication of immunity since it is possible in some situations for an animal to eat the outer bait matrix 

without rupturing the vaccine sachet inside. Other potential sources of "background" tetracycline in a 

study area may include consumption of medicated feeds such as those sometimes used for production 

animals, intentional treatment by humans with tetracycline, and non-specific fluorescence from 

undescribed but similar chemical compounds that may be found naturally (C. Hanlon, CDC, pers. comm. 

2003 as cited in USDA 2004).

In field tests conducted in the U.S. using previous vaccine-bait combinations, the majority of ORV baits 

have been consumed within the first 7 to 14 days after placement, with reports of up to 100 percent of the 

baits being consumed within a 7 day period (Farry et al. 1998b, Hable et al. 1992, Hadidian et al. 1989, 

Hanlon et al. 1989, Linhart et al. 1994, Steelman et al. 2000, USDA 1995). Similar results may be 

expected using the ONRAB® baits. The likelihood of a bait being consumed is dependent upon several 
6

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

factors including animal population densities (target and non-target species), bait preference, and the 

availability of alternative food sources. Those baits that are not consumed may remain in the 

environment for several months after placement, dependent upon environmental conditions (precipitation, 

temperature, etc.) and the condition of the baits. 

Oral wildlife vaccination for raccoon rabies control has been under field evaluation in the U.S. since 

1990. A limited field release of the recombinant vaccine occurred on Parramore Island, VA, prior to 

wider spread use in the U.S. for control of raccoon rabies (Hanlon et al. 1989). A major objective of this 

field trial was to evaluate the free-ranging raccoon population for adverse effects after the distribution of 

V-RG vaccine-laden baits. With the development and field testing of the V-RG vaccine, a potential 

method of rabies control now exists for some rabies variants to complement other methods of control that 

include public education, domestic animal vaccination, and human PEP. In 2004, APHIS-WS, in 

cooperation with the CDC, began conducting small mammal vaccinia monitoring at Parramore Island, 

VA. Because this is the site where vaccinia was first released into the wild in ORV baits and since these 

baits have not been released at this site since the early 1990s, viruses in hosts can be monitored. 

Microtine mammals, especially rodents, are typically the most likely hosts for orthopox viruses, which 

include vaccinia. Thus, these mammals are good sentinel species for indicators for the environmental 

presence of viruses, such as vaccinia. Samples were collected and tested at CDC laboratories to 

determine the presence of vaccinia virus in small mammals collected at this site. Results of this study 

found no evidence of V-RG circulation based upon the serological survey (C. Rupprecht, CDC, pers. 

comm. 2009). 

Since the first field release of the V-RG vaccine in 1990, the number of vaccine-laden baits distributed 

annually in the U.S. has risen exponentially. For instance, APHIS-WS’ involvement in the national rabies 

management program between 1995 and 2010 contributed to 120 million ORV baits disbursed in the U.S 

(USDA 2009, ORV website). Numerous projects have been conducted or are in progress in the eastern 

U.S., Texas, and Arizona (USDA 2010). 

In 2011, APHIS-WS conducted the first ORV field trial since the V-RG field trials of the 1990’s using 

ONRAB® in West Virginia. Results of this field trial are promising and initial results indicate that 

ONRAB® may be used successfully in ORV programs. Raccoons sampled during post-ORV monitoring 

and surveillance activities displayed a 49% seroconversion rate (i.e., these raccoons received a sufficient 

dose of ONRAB® and are considered to be vaccinated against the rabies virus). While raccoons sampled 

pre-ORV activities displayed a 9.6% seroconversion, this may be explained by a possible occurrence of 

naturally acquired immunity from sub-lethal exposures to raccoon rabies or movements of orally 

vaccinated raccoons into sampling cells from the adjacent V-RG zone (USDA 2012b). 

The 49% post-ORV with ONRAB® (uncorrected for the 9.6%) seroconversion represents the highest 

rabies virus neutralizing antibody (RVNA) level that WS has observed after an initial baiting of a naïve 

area at 75 baits/km2 where baselines had been measured prior to ORV. Biomarker presence was also 

significantly higher among seropositive raccoons post-ORV and similar among raccoons during the preORV sampling period (USDA 2012b). 

While this field trial was not specifically designed to compare seroconversion between ONRAB® and VRG, a mean seropositivity of 17% has been observed for V-RG under essentially the same initial ORV 
7

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

baiting characterisitics during the period from 2001 to 2009 in AL, FL, GA, ME, NC, PA, TN, and VA 

(USDA 2012b). These results are similar to those reported by Fehlner-Gardiner et al. (2012) that found 

essentially a two-fold higher seroconversion at 73% for ONRAB® in New Brunswick, Canada when 

compared to 29% for V-RG across the border in Maine. 

Although comparative seroconversion samples were not collected in the adjacent V-RG zone in WV postORV in 2011, in the four years previous to the field trial RVNA population levels ranged from 18.5% to 

46.4%. These percentages represent RVNA levels for areas that have been subject to annual ORV 

campaigns since 2001 (USDA 2012b). 

Skunk sample size was inadequate to establish a baseline for RVNA and to evaluate the response to 

ONRAB® with confidence. However, other studies have not shown a strong RVNA response to 

ONRAB® at 75 baits/km2 (Mainguy and Canac-Marquis 2010, Rosatte et al. 2011). It has been suggested 

that, because of the sedentary nature of skunks, higher densities of baits may be required per unit area of 

baitable habitat so that each skunk will find at least one bait in its home range (Rosatte et al. 2011). 

1.2 PURPOSE OF THE PROPOSED ACTION 

The purpose of the proposed action is to research the human adenovirus type 5-rabies glycoprotein 

recombinant (AdRG1.3) ONRAB® rabies virus vaccine and to evaluate its potential safety and 

immunogenicity as an oral rabies virus vaccine for raccoons, skunks, gray foxes, and coyotes. APHISWS has prepared this EA to facilitate in planning, interagency coordination, streamline program 

management, and clearly communicate with the public and regulators the analysis of the potential for 

impacts resulting from the application of ONRAB® in field trials in New Hampshire, New York, Ohio, 

Vermont, and West Virginia. This EA will assist in determining if the proposed action will have a 

significant impact on the quality of the human environment. 

The specific objective of the proposed action is to use federal funds to purchase and distribute baits laden 

with the oral rabies vaccine ONRAB® and to participate in subsequent monitoring and surveillance 

activities in an effort to determine a safe and immunogenic oral rabies vaccine that will further serve in 

maintaining barriers of immunized target species including raccoons, skunks, gray foxes, and coyotes, 

thus preventing the expansion of rabies epizootics. Although current APHIS-WS’ ORV programs employ 

the use of the V-RG vaccine, which is currently licensed for use in raccoons and coyotes in the U.S. and 

Canada and approved for experimental use in gray fox in Arizona, New Mexico, and Texas; no vaccine is 

currently licensed in the U.S. for use in skunks. Although the V-RG vaccine has proven to be efficacious, 

a higher level of population immunity in raccoons (Procyon lotor) is desired in order to maximize the 

effectiveness of ORV programs. The field trial proposed in this EA will not only assess the safety and 

immunogenicity of ONRAB® in a variety of mesocarnivore target species, but, as discussed below, is 

also a necessary step for licensure of a rabies vaccine for use in these species. 

Additionally, studies indicate that V-RG does not produce sufficient levels of population immunity in 

skunks in the wild at the current dose (Slate et al. 2005), and V-RG may be less effective in skunks than 

other species (Tolsen et al. 1987). Skunks are a major contributor to rabies in North America. During 

2010, skunks accounted for 27.4% of reported cases of rabies in wild animals. Of those, 44.4% were 

from states where the raccoon rabies virus variant is enzootic (Blanton et al. 2011). This trend has raised 
8

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

concerns about an independent maintenance cycle for raccoon rabies in skunks (Guerra et al. 2003). 

Rabies virus containment and elimination in the U.S. will likely remain elusive until an oral vaccine is 

licensed that is immunogenic in all terrestrial rabies reservoir species (Slate et al. 2005). In addition, the 

skunk rabies virus variant, which has the broadest geographic distribution of all terrestrial rabies variants 

in the U.S. (Krebs et al 1995), can currently be addressed only through local trap-vaccinate-release (TVR) 

or population suppression programs. Therefore, it is critical to find a vaccine that is safe and 

immunogenic in skunks. Research has found that after oral instillation of the ONRAB® vaccine, skunks 

will develop rabies neutralizing antibodies, but with no observable adverse effects. 

Although not currently licensed for use in the U.S., ONRAB® has been used in field trials in Ontario, 

Canada since 2006. APHIS-WS conducted an initial field trial in West Virginia in 2011 using ONRAB®. 

APHIS regulates veterinary biologics (e.g. vaccines) to ensure that the veterinary biologics available for 

the diagnosis, prevention, and treatment of animal diseases are pure, safe, potent, and effective. This 

work is done by APHIS, Veterinary Services (VS), Center for Veterinary Biologics (CVB) and is 

centered around enforcement of the Virus Serum Toxin Act. Accordingly, APHIS-CVB has conducted a 

risk analysis and has determined that implementation of the proposal would not significantly affect the 

quality of the human environment (USDA 2011a). APHIS-CVB has permitted experimental use of 

ONRAB® for the proposed field trial. Completion of field safety trials is a required step prior to full 

licensure of a vaccine by APHIS-CVB. 

Overall, APHIS-WS believes the safety and immunogenicity outcomes of the 2011 field trial support 

replicating the WV field trial to determine if raccoon population immunity would increase as a function of 

a second annual ORV campaign as well as broadening the field trial to include other areas of previously 

established ORV zones. 

1.3 NEED FOR ACTION 

Based on surveillance data, raccoon rabies did not exist outside a focus area in Florida before the 1940s 

and is, therefore, considered an exotic rabies virus variant in the U.S. outside this area (C. Rupprecht, 

pers. comm. 2003 as cited in USDA 2004a). After raccoon rabies was described in Florida, it spread 

slowly during the next three decades into Georgia, Alabama, and South Carolina. It was unintentionally 

introduced into the mid-Atlantic states, probably by translocation of infected animals (Krebs et al. 1999). 

The first cases appeared in West Virginia and Virginia in 1977 and 1978. Since then, raccoon rabies in 

the area expanded to form the most intensive rabies outbreak in the U.S. Raccoon rabies is now enzootic 

in all eastern coastal states as well as in Alabama, Ohio, Pennsylvania, Tennessee, Vermont, and West 

Virginia (Blanton et al. 2008). In the past 21 years, all of the mid-Atlantic and New England states have 

experienced at least one outbreak. The raccoon rabies epizootic front reached Maine in 1994, reflecting a 

movement rate of about 30 miles per year (48.3 km/yr). It was also first confirmed in northeastern Ohio 

in 1996 (Krebs et al. 1998). In 1999, the first three cases of raccoon rabies were confirmed in southern 

Ontario (Rosatte et al. 2001). Subsequently, raccoon rabies was also confirmed in New Brunswick and 

Quebec in 2000 and 2006 respectively. 

Raccoon rabies presents a human health threat through potential direct exposure to rabid raccoons, or 

indirectly through the exposure of a pet that had an encounter with a rabid raccoon. To date, one case 

resulting in the death of a human is attributable to the raccoon strain of the rabies virus. A 25-year-old, 
9

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

previously healthy northern Virginia man died in June 2003. A diagnosis of rabies had not been 

considered and was only made 3 months after death when brain tissue was examined. Patient history did 

not reveal contact with animals and no specific exposure experience could be determined (S. Jenkins, 

Virginia Department of Health, pers. Comm. 2003, L. Orciari, CDC, pers. comm. 2003 all as cited in 

USDA 2004a). Adding to the threat of the raccoon strain of the rabies virus are the number of: pets and 

livestock examined and vaccinated for rabies, diagnostic tests, and post-exposure treatments, all of which 

are greater when raccoon rabies is present in an area. Human and financial resources allocated to rabiesrelated human and animal health needs also increase, often at the expense of other important activities and 

services. 

The westward movement of the raccoon rabies front has slowed, probably in response to both natural 

geographic and man-made barriers. The Appalachian Mountains and, perhaps, river systems flowing 

eastward have helped confine the raccoon variant to the eastern U.S. However, a raccoon rabies positive 

case was confirmed outside of the previously established ORV zone in Ohio in 2004 (Krebs et al. 2005) 

prompting a closer look at the potential for westward spread of the virus. With no effective physical 

barrier across the middle of Ohio, rabies would be expected to move more rapidly through this zone than 

in any previously recorded epizootic (Russell et al. 2005). Live trapping results in Ohio (A. Montoney, 

APHIS-WS, pers. comm. cited in Kemere et al. 2001) as well as the status of raccoons in the Midwest 

(Sanderson and Hubert 1982, Glueck et al. 1998, Hasbrouck et al. 1992, Mosillo et al. 1999) suggest that 

raccoon populations are sufficient for rabies to spread westward along a front at a rate similar to or greater 

(Rupprecht and Smith 1994) than the rate at which this rabies strain has spread in the eastern U.S. Figure 

1-2 shows the hypothetical spread of this rabies variant across the central portion of the U.S. if it is not 

stopped. Development of new, more highly efficacious vaccines is critical to maintaining ORV barriers, 

eliminating the further spread, and eventual containment and elimination of this variant of the rabies 

virus. 

Figure 1-2: Potential areas of the U.S into which raccoon rabies could spread if not stopped by rabies management programs (from 

Kemere et al. 2001). 

Current area in which

raccoon rabies variant

occurs. 

Area of potential

westward spread.
10

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

That specific rabies virus variants in North America are maintained in several meso-carnivore species 

including raccoons, gray foxes, coyotes, and skunks further underscores the need for the proposed action. 

Generally, each distinct variant of the virus in mammalian species occurs in geographically discrete areas 

and is strongly associated with its reservoir species (Krebs et al. 2001). Within each area, a spillover of 

rabies into other species occurs, especially during epizootics. As a result of spillover, a variant may 

eventually adapt to a secondary species, which may begin to serve as an alternative reservoir species 

(Bacon 1985). 

Skunks are a major contributor to rabies in North America with 1,448 cases of rabies in skunks reported 

in 2010. Additionally, 44.4% of rabid skunks were reported from states where raccoon rabies is enzootic, 

most of which were presumably the result of spillover infection from raccoons (Blanton et al. 2011). This 

trend also raises concerns that there may be an independent maintenance cycle for raccoon rabies in 

skunks (Guerra et al. 2003). 

If left unmitigated, this spillover of raccoon rabies into skunks could likely compromise the integrity of 

the previously established oral rabies vaccination zones. Currently, V-RG is the only oral rabies vaccine 

licensed for use and applied in field settings in the U.S. It is effective in specific meso-carnivores such as 

raccoons (Procyon lotor), coyotes (Canis latrans), and gray foxes (Urocyon cinereoargenteus), but has 

produced only low levels of population immunity in skunks (primarily Mephitis mephitis) in the wild 

(Slate et al. 2005), and V-RG may be less effective in skunks than other species (Tolson et al. 1987). The 

national rabies management goals of virus containment and elimination will likely remain elusive until an 

oral vaccine is licensed that is immunogenic in all terrestrial rabies reservoir species (Slate et al. 2005). 

In addition, the skunk rabies virus variant, which has the broadest geographic distribution of all terrestrial 

rabies variants in the U.S. (Krebs et al. 1995), can currently be addressed only through local trapvaccinate-release (TVR) or population suppression programs. Thus, development, safety and 

immunogenicity testing, followed by licensing of additional oral vaccines that are effective in all 

terrestrial rabies reservoir species remains among the highest priorities of the APHIS-WS’ National 

Rabies Management Team (Slate et al. 2005). 

1.4 DESCRIPTION OF THE PROPOSED ACTION 

In accordance with the provisions of the Act of September 25, 1981, as amended (7 U.S.C. 147b), the 

Secretary of Agriculture declared that there is an emergency that threatens the agricultural production 

industry in the U.S., and authorized the transfer and use of funds from the Commodity Credit Corporation 

of the USDA in FY2001 for the continuation of ORV programs to address rabies problems in several 

eastern states and Texas (65 FR 76606-76607, December 7, 2000). Additional CCC funds continue to be 

provided to augment the funding obtained through the appropriations process and support the 

continuation and expansion of ORV programs to ensure that raccoon and gray fox rabies spread is 

contained. The APHIS-WS program, in cooperation with the USDA-Forest Service, is proposing to 

continue or expand federal cooperation through funding and direct involvement in new vaccine field trials 

in New Hampshire, New York, Ohio, Vermont, and West Virginia using the ONRAB® rabies vaccine. 

The field trial area will encompass approximately 10,484 mi2 (27,154 km2

) within the states of New 

Hampshire, New York, Ohio, Vermont, and West Virginia, including portions of the USFS National 

Forest System lands, excluding Wilderness Areas (WAs). Baits will be distributed at a common densities 
11

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

of either 75 baits/km2 or 150 baits/km2

. Figures 1-3, 1-4, 1-5, and 1-6 illustrate the field trial’s anticipated 

target locations. These sites were selected for the field trial due to their proximity to the current V-RG 

ORV zone, availability of suitable habitat and target species, and local public support. 

The program would involve the use of APHIS-WS federal funds to purchase and distribute ORV baits to 

vaccinate specific populations of striped skunks and raccoons to determine the immunogenicity of 

ONRAB® in these species. The specific vaccination zone(s) will be determined in cooperation with the 

various state rabies task forces, state health and agriculture departments in the proposed states, and/or 

other agencies with jurisdiction over vaccine use and application in wildlife and domestic animals. The 

proposed action would also include APHIS-WS assistance in monitoring and surveillance activities 

involving the capture and release or lethal collection of the targeted animal species in and around the field 

trial vaccination zone to take biological samples for testing to determine the effectiveness of ONRAB® 

ORV field trials. The role of the USFS would involve cooperation with APHIS-WS in permitting access 

to National Forest System (NFS) lands for bait dispersal and rabies monitoring and surveillance activities. 

Coordination with specific National Forest offices will occur prior to project implementation to ensure 

that the integrity of specially designated areas is maintained (i.e., Research Natural Areas, Wilderness 

Areas, Wild and Scenic Rivers, etc.). 

Figure 1-3: Proposed ONRAB® zones (with bait distribution densities of 75/km2 and 150/km2) and current V-RG zones.
12

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

Figure 1-4: Proposed Northeast NY, VT, NH field trial 

zone. 

Pending the verification of legal authorities to 

do so, ORV baits would be distributed by the 

states (NH, NY, OH, VT, WV) over a variety 

of classes of land ownership, including 

private, public, and other state and federal 

lands. Each bait will have a warning label 

advising persons not to handle or disturb the 

bait, along with a toll-free telephone number 

to call for further information. Wild animal 

collections for purposes of monitoring would 

be conducted using a variety of live capture or 

lethal methods. 

Figures 1-5 and 1-6: Proposed ONRAB® field trial zones in Ohio and West Virginia 

Information from raccoons and skunks would be predominantly collected from cage-trapped individuals 

that, if apparently healthy, would normally be released at or near their site of capture. Only legally 

approved methods would be used in all animal sample collection areas to provide critical data for the 

evaluation of project effectiveness. Project effectiveness would be based in large part on the percentage 

of ORV baits consumed in populations of target species, the presence of sufficient levels of serum 

neutralizing antibodies in a large enough percentage of the population to resist the spread of rabies, and 

the absence of the rabies strain targeted for control with ORV beyond the vaccination barrier established 

to prevent spread of the virus.  In addition to the primary target species, several other species such as red 

foxes, gray foxes, and coyotes would be targeted during monitoring and surveillance. Several of these 

animals would be sampled to help determine efficacy of the treatment. Biological data such as sex, age, 

and weight would also be collected to determine if baits are consumed differently by various age or sex 

groups. Appendix H contains a description of the specific study protocols that will be utilized throughout 

the proposed field trial. 
13

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

The primary goals of this program would be to assess the safety and immunogenicity of the ONRAB® 

rabies vaccine in the raccoon and striped skunk populations, determine the feasibility of using ONRAB® 

to stop the forward advance of specific rabies variants from areas where they occur now by immunizing 

portions of target species populations along the leading edges of the rabies fronts, and to reduce the 

incidence of rabies cases involving wild and domestic animals and rabies exposures to humans in areas 

where the ORV programs are conducted. 

1.5 SCOPE OF THIS ENVIRONMENTAL ASSESSMENT 

1.5.1 Actions Analyzed 

This EA evaluates the environmental effects of APHIS-WS funding of and participation in ORV field 

trials in the states of New Hampshire, New York, Ohio, Vermont, and West Virginia (see Figure 1-3) for 

determining the safety and immunogenicity of ONRAB® as an oral rabies vaccine for meso-carnivores 

including raccoons, skunks, gray foxes, and coyotes in the U.S. Under the proposed action, ORV and 

monitoring and surveillance activities would be conducted on private, federal, state, county, and 

municipal lands in New Hampshire, New York, Ohio, Vermont, and West Virginia including NFS lands, 

but excluding Wilderness Areas. 

1.5.2 Period for which this EA is Valid 

This EA will remain valid until APHIS-WS determines the proposed study to be complete. If APHIS-WS 

modifies the study such that it would have different environmental effects, a new EA will be completed or 

this EA will be supplemented pursuant to NEPA and with the appropriate analyses.

1.5.3 Site Specificity 

This EA analyzes potential impacts of ONRAB® as an oral rabies vaccine for managing rabies in 

raccoons, as well as, skunks, gray foxes, and coyotes. The study will be conducted on lands in portions of 

New Hampshire, New York, Ohio, Vermont, and West Virginia, including NFS lands, but excluding 

Wilderness Areas. This EA examines the potential for significant environmental effects in the specific 

areas of the proposed action whenever possible; however, the issues that pertain to ONRAB® safety and 

immunogenicity are the same, for the most part, whether they would be researched in the proposed states 

or elsewhere in the U.S. 

1.5.4 Coordination 

APHIS-WS is the lead agency and decision-maker for this EA. However, to assure that the concerns of 

other federal land managers have been addressed, the USFS was asked to participate in the development 

and review of this EA. The agency participated in the review of this EA as per 40 CFR 1501.6 and 

ensures compliance with their respective Land and Resource Management Plans. 

The proposed field trial is a collaborative effort among APHIS-WS; the CDC; the vaccine manufacturer 

(Artemis Technologies Inc.); the NH Departments of: Agriculture, Markets, and Food; Health and Human 

Services; and Fish and Game; the NY Departments of: Agriculture and Markets; Health; and 

Environmental Conservation; the OH Departments of Agriculture; Health; and Natural Resources; the VT 

Departments of: Agriculture, Food, and Markets; Health; and Fish and Wildlife; and the WV Departments 
14

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

of: Agriculture; Health and Human Resources; the WV Division of Natural Resources; the Ontario 

Ministry of Natural Resources; and the Quebec Ministry of Natural Resources and Wildlife. 

APHIS-WS will coordinate with all applicable federal and state agencies that will be affected by APHISWS actions on their lands through the NEPA process or other agency-specific coordination including, but 

not limited to, entrance into MOUs, establishment of work plans, or issuance of Special Use Permits. All 

affected agencies will be contacted early and prior to implementation of any APHIS-WS National Rabies 

Management Program (NRMP) activity to ensure that the agencies are in accordance with APHIS-WS 

actions and gain their cooperation with any site-specific issues the affected agency might have. 

1.6 SUMMARY OF PUBLIC INVOLVEMENT 

General issues pertaining to ORV field trials were developed through the scoping process for previous 

EAs prepared to analyze the environmental effects of APHIS-WS’ continued and expanded participation 

with ORV program in the eastern and southwestern United States and were specifically refined for this 

EA by APHIS-WS. These scoping processes involved numerous federal (i.e., Centers for Disease 

Control and Prevention), state (i.e., health, agriculture, and natural resource departments), and local 

government agencies, academic institutions, and Canadian provincial government agencies (i.e., Ontario 

Ministry of Natural Resources). As a part of the process for this proposed action, and as required by the 

Council on Environmental Quality (CEQ) and APHIS’ NEPA implementing regulations, this document is 

being noticed to the public through legal notices published in local print media, through direct mailings to 

parties that have requested to be notified or have been identified to have an interest in ORV programs, 

and by posting the pre-decisional EA on the APHIS website at: 

http://www.aphis.usda.gov/wildlife_damage/nepa.shtml. 

WS will provide a 30-day comment period for the public and interested parties to provide new issues, 

concerns, and /or alternatives. Through the public involvement process, WS will clearly communicate to 

the public and interested parties the analysis of potential environmental impacts on the quality of the 

human environment. New issues or alternatives identified from the public involvement process will be 

fully considered to determine whether the EA should be revisited and, if appropriate, revised prior to the 

issuance of a final Decision or the publication of a Notice of Intent to prepare an EIS. 

1.7 DECISIONS TO BE MADE 

Based on the scope of this EA, the decisions to be made are: 

 Should APHIS-WS undertake field trials in NH, NY, OH, VT, and WV, including portions of 

National Forest System lands, but excluding Wilderness Areas, to determine the immunogenic 

potential of ONRAB® as an oral rabies vaccine for raccoons, skunks, gray foxes, and coyotes? 

 If not, should APHIS-WS implement the other alternative, the “no action” alternative? 

 Would implementing the proposed action or the alternative action have significant adverse 

impacts on the quality of the human environment requiring the preparation of an EIS? 
15

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

1.8 RELATIONSHIP OF THIS EA TO OTHER ENVIRONMENTAL DOCUMENTS 

EA, FONSI, and Decision – Field Trial of an Experimental Rabies vaccine, Human Adenovirus 

Type 5 Vector in West Virginia. This EA and FONSI/Decision, in cooperation with the USFS, (USDA 

2011b) analyzed the environmental effects of APHIS-WS involvement in the funding of and participation 

in an initial field trial to distribute ONRAB® oral rabies vaccine baits in West Virginia and to participate 

in subsequent monitoring and surveillance activities in an effort to determine a safe and immunogenic 

oral rabies vaccine that will further serve in maintaining barriers or immunized target species, thus 

preventing the expansion of rabies epizootics. 

Work Plan for Oral Vaccination by Ground or Aerial Baiting to Control Specific Rabies Virus 

Variant in Raccoons on National Forest System Lands in USFS Regions 3, 8 and 9. This Work Plan 

(March, 2010) was prepared by APHIS-WS in coordination with the USFS to implement ORV program 

activities on National Forest System lands in USFS Regions 3, 8 and 9. 

The USFS has reviewed the proposed action and alternatives described in this EA and has determined the 

proposed action to be consistent with Land and Resource Management Plan (USDA 2006) for the 

Monongahela National Forest located within the proposed field trial location, excluding Wilderness 

Areas. 

A number of other NEPA documents have been prepared that analyzed the potential environmental 

effects of APHIS-WS’ ORV programs and the methods used in rabies monitoring and surveillance. 

Pertinent information from those analyses has been incorporated by reference into this EA. 

Wildlife Services Programmatic EIS. APHIS-WS has issued a final Environmental Impact Statement 

(EIS) (USDA 1997) and Record of Decision on the National APHIS-WS program. Relevant information 

from the EIS has been incorporated by reference in this document. 

EA, FONSI, and Decision – Oral Vaccination to Control Specific Rabies Virus Variants in 

Raccoons, Gray Foxes, and Coyotes in the United States. This EA and FONSI/Decision (USDA 2010) 

analyzed the environmental effects of APHIS-WS involvement in the funding of and participation in 

ORV programs to eliminate or stop the spread of raccoon rabies in a number of eastern states (Alabama, 

Connecticut, Delaware, Florida, Georgia, Indiana, Kentucky, Louisiana, Maine, Maryland, 

Massachusetts, Michigan, Mississippi, New Hampshire, New Jersey, New York, North Carolina, Ohio, 

Pennsylvania, Rhode Island, South Carolina, Tennessee, Vermont, Virginia, and West Virginia) and gray 

fox and coyote rabies in Arizona, New Mexico, and Texas. Additionally, the analysis area included 

Bureau of Land Management (BLM) and National Forest System lands, excluding Wilderness Areas. 

APHIS-WS determined the action would not have any significant adverse impact on the quality of the 

human environment. 

EA, FONSI, and Decision – Oral Rabies Vaccination Program for Midwest Region Park Units. 

APHIS-WS was a cooperating agency in the preparation of this EA and FONSI/Decision (U.S. 

Department of the Interior (USDI) 2005) which analyzed the environmental effects of NPS participation 

in ORV programs on nine NPS units in the states of Indiana, Ohio, and Michigan in the effort of stopping 

the spread of a specific raccoon rabies variant or “strain” of the rabies virus and reducing or eliminating 
16

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

this strain of the virus from the eastern United States. The NPS determined the action would have a 

negligible impact on the quality of the human environment. 

EA, FONSI, and Decision – Oral Rabies Vaccination Program for Northeast Region Eastern Rivers 

and Mountains Network Park Units. APHIS-WS was a cooperating agency in the preparation of this 

EA and FONSI/Decision (USDI 2004a) which analyzed the environmental effects of NPS participation in 

ORV programs on eight NPS units in the states of Pennsylvania and West Virginia in the effort of 

stopping the spread of a specific raccoon rabies variant or “strain” of the rabies virus and reducing or 

eliminating this strain of the virus from the eastern United States. The NPS determined the action would 

have a negligible impact on the quality of the human environment. 

EA, FONSI, and Decision - Oral Rabies Vaccination Program for Northeast Region Northern 

Coastal Barrier Network Park Units. APHIS-WS was a cooperating agency in the preparation of this 

EA and FONSI/Decision (USDI 2004b) which analyzed the environmental effects of NPS participation in 

ORV programs on eleven NPS units in the states of Maine, Maryland, Massachusetts, New York, New 

Jersey, and Virginia in the effort of stopping the spread of a specific raccoon rabies variant or “strain” of 

the rabies virus and reducing or eliminating this strain of the virus from the eastern United States. The 

NPS determined the action would have a negligible impact on the quality of the human environment. 

EA, FONSI, and Decision – Oral Rabies Vaccination Program for Northeast Region Temperate 

Network Park Units. APHIS-WS was a cooperating agency in the preparation of this EA and 

FONSI/Decision (USDI 2004c) which analyzed the environmental effects of NPS participation in ORV 

programs on six NPS units in the states of New Hampshire, New York, and Vermont in the effort of 

stopping the spread of a specific raccoon rabies variant or “strain” of the rabies virus and reducing or 

eliminating this strain of the virus from the eastern United States. The NPS determined the action would 

have a negligible impact on the quality of the human environment. 

EA, FONSI, and Decision – Oral Rabies Vaccination Program for Northeast Region Mid-Atlantic 

Network Park Units. APHIS-WS was a cooperating agency in the preparation of this EA and 

FONSI/Decision (USDI 2004d) which analyzed the environmental effects of NPS participation in ORV 

programs on 8 NPS Units in the states of Pennsylvania and Virginia as well as the Appalachian Scenic 

Trail located in the states of Connecticut, Georgia, Massachusetts, Maryland, Maine, North Carolina, 

New Hampshire, New Jersey, New York, Pennsylvania, Tennessee, Virginia, Vermont, and West 

Virginia in the effort of stopping the spread of a specific raccoon rabies variant or “strain” of the rabies 

virus and reducing or eliminating this strain of the virus from the eastern United States. The NPS 

determined the action would have a negligible impact on the quality of the human environment. 

EA, FONSI, and Decision – Oral Rabies Vaccination Program for Southeast Region Park Units. 

APHIS-WS was a cooperating agency in the preparation of this EA and FONSI/Decision (USDI 2004e) 

which analyzed the environmental effects of NPS participation in ORV programs on fifteen NPS units in 

the states of Alabama, Florida, Georgia, North Carolina, and Tennessee in the effort of stopping the 

spread of a specific raccoon rabies variant or “strain” of the rabies virus and reducing or eliminating this 
17

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

strain of the virus from the eastern United States. The NPS determined the action would have a negligible 

impact on the quality of the human environment. 

EA, FONSI, and Decision – Oral Rabies Vaccination Program for Big Bend National Park, 

Guadalupe Mountains National Park, and Amistad National Recreation Area in Texas. APHIS-WS 

was a cooperating agency in the preparation of this EA and FONSI/Decision (USDI 2003) which 

analyzed the environmental effects of NPS participation in ORV programs to eliminate or stop the spread 

of gray fox rabies on three NPS units in Texas. The NPS determined the action would have a negligible 

impact on the quality of the human environment. 

EA, FONSI, and Decision – Oral Rabies Vaccination Program for Palo Alto Battlefield National 

Historic Park in Texas. APHIS-WS was a cooperating agency in the preparation of this EA and 

FONSI/Decision (USDI 2007) which analyzed the environmental effects of NPS participation in ORV 

programs to eliminate or stop the spread of gray fox rabies on one NPS unit in Texas. The NPS 

determined the action would have a negligible impact on the quality of the human environment. 

1.9 AUTHORITIES 

Wildlife disease and damage management are based on interagency relationships, which require close 

coordination and cooperation because of related or overlapping authorities or legal mandates. The 

APHIS-WS National Rabies Management Program (NRMP) cooperates and coordinates closely with the 

United States Forest Service (USFS) and the Bureau of Land Management (BLM). Additionally, the 

APHIS-WS NRMP consults with the United States Fish and Wildlife Service (USFWS), the Tennessee 

Valley Authority (TVA), the United States Army Corps of Engineers (USACE), the United States Coast 

Guard (USCG), the Department of Defense (DoD), the National Aeronautics and Space Administration 

(NASA), the Federal Bureau of Investigation (FBI), the Bureau of Indian Affairs (BIA), and other 

agencies when necessary and as appropriate. Finally, the NRMP cooperates closely with state agencies 

such as the State Health and Wildlife Departments. 

1.9.1 Federal Authorities 

APHIS – Wildlife Services. USDA is authorized and directed by law to protect American agriculture 

and other resources from damage associated with wildlife. The primary statutory authorities for the 

APHIS-WS program are the Act of March 2, 1931 946 Stat. 1468; 7 U.S.C. 426-426b as amended, and 

the Act of December 1987 (101 Stat. 1329-331, 7 U.S.C. 426c). 

WS recognizes that wildlife is an important public resource greatly valued by the American people. By its 

very nature, however, wildlife is a highly dynamic and mobile resource that can damage agricultural 

resources, pose risks to human health and safety, and affect other natural resources. The WS program 

provides Federal leadership in helping to solve problems that occur when human activity and wildlife are 

in conflict with one another. 

The Act of September 25, 1981, as amended (7 U.S.C. Sec. 147b). This law authorizes the Secretary of 

Agriculture, in connection with emergencies which threaten any segment of the agricultural production 

industry of the U.S., to transfer from other appropriations or funds available to the agencies or 
18

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

corporations of USDA such sums as the Secretary may deem necessary, to be available only in such 

emergencies for the arrest and eradication of contagious or infectious diseases of animals. It is under this 

authority that funds from the federal Commodity Credit Corporation have been transferred to APHIS-WS 

to expend for the continuation and expansion of ORV programs in the states identified herein (65 FR 

76606-76607, December 7, 2000). 

Virus-Serum-Toxin Act (21 U.S.C. 151 et seq.). Vaccines shipped in or from the U.S. must be prepared 

under and cannot be imported without a USDA license. Federal regulations implementing the VirusSerum-Toxin Act (VSTA) (9 CFR 103.3) require authorization by APHIS before an experimental 

biological product can be shipped for the purpose of treating limited numbers of animals as part of an 

evaluation process. 

Public Health Service Act. CDC, located in Atlanta, Georgia, is an agency of the U.S. Department of 

Health & Human Services. CDC's mission is to promote health and quality of life by preventing and 

controlling disease, injury, and disability. CDC is authorized under 42 U.S.C. 241 to render assistance to 

other appropriate public authorities in the conduct of research, investigations, demonstrations, and studies 

relating to the causes, diagnosis, treatment, control, and prevention of physical and mental diseases and 

impairments of man. In addition, under 42 U.S.C. 243(a), the Secretary of Health & Human Services 

may assist states and their political subdivisions in the prevention and suppression of communicable 

diseases. 

National Forest Management Act of 1976 (16 U.S.C. section 2101 [note]). This law amended the 

Forest and Rangeland Renewable Resources Planning Act of 1974, which called for the management of 

renewable resources on national forest lands. The National Forest Management Act requires the Secretary 

of Agriculture to assess forest lands, develop a management program based on multiple-use, sustainedyield principles, and implement a resource management plan for each unit of the National Forest System. 

This Act is the primary statute governing the administration of national forests. 

Cooperative Forestry Assistance Act of 1978 (16 U.S.C. section 2101 [note]). This law authorizes the 

Secretary of Agriculture to assist in controlling forest insects and diseases directly on National Forest 

System lands and in cooperation on other federal and non-federal lands of all ownerships. 

U.S. Forest Service (USFS). Under the Act of March 2, 1931 (46 Stat. 1468; 7 U.S.C. 426-426b) as 

amended, and the act of December 22, 1987 (101 Stat. 1329-331, 7 U.S.C 426c), the USFS and the 

APHIS-WS, along with the states, cooperate to manage wildlife damage on National Forest System lands. 

Under the framework of an MOU, signed June 4, 2004, between the USFS and APHIS-WS, APHIS-WS 

is designated as the lead agency concerning animal damage and disease management activities on USFS 

lands. This includes a responsibility to maintain technical expertise in the science of wildlife damage 

management, control tools and techniques, conducting management programs, and complying with 

NEPA for APHIS-WS activities. The MOU directs the USFS to coordinate with APHIS-WS in the 

development and review of work plans governing APHIS-WS’ activities on NFS lands and to cooperate 

in APHIS-WS’ NEPA processes. 

1.9.2 State and Local Authorities 

Each of the states involved in APHIS-WS’ national ORV program, including NH, NY, OH, VT, and WV, 
19

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

the states involved in this proposed action, has a state agency or agencies with authority under state law 

to approve, conduct or coordinate rabies control programs. APHIS-WS involvement in rabies control in 

each state has previously occurred and, under the proposed action, would only occur in complete 

cooperation with the appropriate state agency(ies) and in accordance with state authorities as identified by 

those agencies. 

With regard to ORV programs, it is the cooperating states that exercise their authorities under state law to 

propose or approve the distribution of ORV baits onto lands owned or managed by a variety of entities 

including private persons, federal land management agencies [e.g., USDA Forest Service and others], 

state, county, and city governments, and American Indian Tribes. APHIS-WS would not be making the 

decision to distribute baits on the various land ownerships. Those decisions are made by the states. The 

proposed action assumes that ORV baits would be distributed under state authorities, consistent with 

pertinent property rights laws and regulations and would include acquiring permission from public land 

managers and American Indian tribes when appropriate.  

1.10 OTHER RELEVANT LAWS AND REGULATIONS

National Environmental Policy Act (NEPA) (42 U.S.C. 4321 et seq.). All federal actions are subject to 

NEPA (42 U.S.C. §§ 4321 et seq.). WS follows CEQ regulations implementing NEPA (40 CFR 1500 et 

seq.) and USDA (7 CFR 1b) and APHIS implementing regulation (7 CFR 372) as part of the decisionmaking process. These laws and regulations generally outline five broad types of activities to be 

accomplished as part of any project: public involvement, analysis, documentation, implementation, and 

monitoring. NEPA also sets forth the requirement that all major federal actions be evaluated in terms of 

their potential to significantly affect the quality of the human environment for the purpose of avoiding or, 

where possible, mitigating and minimizing adverse impacts. 

Pursuant to NEPA and CEQ regulations, this EA documents the analysis for potential impacts of a 

proposed federal action, informs decision-makers and the public of reasonable alternatives capable of 

avoiding or minimizing adverse impacts, and serves as a decision-aiding mechanism to ensure that the 

policies and goals of NEPA are infused into federal agency actions. This EA was prepared by integrating 

as many of the natural and social sciences as warranted, based on the potential effects of the proposed 

action. The direct, indirect, and cumulative impacts of the proposed action are analyzed. 

Endangered Species Act (ESA) (16 U.S.C. 1531 et seq.). It is federal policy, under the ESA, that all 

federal agencies shall seek to conserve threatened and endangered (T&E) species and shall utilize their 

authorities in furtherance of the purposes of the Act (Sec.2(c)). For actions that “may affect” listed 

species, APHIS-WS conducts Section 7 consultations with the U.S. Fish & Wildlife Service (USFWS) to 

ensure that "any action authorized, funded or carried out by such an agency . . . is not likely to jeopardize 

the continued existence of any endangered or threatened species . . . Each agency shall use the best 

scientific and commercial data available" (Sec.7(a)(2)). WS obtained a Biological opinion (BO) from the 

USFWS in 1992 describing potential effects on T&E species and prescribing reasonable and prudent 

measures for avoiding jeopardy (USDA 1997, Appendix F). 

National Historic Preservation Act (NHPA) of 1966 as amended (16 U.S.C. § 470). NHPA and its 

implementing regulations (36 CFR 800) require federal agencies to: 1) determine whether activities they 
20

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

propose constitute “undertakings” that can result in changes in the character or use of historic properties 

and, 2) if so, evaluate the effects of such undertakings on such historic resources and consult with the 

State Historic Preservation Office regarding the value and management of specific cultural, 

archaeological, and historic resources, and 3) consult with appropriate American Indian Tribes to 

determine whether they have concerns for traditional cultural properties in areas of these federal 

undertakings. 

ORV activities described under the proposed action (Section 1.4) do not cause major ground disturbance, 

do not cause any physical destruction or damage to property, do not cause any alterations of property, 

wildlife habitat, or landscapes, and do not involve the sale, lease, or transfer of ownership of any property. 

In general, such methods also do not have the potential to introduce visual, atmospheric, or audible 

elements to areas in which they are used that could result in effects on the character or use of historic 

properties. Therefore, the methods that would be used under the proposed action are not generally the 

types of activities that would have the potential to affect historic properties. If an individual activity with 

the potential to affect historic resources is planned under an alternative selected as a result of a decision 

on this EA, then site-specific consultation as required by Section 106 of the NHPA would be conducted 

as necessary. 

Executive Order on Environmental Justice. Executive Order (EO) 12898, Federal Actions to Address 

Environmental Justice in Minority Populations and Low-Income Populations requires federal agencies to 

analyze disproportionately high and adverse environmental effects of proposed actions on minority and 

low-income populations. APHIS-WS has analyzed the effects of the proposed action and determined that 

implementation would not have adverse human health or environmental impacts on low-income or 

minority populations. 

Executive Order on Protection of Children from Environmental Health and Safety Risks. 

Executive Order 13045 was passed to help protect children who may suffer disproportionately from 

environmental health and safety risks for many reasons. ORV activities as proposed in this EA would 

only involve legally available and approved methods that have been subjected to safety evaluations and 

testing. The analysis in Section 4.1.3 of this EA supports a conclusion of very low to no risk of adverse 

effects on children from the ORV baiting strategy. Implementation of the proposed action would not 

increase environmental health or safety risks to children, but would in fact reduce such risks by 

minimizing the potential for children to contract rabies. Children are particularly at risk from rabies 

because they are more prone to experiencing “undetected” or “unappreciated” exposures (Huntley et al. 

unpublished 1996) that do not lead to post-exposure vaccine treatments. Therefore, federal involvement in 

ORV programs is consistent with and helps to achieve the goals of EO 13045. 

Native American Graves Protection and Repatriation Act of 1990. The Native American Graves 

Protection and Repatriation Act requires federal agencies to notify the Secretary of the Department that 

manages the federal lands upon the discovery of native American cultural items on federal or tribal lands. 

Federal projects would discontinue work until a reasonable effort has been made to protect the items and 

the proper authority has been notified. 

Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 360). This law places administration of 

pharmaceutical drugs, including those used in wildlife capture and handling, under the Food and Drug 
21

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

Administration (FDA). 

Controlled Substances Act of 1970 (21 U.S.C. 821 et seq.). This law requires an individual or agency 

to have a special registration number from the federal Drug Enforcement Administration (DEA) to 

possess controlled substances, including those that are used in wildlife capture and handling. 

Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA). The AMDUCA and its 

implementing regulations (21 CFR Part 530) establish several requirements for the use of animal drugs, 

including those used to capture and handle wildlife in rabies management programs. Those requirements 

are: (1) a valid “veterinarian-client-patient” relationship; (2) well defined record keeping; (3) a 

withdrawal period for animals that have been administered drugs; and (4) identification of animals. A 

veterinarian, either on staff or on an advisory basis, would be involved in the oversight of the use of 

animal capture and handling drugs under the proposed action. Veterinary authorities in each state have 

the discretion under this law to establish withdrawal times (i.e., a period of time after a drug is 

administered that must lapse before an animal may be used for food) for specific drugs. Animals that 

might be consumed by a human within the withdrawal period must be identified; the Western Wildlife 

Health Committee of the Western Association of Fish and Wildlife Agencies has recommended that 

suitable identification markers include durable ear tags, neck collars, or other external markers that 

provide unique identification (WAFWA 2010). APHIS-WS establishes procedures in each state for 

administering drugs used in wildlife capture and handling that must be approved by state veterinary 

authorities in order to comply with this law. 

Wilderness Act of 1964 – An Act (Public Law 88-577; 88th Congress, S.4; September 3, 1964). The 

Wilderness Act allows federally owned lands meeting specific criteria to be designated as “wilderness 

areas.” The act prohibits and restricts certain uses of these designated lands. The act provides special 

provisions to allow certain activities to take place within designated wilderness areas such as the use of 

aircraft to control fire, insects, and diseases (Sec. 4 (d)). APHIS-WS obtains USFS Forest Supervisor or 

BLM State Director approval to conduct control activities in Wilderness areas where necessary. 

However, the proposed action will not occur on any Wilderness Area. 
22

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

CHAPTER 2: ISSUES AND AFFECTED ENVIRONMENT 

2.1 ISSUES 

In preparation for previous ORV EAs, APHIS-WS compiled issues from public input received in 

response to a Federal Register Notice (66 FR 13696-13700, March 7, 2001) and agency concerns 

discussed during scoping meetings held with state and local departments of health and the CDC. Many 

issues were discussed in previous EAs and FONSIs (USDA 2001a, 2002, 2003b, 2004c, 2007b, and 

2010), but the following issues were considered to be germane to the proposed action analyzed in this EA 

and are considered in detail in this EA: 

 Potential for adverse effects on target wildlife species populations. 

 Potential for adverse effects on nontarget wildlife species, including threatened and endangered 

species. 

 Potential for adverse effects on people, pets, and livestock that are exposed to or consume the vaccine 

laden baits. 

 Potential for ONRAB® to “revert to virulence” or recombine with other viruses and result in a virus 

that could cause disease in humans. 

 Potential for aerially dropped baits to strike and injure people or domestic animals. 

 Humaneness of methods used to collect wild animal species critical for timely program evaluation. 

2.2 OTHER ISSUES CONSIDERED BUT NOT ANALYZED IN DETAIL, WITH 

RATIONALE 

2.2.1 Potential for Drugs Used in Animal Capture and Handling to Cause Adverse Health Effects 

in Humans that Hunt and Eat the Species Involved 

Among the species to be captured and handled under the proposed action, this issue is expected to be of 

the most concern for raccoons and skunks which are hunted and sometimes consumed by people as food. 

Drugs used in capturing and handling raccoons for surveillance and monitoring purposes in rabies 

management programs include ketamine hydrochloride, xylazine (Rompun®, Bayer Health Care, 

Monheim, Germany), and a mixture of tiletamine and zolazepam (Telazol®, Wyeth Pharmaceuticals, Fort 

Dodge Animal Health, IA). Meeting the requirements of the AMDUCA (see Section 1.9) should prevent 

any significant adverse impacts on human health with regard to this issue. Standard operating procedures 

(SOPs) followed in each state include: 

 All drugs used in capturing and handling raccoons, coyotes, gray foxes, skunks, and other animals 

would be under the direction of state or federal veterinary authorities, either directly or through 

procedures agreed upon between those authorities and APHIS-WS. 
23

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

 As determined on a federal- or state-level basis by these veterinary authorities (as allowed by 

AMDUCA), ORV program participants may choose to avoid capture and handling activities that use 

immobilizing drugs within a specified number of days prior to the hunting or trapping season for the 

target species to avoid release of animals that may be consumed by hunters prior to the end of 

established withdrawal periods for the particular drugs used. However, capture and handling 

activities would likely extend into the hunting season during late summer/fall ORV baiting 

schedules. Therefore, target species would either be marked or euthanized if immobilizing drugs are 

used within 30 days of hunting or trapping seasons. These measures would be taken to avoid release 

of animals that could be consumed by hunters prior to the end of established withdrawal periods for 

the particular drugs used. 

 Animals that have been immobilized and released are ear tagged or marked in some way to alert 

hunters and trappers that they should contact APHIS-WS personnel before consuming the animal. 

By following these procedures in accordance with AMDUCA, rabies management programs would avoid 

any significant impacts on human health with regard to this issue. 

2.2.2 Potential for Drugs Used in Animal Capture and Handling to Cause Adverse Health Effects 

in Scavengers or other Nontarget Animals that May Consume the Species Involved 

Drugs used in the capturing and handling of raccoons, skunks, gray foxes, or coyotes for surveillance and 

monitoring purposes in the rabies management program include ketamine hydrochloride, xylazine, and a 

mixture of tiletamine and zolazepam. These drugs are generally injected intravenously or intramuscularly 

and, less-often, subcutaneously. Oral delivery of immobilizing drugs may be used to calm animals caught 

in traps. For example, oral delivery of ketamine can calm the animal enough to allow injection of 

additional drug via syringe (USDA 2001b). However, oral delivery is not recommended for anesthetizing 

the animal due to the much higher dosage required to compensate for the slower uptake rate and correct 

dosages cannot be guaranteed (USDA 2001b). 

APHIS-WS personnel would not release an animal until it has returned to full and normal function, 

thereby reducing its chances of succumbing to potential predators or other dangers. Most immobilizing 

drugs used, such as ketamine and xylazine, are metabolized and excreted within hours after the animal 

returns to full function (Dr. L. Bigler, New York State Animal Health Diagnostic Laboratory, pers. 

comm. 2004 as cited in USDA 2004c). In addition, reversal agents, such as yohimbine, may be used to 

rouse the animal more quickly. Therefore, if a previously immobilized animal dies in the field sometime 

later, even if a scavenging animal were to ingest the entire animal previously immobilized, the scavenger 

should suffer no adverse effects (Dr. G. Gathright, DVM, APHIS-WS, National Wildlife Research 

Center, pers. comm. 2004 as cited in USDA 2004c). Furthermore, the scavenger would be consuming the 

animal by oral route, thus requiring a much larger dosage of the drug. Immobilizing drugs would produce 

carcasses that are not considered toxic to scavengers (USDA 2001b). If an animal must be euthanized, 

APHIS-WS personnel would remove it from the field immediately, thereby eliminating the chance of 

scavengers finding the carcass. Due to these factors, immobilizing drugs will have no adverse effect on 

scavengers or predators that consume previously immobilized animals. 
24

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

2.2.3 Potential for Adverse Impacts on Wildlife from Aircraft Overflights Conducted in ORV 

Programs 

An issue that has arisen is the potential for low-level flights associated with ORV bait distribution to 

disturb wildlife, including T&E species, to the point that they are impacted. APHIS-WS uses aircraft in 

ORV bait distribution, and these aircraft typically fly at about 500 feet above ground level and in straight 

transects for many miles to distribute baits equally across the landscape. A number of studies have 

looked at responses of various wildlife species to aircraft overflights. The National Park Service (1995) 

reviewed studies on the effects of aircraft overflights on wildlife. The report revealed that a number of 

studies have documented responses by certain wildlife species that suggest adverse impacts could occur. 

Few, if any studies, have proven that aircraft overflights cause significant adverse impacts on wildlife 

populations, although the report stated it is possible to draw the conclusion that impacts to populations are 

occurring. The Air National Guard (ANG) concluded that military training flights which occur frequently 

and generate much more noise were not expected to cause adverse effects on wildlife after extensive 

review of numerous studies of this issue (ANG 1997a, 1997b). In general, it appears that the more 

serious potential impacts occur when overflights are frequent such as hourly and over long periods of 

time, which represents a chronic exposure. Chronic exposure situations generally involve areas near 

commercial airports and military flight training facilities. WS ORV bait distribution operations occur 

over the landscape , occur in any given area only for a short time period, and typically occur only once or 

twice per year in any given area. 

Several examples of wildlife species that have been studied with regard to low-level flights are available 

in the literature. Colonial waterbirds were reported that low-level overflights of 2-3 minutes in duration 

by a fixed-wing airplane and a helicopter produced no drastic disturbance of tree-nesting colonial 

waterbirds, and, in 90% of the observations, the individual birds either showed no reaction or merely 

looked up (Kushlan 1979). Conomy et al. (1998) quantified behavioral responses of wintering American 

black ducks (Anas rubripes), American wigeon (A. americana), gadwall (A. strepera), and American 

green-winged teal (A. crecca carolinensis) exposed to low-level flying military aircraft in North Carolina 

and found that only a small percentage (2%) of the birds reacted to the disturbance. They concluded that 

such disturbance was not adversely affecting the time-activity budgets of the species. Mexican spotted 

owls (Delaney et al. 1999) did not flush when chain saws and helicopters were greater than 110 yards 

away; owls flushed to these disturbances at closer distances and were more prone to flush from chain 

saws. Owls returned to their predisturbance behavior 10-15 minutes following the event and researchers 

observed no differences in nest or nestling success (Delaney et al. 1999). Johnson and Reynolds (2002) 

found that Mexican spotted owls showed only minor behavioral changes to F-16 fly-bys during training 

runs, but less behavioral changes than to natural occurrences. Andersen et al. (1989) conducted low-level 

helicopter overflights directly at 35 red-tailed hawk (Buteo jamaicensis) nests and concluded their 

observations supported the hypothesis that red-tailed hawks habituate to low level flights during the 

nesting period; results showed similar nesting success between hawks subjected to such overflights and 

those that were not. White and Thurow (1985) did not evaluate the effects of aircraft overflights, but 

found that ferruginous hawks (B. regalis) are sensitive to certain types of ground-based human 

disturbance to the point that reproductive success may be adversely affected. However, military jets that 

flew low over the study area during training exercises did not appear to bother the hawks, and nor did the 

hawks get alarmed when the researchers flew within 100 feet in a small fixed-wing aircraft (White and 
25

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

Thurow 1985). White and Sherrod (1973) suggested that disturbance of raptors by aerial surveys with 

helicopters may be less than that caused by approaching nests on foot. Ellis (1981) reported that five 

species of hawks, two falcons (Falco spp.), and golden eagles (Aquila chrysaetos) were incredibly 

tolerant of overflights by military fighter jets, and observed that, although birds frequently exhibited 

alarm, negative responses were brief and the overflights never limited productivity. 

Krausman et al. (1986) reported that only 3 of 70 observed responses of mule deer to small fixed-wing 

aircraft overflights at 150 to 500 feet above ground resulted in the deer changing habitats. They believed 

that the deer may have been accustomed to overflights because the study area was near an interstate 

highway that was frequently followed by aircraft. VerCauteren and Hygnstrom (2002) noted that when 

studying the efficacy of hunting to manage deer populations, that when deer were flown over during their 

censuses, they typically just stood up from their beds, but did not flush. In addition, WS aerial hunting 

personnel frequently observe deer and antelope standing apparently undisturbed beneath or just off to one 

side of aircraft. Krausman and Hervert (1983) reported that, in 32 observations of the response of bighorn 

sheep to low-level flights by small fixed-wing aircraft, 60% resulted in no disturbance, 21% in slight 

disturbance, and 19% in great disturbance. Another study (Krausman et al. 1998) found that 14% of 

bighorn sheep had elevated heart rates that lasted up to 2 minutes after an F-16 flew over at an elevation 

of 400 feet, but it did not alter the behavior of penned bighorns. Weisenberger et al. (1996) found that 

desert bighorn sheep and mule deer had elevated heart rates for 1 to 3 minutes and changed behavior to 

alerted for up to 6 minutes following exposure to jet aircraft. Fancy (1982) reported that only 2 of 59 

bison (Bison bison) groups showed any visible reaction to small fixed-wing aircraft flying at 200-500 feet 

above ground. These studies indicate that ungulates are relatively tolerant of aircraft overflights, even 

those that involve noise at high decibels. 

APHIS-WS has actively used fixed-wing aircraft and some helicopters at low levels for years in areas 

inhabited by wildlife in operational wildlife damage management. No known problems to date have 

occurred from APHIS-WS aircraft overflights on wildlife and the effects of these overflights were 

analyzed in detail in several APHIS-WS predator damage management EAs (e.g., USDA 2005b, 2006b). 

Overflights for the purposes of ORV bait distribution activities for this proposed action would only occur 

once or twice per year and aircraft would only fly quickly over any one point on the ground. The aircraft 

do not circle over areas repeatedly, but fly in straight “transect” lines for the purposes of bait distribution. 

The potential impact would be of short-term (only momentary) duration, on a local scale, with negligible 

intensity and should not add appreciably to the frequency of overflights. The addition of one more 

overflight per year for ORV bait distribution should not constitute a substantive increase in any effects 

that might occur as a result of overflights. Furthermore, the types of aircraft used in bait distribution, the 

DeHavilland (DHC-6) Twin Otter and Beechcraft King Air B200, meet all Federal Aviation Regulation 

(FAR) requirements regarding noise limits (FAR Part 36). No evidence has been found to indicate harm 

to nontarget wildlife, including bald eagles. In addition, the annual overflight is even less likely to 

adversely impact migratory birds if flights occur in the fall after the birds have dispersed. Thus, the shortterm duration, infrequency, and negligible intensity of flights over any given area, in addition to the 

tolerance of wildlife of such activity, indicates ORV program overflights would have a negligible adverse 

environmental impact on wildlife. Based on the above information and analysis, it is reasonable to 

conclude that the APHIS-WS ORV bait distribution program low-level flights should not cause any 
26

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

adverse impacts to nontarget wildlife, including T&E species. Therefore, this issue will not be considered 

further. 

2.2.4 Potential for ORV bait Distribution to Affect Organic Farming 

This issue concerns the potential for ORV baits dropped on crops and livestock operations certified as 

“organic” under federal regulations to affect the status of the organic certification of such farms. A 

concern was raised by farmers and livestock producers, as a result of APHIS-WS’ national ORV program, 

that they would not be able to sell, label, or represent their harvested crop or plant as organically produced 

if it had contact with the prohibited substance, which is the vaccine (V-RG in the case of the national 

ORV program and ONRAB® in the case of the proposed field trial) (7 CFR Part 205.672). The ORV 

baits to be used in the proposed field trial are comprised of partially hydrogenated vegetable shortening, 

Microbond® wax, stearine, icing sugar, vegetable oil, artificial marshmallow flavor, artificial sweet 

flavor, and a fat-soluble dye. The ONRAB® baits vaccine baits are all individually tested for leaks 

before leaving the manufacturing facility. The vaccine baits should remain intact when dropped out of 

airplanes, and thus are designed to resist breaking until an animal actually chews on them (G. Gifford, 

Canadian Food Inspection Agency, pers. comm. to F. Lord, Canadian Food Inspection Agency. 2009) 

On April 15, 2003, the USDA-Agricultural Marketing Service (AMS) ruled that the V-RG ORV bait 

blocks on an organic operation would not have an adverse impact on organic operations (R. Mathews, 

National Organic Program, pers. comm., 2003). The USDA-AMS considers the ORV program to be an 

emergency disease treatment for the control of rabies, and as such, is addressed under National Organic 

Program (NOP) Section 205.672, Emergency Pest or Disease Treatment. The USDA-AMS determined 

that “...in the unlikely event that a bait block breaks and exposes a plant(s) to the vaccine, the organic 

producer can remove the affected plant(s) with no adverse effect on the operation’s certification. This 

would comply with NOP Section 205.672(a). The organic status of animals feeding on the ORV bait 

block and not penetrating that vaccine would not be adversely affected. In the unlikely event that an 

animal consumes the vaccine within the ORV bait block that animal would lose organic status as provided 

in NOP Section 205.672(b)”. The USDA-AMS believes there to be little chance that an organic animal 

would consume the vaccine within an ORV bait block; however to reduce the chances of livestock 

consumption, producers can relocate any bait found within an area containing livestock to a point outside 

of that area. The USDA-AMS agrees that this previous V-RG ruling still stands for the ONRAB® field 

trial (M. Bailey, National Organic Program, pers. comm., 2012). 

2.2.5 Potential for ORV to Cause Abortions in Cattle 

This issue was raised by a cattle producer in Ohio who reported an increase in abortions of pregnant cows 

following an ORV bait distribution project involving the V-RG vaccine and was addressed in previous 

ORV EAs (USDA 2010). It was determined that the increase in cattle abortions was coincidental and not 

related to V-RG ORV. 

ONRAB® was found to be safe in experimental studies in skunks as well as several nontarget species. A 

variety of domestic animal species have been included in safety studies on ONRAB®, including cows, 

horses, pigs, sheep, chickens, dogs, and cats (Knowles et al. 2009). No adverse reactions in the animals 

studied were found following oral inoculation with the experimental vaccine, while in most cases 
27

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

antibodies against the rabies viral protein were detected on day 28 post-exposure (CFIA 2008, 2010). 

Although all the animals were deemed to be clinically normal after ONRAB®, viral nucleic acids were 

detected in some tissues or feces of vaccinated animals, suggesting that ONRAB® was replicating or 

persisting in these hosts for a few weeks post-vaccination. Replication of adenovirus in 

immunocompromised animals such as nude mice or severe combined immunodeficient (SCID) mice did 

not appear to result in adverse reactions, but these animals failed to produce neutralizing antibodies 

against rabies due to their inherent immune deficiency. Collectively, these results indicate that ONRAB® 

may retain some replication capability in both healthy and immunocompromised animals, but does not 

cause adverse reactions (toxicity) in these animals (CFIA 2008, 2010). 

2.2.6 Potential Human Health Impacts in the Event of Human Consumption of Vaccinated 

Wildlife 

The issue expressed here is the potential to develop an adenovirus infection from eating a vaccinated 

raccoon or some other animal that has eaten one or more ORV baits. Much like vaccinia found in the VRG vaccine used in current ORV programs, ONRAB® is taken up by tissues of the oral cavity and 

pharynx. The virus will invade these cells and start the expression of the virus genes, including the rabies 

glycoprotein gene. While the virus is able to penetrate the cells and start the expression of early stage 

genes, it is unable to utilize the non permissive cells to express the late stage genes necessary for 

assembly and release of new infectious virus particles. Therefore the animal is able to mount an immune 

response to the rabies glycoprotein and other early stage proteins, but new infectious particles are not 

released and further infection of other cells does not take place (A. Beresford, Artemis Technologies, Inc. 

pers. comm. 2011). Those particular tissues are rarely consumed by humans, but if they were, they would 

most likely be cooked which would kill the virus. 

As suggested above, even if tissues containing virus were consumed by humans they would likely be 

cooked to a safe temperature. The literature indicates that exposure of adenovirus to temperatures greater 

than 56°C (133°F) results in reduction of infectivity. It is reported in Maheshwari et al. (2004) that 

exposure of Ad5 to temperatures greater than 70°C for longer than 20 minutes result in greater than eight 

log10 reduction in virus titer. 

Studies have been conducted at Artemis Technologies Inc. on the thermal stability of the ONRAB® 

construct at temperatures associated with certain food processing. Exposure of the ONRAB® virus to 

89°C (192°F) results in a loss of infectivity of more than 3 log10 (1000 fold reduction) in the first 30 

seconds of exposure, followed by a linear phase of approximately 0.6 log10 reduction per minute (A. 

Beresford, Artemis Technologies Inc., pers. comm. 2011). 

Therefore, the potential for adverse health effects from consuming animals that have eaten ORV baits 

should be negligible. 

2.2.7 Potential Impacts on Water Resources, including Aquaculture, Fish, Reptiles, and 

Amphibians 

The concern here is for potential impacts of unconsumed ONRAB® vaccine and baits adversely 

impacting ground and surface water resources and aquaculture through direct and indirect exposure. 

Baits that are not consumed may remain in the environment for several months after placement, which is 
28

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

dependent upon environmental conditions (precipitation, temperature, etc.) and the physical condition of 

the baits. Potential impacts to water resources are greatly reduced by the limited number of baits dropped 

in a specific area, the biodegradability of the vaccine liquid and baits, the high consumption rate of ORV 

baits by animals, the safety and efficacy of the vaccine, and the Standard Operating Procedures (SOPs) 

that are used when dropping baits near a large water source. This conclusion is based upon: 

 The possibility of a large quantity of ORV baits being exposed to a specific water resource is 

extremely low due to the bait distribution densities used by the program. Under the proposed 

program, ORV baits would be distributed from aircraft at an average density of 75 baits per km2

. 

 The ONRAB® bait matrix contains a mixture of vegetable shortening, Microbond® wax, stearine, 

icing-sugar, vegetable oil, artificial marshmallow flavor, artificial sweet flavor, and a fat-soluble food 

dye. Therefore, the unconsumed bait material would biodegrade when exposed to the environment 

causing little to no effect on water resources. 

 Adenoviruses are extremely host specific. Except under certain laboratory conditions, a human 

adenovirus will not replicate in anything other than human cells (A. Beresford, Artemis Technologies 

Inc., pers. comm. 2011) Therefore, target and non-target species exposed to ONRAB® will not 

support active replication of the virus and, as such, ONRAB® is not expected to cause any adverse 

effects on fish, reptiles, amphibians, or any invertebrate species should any members of these species 

groups consume ONRAB® baits or otherwise be exposed to the vaccine. 

 Although the vaccine virus is stable at room temperature for days to weeks (Artemis 2010), the ORV 

baits are readily taken up and consumed by animals, thereby limiting long term exposure to the 

environment. The likelihood of a bait being consumed is dependent upon several factors including 

animal population densities (target and non-target species), bait preference, and the availability of 

alternative food sources. In field tests conducted in the U.S., the majority of ORV baits have been 

consumed within the first 7 to 14 days after placement, with reports of up to 100 percent of the baits 

being consumed within a 7 day period (Farry et al. 1998, Hable et al. 1992, Hadidian et al. 1989, 

Hanlon et al. 1989, Linhart et al. 1994, Steelman et al. 2000, USDA 1995). 

In regard to ONRAB® bait distribution in New Brunswick, Canada, the New Brunswick Department of 

Health (NBDOH) requested an exemption to the Wellfield and Watershed Protection Area Designation 

Orders. In New Brunswick, the Minister of the Environment issues Designation Orders under the Clean 

Water Act (1989) to establish Wellfield and Watershed Protected Areas. Wellfield and Watershed 

Protected Area Designations are the primary source water protection tool in New Brunswick. In their 

response granting this exemption, the New Brunswick Department of Environment (NBDOE) found that 

the health risks associated with the placement of ONRAB® vaccine baits is minimal and that the potential 

for human exposure is low. Further, the NBDOE found that chlorination of municipal water supplies 

referenced by the NBDOH is effective at inactivating the adenovirus (R. Haché, New Brunswick 

Department of Environment, pers. comm. to S. Griffin, 2008). 

Program SOPs limit the possibility of ORV baits being directly dropped into large water sources such as 

rivers, lakes, and reservoirs. When the aircraft approaches a large body of water the bait dropping 

equipment is shut off approximately 0.25 mile from the water source to reduce the possibility of ORV 
29

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

baits falling into the water. Nevertheless, due to changing environmental conditions and the limited 

possibility of human error when operating the bait dropping equipment, there is the possibility that baits 

may inadvertently be dropped into a body of water. Exposure of ONRAB® vaccine into a water source 

from an intact bait and sachet is highly unlikely. The vaccine is enclosed in a sealed sachet, thereby 

limiting the possibility of the vaccine liquid being directly released into a water source. 

The above information indicates that the risks of ONRAB® vaccine and baits pose no more than a 

negligible threat to groundwater or surface water through direct or indirect means. 

2.2.8 Effects on Carnivore Populations in the Absence of Rabies 

Concern has been expressed that specific carnivore populations, namely raccoons, may increase in the 

absence of the rabies virus as a mortality factor, leading to adverse effects on prey populations such as 

T&E species. The raccoon strain of the rabies virus has only relatively recently spread, and is 

contiguously distributed from Alabama to Maine, west to the eastern Ohio border with Pennsylvania 

(Krebs et al. 2000, Kemere et al. 2001). Translocation of rabid raccoons to the mid-Atlantic states has 

been implicated in establishing a new rabies foci in the mid-1970’s (Krebs et al. 1999), from which rabies 

has spread through the raccoon population at rates averaging about 30 miles/year (48.3 km/year) (Kemere 

et al. 2001). 

Rabies is only one of several diseases that may help regulate carnivore populations. In fact, the article by 

Guerra et al. (2003) does not support the idea that rabies exists specifically to control raccoon 

populations. Guerra et al. (2003) state that after an initial peak, populations approach lower ‘steady-state’ 

conditions. Based on surveillance data, raccoon rabies did not exist outside a focus area in Florida before 

the 1940s. Therefore, elimination of raccoon rabies should merely create the scenario before raccoon 

rabies spread in the eastern U.S. (Rupprecht and Smith 1994). No evidence exists that the carrying 

capacity for raccoons could be increased by the implementation of ORV programs compared to 

population levels before the introduction of rabies (C. Rupprecht, CDC, pers. comm. 2003 as cited in 

USDA 2004c). 

Prior to the introduction of raccoon rabies into the mid-Atlantic region in the late 1970’s, canine 

distemper was considered a primary disease mortality factor in raccoons, gray foxes, and skunks (Roscoe 

1993, Davidson et al. 1992). The epizootiology of canine distemper in raccoons in New Jersey and 

Florida has been characterized by outbreaks at the end of the mating season in March and with increased 

movements of young in September (Roscoe 1993, Hoff et al. 1974). Because of the cyclic nature of 

canine distemper outbreaks (4 year intervals), the wide distribution of canine distemper cases, and the low 

incidence of the disease between epizootic peaks in New Jersey, Roscoe (1993) proposed an enzootic 

status for canine distemper for raccoons that becomes epizootic when raccoon densities reach high levels. 

Evans (1982) found that 50 to 90 percent of raccoons and gray foxes may be incapable of producing 

protective levels of antibodies against the canine distemper virus, implicating it as a potentially important 

disease mortality factor. Davidson et al. (1992) diagnosed canine distemper in 78 percent of gray foxes 

studied in the southeastern U.S. and found canine distemper to be more significant as a mortality factor 

for gray foxes than all other infectious and noninfectious diseases combined. Roscoe (1993) reported that 

the effects of canine distemper on raccoon populations may diminish if raccoon rabies spreads and that 

concurrent canine distemper and rabies epizootics may become more common. The dynamics of 
30

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

sympatric rabies and canine distemper are not well understood; however, rabies may compensate for 

deaths that would have historically occurred due to canine distemper infection. Important attributes of 

canine distemper include that it is not a zoonotic disease like rabies and, historically, it has been 

implicated as a virus of importance to carnivore mortality. 

2.2.9 Effects of Nontarget Consumption of ORV Baits on Program Effectiveness 

Consumption of ORV baits by nontarget species is not expected to impact program effectiveness. As 

described in Section 1.1.3, baits are developed to attract target species. The use of target-preferred baits 

increases the likelihood of the target species consuming the baits prior to the discovery of baits by 

nontarget species. Furthermore, bait distribution densities are developed to compensate for the uptake of 

baits by nontarget species. Baits are distributed at densities that allow raccoons, gray foxes, and coyotes 

the opportunity to find intact baits. It has been determined, based upon the success of previous ORV bait 

distribution activities, that baits should be disbursed at an average density of 27 baits per km2 (69/mi2) in 

the coyote rabies zone and 39 baits per km2

 (100/mi2) the gray fox rabies zone in Texas. Baiting density 

averages 75 baits per km2

 (194/mi2) in eastern states where raccoon rabies is targeted. In addition, 

surveillance activities have been and continue to be conducted to assess aerial or ground ORV baiting 

efficacy, summer versus fall baiting schedules, and seasonal raccoon movement in a number of states. 

Numerous density studies also continue to be conducted in the majority of participating states to 

determine raccoon densities in relation to habitat, elevation, and numbers of baits distributed. In areas 

where raccoon densities are low, bait distribution numbers may be reduced (USDA 2011c). 

2.2.10 Effects of Global Warming, Habitat Loss, and Pollution on Wildlife Populations 

Program activities likely to result from the proposed APHIS-WS ORV field trials would have a negligible 

effect on atmospheric conditions including the global climate. Meaningful direct or indirect emissions of 

greenhouse gasses would not occur as a result of the proposed action. The proposed action would meet 

the requirements of applicable Federal laws, regulations, and Executive Orders including the Clean Air 

Act and Executive Order 13514. 

2.3 AFFECTED ENVIRONMENT 

This section presents some descriptive information on the environment of the area that may be affected by 

the proposed action. Other descriptive aspects of the affected environment are included in Chapter 4 in 

the analysis of effects which is based on environmental and other types of issues identified in Section 2.1. 

The area of the proposed action includes the states of New Hampshire, New York, Ohio, Vermont, and 

West Virginia, including portions of NFS lands, but excluding Wilderness Areas, where raccoon rabies 

outbreaks are expected to occur. ORV baiting programs using alternative rabies vaccines are currently or 

are expected to be conducted in these areas. Currently, cooperative rabies surveillance activities are 

conducted in the aforementioned states and would continue under the proposed action. 

The potential area involved in the ORV program field trial may cover several land ownership types and 

diverse land uses, including cultivated agricultural lands, forests, meadows, wetlands, pastures, and 

developed lands. Aerial distribution of ORV baits would avoid urban and suburban areas that support 

high human population densities, as well as lakes and rivers. Aerial distribution of baits would primarily 
31

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

target rural areas as well as known areas of suitable target species habitat. When aerial distribution by 

fixed-wing or helicopter aircraft is not practical, baits would be distributed by careful hand placement to 

help minimize contact by humans, pets, and other domestic animals. 

Figures 1-3, 1-4, 1-5, and 1-6 show the areas within the proposed states where APHIS-WS would 

participate in ORV field trials under the proposed action and the approximate V-RG ORV bait 

distribution zones. In addition, the ORV bait dispersal areas are also the primary expected areas where 

assistance by APHIS-WS is expected to be requested to collect blood, tooth and other biological samples 

from target animals for monitoring and surveillance. 

“Major Habitat Types” as described by Ricketts et al. (1999) that are found within the proposed project 

location are: Temperate Broadleaf and Mixed Forests (NH, NY, OH, VT, and WV). Appendix F shows 

the “ecoregions” (i.e., broadlevel ecosystems) that occur in the potentially affected states (Bailey 1995). 

Table 2-1 shows some descriptive statistics for the four states proposed for the ONRAB® field trial. 

These states contain about 10.8% of the U.S. resident population and possess average state population 

densities that range from about 77.1to 411.2 people per mi2

. Rural area (i.e., non-developed) averages 

89% for the proposed states. Population densities in rural areas are much lower than the statewide 

average figures shown. 

Table 2-1. Some Descriptive Statistics of States Proposed for ONRAB® Field Trials by APHIS-WS (data from USDC 2012a, 2012c; 

USDA 2009b, 2011d) 

State Resident 

Population 

from 2010 

Population 

per sq 

mile from 

2010 

% popn. in 

nonmetropolitan 

areas from 

2000 

Popn. of 

nonmetropolitan 

areas 

(1000s) 

from 2000 

Total nonFederal 

area (1000 

acres) 

from 2007 

Developed 

nonFederal 

area (1000 

acres) 

from 2007 

Rural 

nonFederal 

area (1000 

acres) 

from 2007 

% rural 

area from 

2007 

Land in 

farms 

(mil. 

acres) 

from 

2010 

National 

Forest 

Land 

(1000 

acres) 

from 2011 

Total area 

owned by 

federal 

govt. 

(1000 

acres) 

from 2007 

% total area 

owned by 

federalgovt. 

from 2007 

NH 1,316,470 147.0 40.5% 503 4,941.6 695.5 4,246.1 85.9% <0.5 763.2 12.8% 

NY 19,378,102 411.2 12.5% 2,374 29,865.6 3,793.9 26,071.7 87.3% 7 16 205.3 0.7% 

OH 11,536,504 282.3 22.6% 2,571 25,663.0 4,140.3 21,522.7 83.9% 14 241 373.3 1.4% 

VT 625,741 67.9 61.8% 376 5,469.1 393.2 5,075.9 92.8% 1 401 422.6 6.9% 

WV 1,852,994 77.1 53.9% 976 14,115.7 1,079.5 12,964.1 91.8% 4 1,045 1,211.9 7.8% 

The field trial area will be located in northwestern New Hampshire, northeastern New York, northeastern 

Ohio, northern Vermont, and south-central West Virginia (see figures 1-3, 1-4, 1-5, and 1-6). Human 

population density in the specific field trial area is variable, ranging from a relative low of 9.5 people/mi2 

in Essex County, VT to as high as 2,800 people/mi2 in Cuyahoga County, OH. In general, larger 

population concentrations occupy major towns and along highways, while other areas, including public 

and private forest, may be largely uninhabited. 

Chapter 4 contains further information on the affected environment with respect to target and nontarget 

species, including T&E species. 
32

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

CHAPTER 3: ALTERNATIVES 

3.1 ALTERNATIVES CONSIDERED, INCLUDING THE PROPOSED ACTION 

Alternative 1. Current Action (the No Action Alternative). The “No Action” alternative is a 

procedural NEPA requirement (40 CFR 1502.14 (d)), is a viable and reasonable alternative that could be 

selected, serves as a basis for comparison with the other alternatives, and can be defined as the 

continuation of the current management practices (CEQ 1981). 

This alternative would involve the use of federal funds to continue ONRAB® field trials in West Virginia 

under the authority of the appropriate state agencies and to evaluate the immunogenic characteristic of 

ONRAB® for wildlife rabies under limited field conditions. Under this alternative APHIS-WS would 

also assist in monitoring and surveillance efforts by capturing and releasing or killing target species for 

purposes of obtaining biological samples. 

Alternative 2. Proposed Action (the Preferred Alternative). Under this alternative APHIS-WS would 

use federal funds to purchase ONRAB® oral vaccine baits and to participate in expanded ORV field trials 

involving the distribution of ONRAB® oral vaccine baits under the authorities of the appropriate New 

Hampshire, New York, Ohio, Vermont, and West Virginia state agencies and to evaluate the 

immunogenic characteristic of the ONRAB® vaccine for wildlife rabies under limited field conditions at 

sites listed in section 2.3. Under this alternative APHIS-WS would also assist in monitoring and 

surveillance efforts by capturing and releasing or killing target species for purposes of obtaining 

biological samples. 

Alternative 3. No ORV Field Trials. The alternative would imply no involvement by APHIS-WS in 

ORV field trials in the states identified in Section 1.4. Under this alternative, no APHIS-WS funds would 

be available for purchase ONRAB® ORV baits and no immunogenicity trials would be conducted. 

3.2 ALTERNATIVES CONSIDERED BUT NOT ANALYZED IN DETAIL, WITH 

RATIONALE 

3.2.1 Depopulation of Target Species 

This alternative would result in the lethal removal of raccoons, skunks, gray foxes and coyotes throughout 

the zones where outbreaks of the targeted strains of rabies are occurring or are expected to occur. The 

goal would be to achieve elimination of the rabies strains by severely suppressing populations of the 

target animal species over broad areas so that the specific strains of rabies could not be transmitted to 

susceptible members of the same species. This could theoretically stop the forward advance of the 

disease and potentially result in elimination of the particular rabies variants as infected animals die from 

rabies before they could transmit it to other members of the same species. 

Localized population reduction has been proposed as part of local programs to address raccoon rabies 

outbreaks as they are just beginning (Rosatte et al. 1997). This has been deemed necessary because by 

the time a suspected rabies case is confirmed through animal testing, other raccoons in the area have 

invariably been infected and are incubating the disease, at which point vaccination would not be effective 

for those individuals (Rosatte et al. 1997). 
33

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

Population reduction is often suggested as a method to control rabies in wildlife populations since the 

disease is density dependent (Debbie 1991). Bounty incentives, regulated hunting and trapping, 

ingestible poisons, and fumigation of dens have all been employed to control populations with varying 

levels of success. MacInnes (1998) reviewed some of the past efforts to control rabies with population 

reduction of carrier species and concluded that, with a couple of exceptions, most such efforts have failed. 

In some of the situations, it could not be determined whether an observed decline or disappearance of 

rabies cases was attributable to population control or to the disease simply reaching some unexplainable 

geographical limitation or just dying out on its own (MacInnes 1998). Also, population control as a 

strategy can be questionable because the leading edges of rabies outbreaks do not necessarily coincide 

with the edge of the range of the principal “vectors” (e.g., raccoons, gray foxes, and coyotes), nor are they 

always related to the population density of such vectors (MacInnes 1998). 

Hanlon et al. (1999) reviewed historical efforts to control rabies through population reduction and 

evaluated the potential for success with this strategy. Information and conclusions they presented are 

summarized as follows: 

Skunk rabies was successfully controlled in Alberta, Canada by population reduction (Pybus 1988). 

Success was attributed to a high level of effort during several years, the well-defined behavior of skunks 

in prairie habitats, and access to an effective method (Pybus 1988). Compensatory changes in carnivore 

reproduction (i.e., the tendency for larger litters and larger percentages of adult females to have litters) 

and dispersal (i.e., immigration of animals from surrounding uncontrolled populations) can limit the 

effectiveness of controlling population numbers of other species in different conditions (Clark and Fritzell 

1992, Thompson and Fleming 1994). 

Population reduction with toxicants as a broad scale control alternative for rabies is impractical. The only 

approved toxicants currently registered are sodium cyanide in the M-44 device (registered for zoonotic 

disease control involving wild canids), and carbon monoxide-producing gas cartridges that can be used to 

kill skunks, coyotes, and red foxes in dens. Currently, these methods are primarily used in limited areas 

of the western U.S. for livestock protection. Presently, population reduction is most likely to be publicly 

accepted and effective in localized or site-specific scenarios in the U.S. (e.g., reducing the density of 

raccoon populations in parks where visitors could potentially come into contact with rabid animals). 

Population reduction using strychnine baits was successful in stopping the spread of rabies in foxes in 

Denmark (Gaede 1992). However, carcass recovery statistics indicated nontarget species [498 martens 

(Martes sp.), twelve European badgers (Meles meles), and four domestic dogs] were killed in slightly 

greater numbers than the targeted red foxes (n=482). The number of rabies cases declined sharply and the 

country has reportedly remained free of terrestrial rabies since 1982 (Gaede 1992). Broad scale 

population control with toxicants is most likely politically infeasible in the U.S. due to opposition by the 

public and state wildlife agencies. 

This alternative was not considered in detail because it would be impractical to obtain approval from the 

many landowners on whose properties the lethal control methods would have to be conducted. The 

greatest difficulty with population reduction as a strategy for reducing or eliminating rabies is that the 

high level of effort must be maintained almost indefinitely and would also undoubtedly be opposed by 

most members of the public (MacInnes 1998). Population suppression can be a challenge to maintain in 
34

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

many situations due to immigration (of other members of the same species from surrounding populations) 

and possibly compensatory reproduction (i.e., larger litters and greater percentages of females breeding 

following population reduction) (Clark and Fritzell 1992, Connolly and Longhurst 1975). These factors 

can mean local populations can recover to their previous levels within a year, thus requiring annual or 

more frequent suppression efforts to maintain such populations at low levels. Nevertheless, temporary 

localized population suppression activities could be conducted in an integrated program of ORV use as 

part of the proposed action, but such activities, if conducted at all, would be expected to occur as a part of 

contingency actions in response to a breach in a vaccination barrier. APHIS-WS has covered predator 

removal including to control disease, but mostly to resolve damage associated with them to resources 

such as livestock, in other EAs for Texas, New Mexico, and Arizona (Predator Damage Management 

EAs) and some eastern states for raccoons (APHIS-WS EAs can be found at 

http://www.aphis.usda.gov/wildlife_damage/ nepa.shtml). 

3.2.2 Population Control through Birth Control 

Under this alternative, APHIS-WS would provide funds or operational assistance to implement one or 

more methods to control populations of the target species by reducing reproduction. Such methods could 

involve live capture and surgical sterilization [reviewed by Kennelly and Converse (1997)], the use of 

chemical reproductive inhibitors placed out in baits or delivery devices (Balser 1964, Linhart et al. 1968), 

or the application of immunocontraception strategies (i.e., vaccines that can cause infertility in treated 

animals). 

The suppression of reproduction over time would eventually reduce the size of target species populations 

and lead to a reduction in the potential for the spread of rabies by reducing the chances of contact between 

infected and healthy animals. However, this approach would do nothing in the short term to reduce the 

risk of rabies spread in the existing populations, since those animals would continue to be present and 

capable of contracting and passing on the disease. Therefore, this type of strategy would be viewed as a 

long-term remedy for stopping rabies spread. It would probably not be useful in meeting the immediate 

needs for stopping a localized outbreak of rabies that occurs beyond designated ORV baiting zones. 

Live capture and surgical sterilization of whole local populations of animals would be extremely 

expensive, time-consuming, and difficult to achieve. Considerable expense would be involved in 

employing experienced and qualified veterinarians to perform large numbers of surgical procedures on 

captured animals. From a rabies control standpoint, if all or nearly all of a local population could be live 

captured, it would be more effective and less costly to administer rabies vaccinations by injection, which 

is already considered as Alternative 3 in USDA 2010. 

Immunocontraception is a potentially useful concept for mammalian population suppression but is still in 

the early stages of research and development (Bradley 1995, Miller 1997). Genetically engineered 

vaccines that cause a target species to produce antibodies against its own sperm or eggs or that affect 

reproductive hormone functions have been produced (Miller 1997). Several logistical concerns still 

would need to be addressed before this method could be applied successfully in the field. These concerns 

include: 1) durability of the contraceptive vaccines in baits after distribution in the field; and 2) the 

limitation of some current vaccine designs that require baiting an animal population twice, about one 

month apart, to successfully treat individual wild animals (Miller 1997). Furthermore, it is likely that a 
35

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

greater proportion of the population would have to be treated with contraceptive vaccines than with rabies 

vaccines in order to achieve effective rabies control. Thus, achieving effective control would be more 

costly and difficult under this alternative than under ORV programs (C. MacInnes, Ontario Ministry of 

Natural Resources, pers. comm. 2001 as cited in USDA 2001a). In addition, several environmental 

concerns regarding this strategy still need to be addressed, including safety of the proposed genetically 

engineered vaccines to humans, other wildlife species, and even nontarget members of the target species 

(e.g., juveniles) that might consume baits (Miller 1997, Guynn 1997, Hanlon and Rupprecht 1997). 

No contraceptive agents are currently registered for use on raccoons, gray foxes, or coyotes and, thus, are 

not legal for use. For all of the above reasons, birth control strategies to control rabies will not be 

considered further. 

3.2.3 Employ Other Types of ORV Instead of the ONRAB® Vaccine 

Under this alternative, APHIS-WS would provide funds to purchase and use “modified-live-virus” (i.e., 

“attenuated” or weakened strains that have been shown to have little chance of causing rabies in treated 

animals), “killed-virus” (i.e., “inactivated” virus) oral vaccines, or recombinant vaccines such as the VRG vaccine in ORV baits. Modified-live-virus vaccines include those that have been used in the past in 

the U.S. to vaccinate domestic animals by injection. Oral baits that employed several strains of these 

types of virus vaccines have been investigated and used in Europe to stop the spread of rabies in red foxes 

(Flamand et al. 1993, Artois et al. 1993, Artois et al. 1997). They have also been tested in red foxes in 

Canada (Lawson et al. 1989, Lawson et al. 1997), and in red foxes and raccoons in the U.S. (Rupprecht et 

al. 1989, Rupprecht et al. 1992c). 

The primary concern with attenuated or “live” virus vaccines (e.g., SAD and ERA) is that they can 

sometimes cause rabies (Flamand et al. 1993, Pastoret et al. 1992). Flamand et al. (1993) reported that 

one strain used widely in oral baits in Europe to vaccinate wild red foxes in the 1970s could cause rabies 

in rodents when injected and that the ability to cause rabies in nontarget animals by other modes (i.e., oral 

administration) could not be ruled out. Previously used attenuated strains are also “heat sensitive” which 

can limit their use in warmer seasons or climates (Pastoret et al. 1992). These types of safety concerns 

with attenuated rabies virus vaccines have been sufficient to prevent their approval for use in the U.S. 

(Rupprecht et al. 1992c). 

The Street Alabama Gif 2 (Rabigen® SAG2, Virbac S.A., Carros, France) vaccine, itself a live 

“attenuated” rabies vaccine, shows great promise both in terms of safety and efficacy in multiple species. 

Unlike its predecessors, SAD and Era, SAG2 is a more highly attenuated virus strain and has been found 

to be completely safe for mice, wild rodents, and in more than 35 other nontarget species (Masson et al. 

1996, Follman et al. 1996, Bingham et al. 1997, Aubert. Unpublished, Bingham et al. 1999, Rupprecht et 

al. 1998, Fekadu et al. 1996, Garniere. Unpublished ). In contrast to traditional modified-live rabies virus 

vaccines, the SAG2 virus does not cause rabies when inoculated intramuscularly and intracerebrally in 

adult laboratory mice (Hanlon et al. 2002). SAG2 is a double mutant and remains avirulent after three 

successive passages in suckling mouse brain or after ten successive cycles of multiplication in cell culture 

(Lafay et al. 1994). However, SAG2 is also not licensed for use in North America. 

“Inactivated” virus or “killed-virus” rabies vaccines are safer than “live” vaccines in that they cannot 
36

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

cause rabies. This type of vaccine was found to be less effective in causing immunity when delivered into 

the intestinal tract in foxes (only 30 percent effective in test animals) and took two doses to cause 

immunity in the foxes that were successfully immunized (Lawson et al. 1989). Also, the amounts of virus 

particles that would have to be ingested in oral baits by wild carnivores to effectively vaccinate them 

would be 100 to 1000 times the amount of the live-attenuated virus particles required (Rupprecht et al. 

1992c). To manufacture vaccines with these amounts would likely be cost-prohibitive (Rupprecht et al. 

1992c). 

The recombinant V-RG vaccine has been used throughout the U.S. since 1990 and is currently the only 

licensed oral rabies vaccine in the U.S. The nature of the recombinant virus used in the V-RG vaccine is 

such that it cannot cause rabies, although the vaccinia virus portion of the V-RG vaccine has been 

recognized as having the potential to cause infections to persons exposed to the vaccine. However, of the 

more than 120 million baits distributed by ORV programs in the U.S., only 2 known adverse reactions 

have been reported (USDA 2010). 

Despite the increased safety of the V-RG vaccine, it remains limited in its efficacy among multiple 

species, including skunks and mongoose. The V-RG vaccine does not produce significant detectable 

virus neutralizing antibodies in skunks, a major terrestrial reservoir for rabies (based on seroconversion 

from field samples) (USDA 2010b). The majority of spillover infections from raccoons are into skunks 

(predominantly Mephitis mephitis) and this species may have a role in maintaining the raccoon rabies 

variant within ORV zones (Blanton et al. 2011). 

ONRAB® has been used in field trials in Canada since 2006 (Rosaette et al. 2009), producing both 

efficacious and safe results. For these and the above reasons, ONRAB® has been chosen for use in 

APHIS-WS’s ORV field trials. 

3.3 SOPS TO MINIMIZE POTENTIAL IMPACTS OF THE RABIES ORV FIELD TRIAL 

APHIS-WS has adopted Standard Operating Procedures (SOPs) that serve to prevent, reduce, or 

compensate for negative impacts that otherwise might result from an action. The current ORV program 

and the West Virginia ONRAB® field trial use many such SOPs that would be incorporated into the 

expanded field trial activities. Many APHIS-WS SOPs are discussed in depth in USDA (1997, Chapt. 5). 

The key SOPs are incorporated into both action alternatives (1 and 2) as applicable. Most SOPs are 

instituted to abate specific issues while some are more general and relate to the overall program. SOPs 

include those recommended or required by regulatory agencies such as EPA, and these are listed where 

appropriate. Additionally, specific measures to protect resources such as T&E species that are managed 

by other agencies (USFWS and State Departments of Wildlife) are included in the lists below. 

 Public information, education, and media announcements would be made available to inform the 

public about ORV bait distribution activities in each county before they occur. APHIS-WS would 

coordinate with the appropriate state agency involved in the ORV program on preparing leaflets, 

posters, press releases, or other media to distribute to the public. Leaflets and posters would be 

posted in schools, hospitals, campgrounds, visitor centers, and state and county public agency offices. 

Notification of ORV bait drops would be sent to the state police, state emergency management 

associations, county hazardous materials coordinators, county cooperative extension agents, state and 
37

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

federal correctional facilities, wildlife rehabilitators, and medical and veterinary facilities within the 

ORV area informing them of the program and providing information about the ORV bait and vaccine 

and potential exposure issues. 

 Toll-free telephone numbers would be advertised in the media and on web sites for people to call for 

answers to questions. 

 Should a human exposure to the ONRAB® vaccine occur, that person would be referred to their 

primary care physician or local public health official as appropriate. In the unlikely event of an 

adverse reaction to the Ad5 virus, local health officials may engage with the CDC for diagnostic 

confirmation and consultation (C. Rupprecht, CDC, pers. comm., 2011). 

 Bait distribution navigators would be trained to avoid dropping baits on people or structures. During 

aerial bait drop operations, the bait dispensing equipment is temporarily turned off over human 

dwellings, cities, towns, greenhouses, certain sensitive domestic animal pens, and when people are 

observed below. 

 APHIS-WS personnel would adhere to air safety standards. 

 ORV baits would not be distributed by aircraft within 0.25 miles of large water bodies to reduce the 

potential of baits entering the water source. 

 APHIS-WS personnel would be trained in hand distribution of baits to avoid properties with greater 

risk of human or pet encounters with baits. 

 Labels would be placed on each ORV bait, instructing persons not to disturb or handle them. Labels 

would contain a toll-free telephone number to call for further information and guidance in the event 

of accidental exposure to the vaccine (see Figure 1-1 in Chapter 1). 

 Methods used to capture raccoons, skunks, and other target species would mainly involve the use of 

cage traps; however, other methods such as snap traps may be used for small mammal surveys. 

Animals caught in cage traps that are killed for monitoring and testing purposes, local depopulation, 

or per cooperating landowner’s request would be euthanized in accordance with APHIS-WS policy in 

a manner as humane as allowable under the circumstances. 

 Capture devices would be checked on a daily basis. 

 Field personnel involved in trapping and handling animals for monitoring and surveillance purposes 

would be immunized against rabies and tetanus. 
38

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

 All drugs designated for capturing and handling raccoons and other animals would be used under the 

direction of state or federal veterinary authorities, either directly or through procedures agreed upon 

between those authorities and APHIS-WS. 

 Monitoring and surveillance activities may extend into the hunting season during late summer/fall 

ORV field trial baiting schedules. Therefore, target species would either be ear tagged, marked in 

some other way, or euthanized if capture and handling activities that utilize immobilizing drugs are 

used within 30 days of hunting or trapping seasons. These measures would be taken to avoid release 

of animals that may be consumed by hunters prior to the end of established withdrawal periods for the 

particular drugs used. Most animals administered immobilizing drugs, however, would be released 

well before state controlled hunting/trapping seasons, which would give the drug time to completely 

metabolize out of the animals’ systems before they might be taken and consumed by humans. 

3.3.1 Monitoring 

APHIS-WS, in coordination with the appropriate agencies, will monitor the program that results from this 

EA. The impacts discussed in this EA would be monitored and used in two ways: 

1) APHIS-WS would determine if any additional information that arises subsequent to a NEPA decision 

from this EA would trigger the need for additional NEPA compliance. APHIS-WS would review 

program results and related NEPA documents annually, or as needed, to ensure that the need for 

action, issues identified, alternatives, regulatory framework, and environmental consequences are 

consistent with those identified in the final NEPA documents. 

2) APHIS-WS would monitor impacts on target and nontarget wildlife populations through its 

Management Information System (MIS) database. The MIS information would be used to assess the 

localized and cumulative impacts of the program on wildlife populations. APHIS-WS provides 

detailed information on animals removed to the involved state agencies to assist those agencies with 

managing species and resources under their jurisdiction. 
39

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

CHAPTER 4: ENVIRONMENTAL CONSEQUENCES 

This chapter analyzes potential environmental consequences using Alternative 1 (the current action) as 

the baseline for comparison with the other alternatives to determine if the real or potential impacts are 

greater, lesser or the same. Table 4-2 at the end of this chapter summarizes a comparison of the issues 

and impacts to each alternative. 

The following resource values within the states are not expected to be negatively impacted by any of the 

alternatives analyzed: soils, geology, minerals, floodplains, wetlands, visual resources, air quality, aquatic 

resources and range. These resources will not be analyzed further. 

Other than minor uses of fuels for motor vehicles and other materials, there are no irreversible or 

irretrievable commitments of resources. The contribution of the proposed action to the emission of gases 

that potentially contribute to global warming will be similar to the other alternatives and is expected to be 

minimal. Thus, these will not be analyzed further. 

The proposed action does not involve construction, major ground disturbance, or habitat modification. 

Therefore the following resource values are not expected to be affected by the proposed action: soils, 

geology, minerals, water quality/quantity, flood plains, wetlands, visual resources, air quality, prime and 

unique farmlands, aquatic resources, vegetation, timber, and range. These resources will not be analyzed 

further. 

4.1 ENVIRONMENTAL CONSEQUENCES 

4.1.1 Potential for Adverse Effects on Target Wildlife 

4.1.1.1 Alternative 1: Current Action (the No Action Alternative) 

Effects of ONRAB® Vaccine on Target Species (Raccoons and Striped Skunks)

The primary concern here is whether the ONRAB® vaccine might cause disease in target animals that 

consume the ORV baits. In order for such vaccines to be licensed for use they must be shown to be safe, 

pure, potent, efficacious, and genetically stable (Agriculture Canada 1989). Raccoons and striped skunks 

are the target species for purposes of the ONRAB® field trial. 

The V-RG construct was the first recombinant rabies vaccine distributed in the field (Pastoret et al. 1988) 

and several safety studies evaluated the generation of pathological lesions, explored the short-term 

persistence of the virus in foxes, raccoons, a variety of European non-target wildlife, and 

immunodeficient animals (Blancou et al. 1986, Brochier, et al. 1989, Thomas et al. 1990, Rupprecht et al. 

1988, and Hanlon et al. 1997 in Knowles et al. 2009). Based on these prior studies, Knowles et al. (2009) 

designed studies to investigate the safety of ONRAB®. These studies concluded that in regard to gross 

pathological consequences and the possible long-term presence of virus in species tested, all data indicate 

very low recovery of ONRAB® from tissues, feces, and oral samples of animals given a relatively high 

dose of vaccine, thus making the likelihood of ONRAB® spread by horizontal transmission in wildlife 

species unlikely (Knowles et al. 2009). 

Adenovirus infections occur worldwide in humans as well as in a variety of animals. Adenoviruses are 
40

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

extremely host specific. Except under exceptional laboratory conditions, a human adenovirus will not 

replicate in anything other than human cells (A. Beresford, Artemis Technologies Inc., pers. comm., 

2011). With few exceptions, the human adenovirus serotypes are generally not pathogenic to animals, and 

animal adenoviruses are only pathogenic within the species of origin (Taylor 1977). Therefore target 

species exposed to the ONRAB® vaccine virus would not be expected to support active replication of the 

virus. 

Additionally, both Charlton et al. (1992) and Prevec et al. (1990) confirmed that, after oral immunization 

of skunks and foxes with AdRG1, no pathogenic effect related to AdRG1 was observed. These results 

indicate that recombinant adenoviruses (rAd) such as AdRG1 may be an attractive candidate for a wildlife 

oral rabies vaccine (Randrianarison-Jewtoukoff and Perricaudet 1995). Also, experiments have shown 

that when skunks and raccoons receive four to five times the anticipated dose of ONRAB® to be used in 

baits, no adverse reactions occurred (Artemis 2010). 

Knowles et al. (2009) conducted safety studies on several species including raccoons and striped skunks. 

Vaccine was administered by direct instillation into the oral cavity with a syringe and polyethylene tubing 

while the skunks and raccoons were recovering from sedation. Tissues were collected post vaccination 

and analyzed for the presence of ONRAB®. Among skunks and raccoons, only lung tissue tested 

positive for vaccine virus. Oral swabs taken from rabies vector species did not show any recovery of 

virus at 7 days post vaccination. The duration of fecal contamination by vaccine was short lived, being 3-

4 days in most of the species tested. Skunks given the vaccine dose to be used in the field excreted virus 

in feces over 3 days only. Possible aspiration of vaccine during oral instillation was associated with 

finding of acute bronchopneumia and necrosis in one skunk tested. 

ONRAB® has been used in field trials in Ontario, Canada since 2006. Before approval to field test 

ONRAB® vaccine-baits in Ontario was granted by the Canadian Food Inspection Agency (CFIA), 

Veterinary Biologics Section (VBS), extensive laboratory testing of the experimental vaccine had to be 

completed (Rosatte et al. 2009). In 2010, the OMNR distributed 870,000 ONRAB® baits in ON and 

1,052,402 ONRAB® baits were used in Quebec. Post-baiting serology data indicate a positive antibody 

response (seroprevalance) rate of as high as 44.5% in striped skunks during 2010 in ON (OMNR RRDU 

2010-2011). Data from 2009 and 2010 indicate seroprevalance rates ranging from a low of 19.6% to a 

high of 61.6% of skunks samples during post-baiting activities in ON. Post-bait surveillance in QC 

indicatd seroprevalance rates of 20.7 to 60.3% in raccoon populations and 8.3 to 17.7% in skunk 

populations (Mainguy and Canac-Marquis 2010). These values were affected by a variety of factors 

including bait densities and flight line spacing. 

The limited host range of human adenovirus reduces the risk of spread in target and non target wildlife or 

domestic animals. The risk of release of this vaccine is expected not to be greater than that for other 

licensed vaccines (ERA, V-RG), and is actually considered to have less potential adverse consequences 

(CFIA 2008, 2010). 

Effects of Monitoring and Surveillance on Raccoon Populations

The estimated cumulative size of the WV field trial area to be treated with ONRAB® ORV baits is 

approximately about 2,667 km2

 (or about 1,030 mi2). Raccoon densities range from 0.9 to as high as 250 
41

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

per km2

 (about 2 to 650 per mi2) with most reported densities ranging from 4 to 30 per km2 (about 10 to 

80 per mi2

.) in rural areas (Riley et al. 1998). Assuming that this range of raccoon densities occurs in 

WV, the statewide raccoon density estimate ranges between 251,032 – 1.8 million individuals. 

Raccoon populations can generally be expected to withstand harvest rates of about 49 percent or more 

annually (Sanderson 1987, USDA 1997). APHIS-WS and cooperating state or local agencies expect to 

continue to live-trap or lethally remove less than one percent of the lowest estimated number of raccoons 

in West Virginia combined for monitoring and surveillance purposes or implementation of localized 

contingency plans involving lethal population reduction in all ORV programs, including ONRAB® field 

trials.

The 2008 Monitoring Report (USDA 2011c) for the APHIS-WS EA – Oral Vaccination to Control 

Specific Rabies Virus Variants in Raccoons, Gray Foxes, and Coyotes in the U.S. (2010) indicates the 

lowest estimated size of the raccoon population totaled from those states participating in the current ORV 

program was 2,475,377 raccoons in 2008. The APHIS-WS program killed 1,321 raccooons for enhanced 

rabies surveillance as a part of cooperative ORV efforts, or 0.05 percent of the lowest estimated 

population in 2008. The Monitoring Report and EA summarize that the ORV program continues to have 

no adverse impacts to raccoon densities and that, in the absence of the ORV program, it is highly likely 

that far more raccoons would die from rabies than are killed for surveillance and monitoring purposes to 

critically evaluate the integrity of ORV campaigns. In comparison, during 2005-2006, sportsmen in 

Pennsylvania and Ohio harvested 106,082 and 46,886 raccoons respectively (or 11.4% and 5.5% of the 

total raccoon populations in those states) (ODNR 2009, PGC 2009A, USDA 2010). 

The majority of raccoons captured for monitoring or surveillance purposes would be released at their site 

of live capture once they have fully recovered from anesthesia. Individual raccoons may be lethally 

removed and tested for rabies if they were demonstrating strange behavior symptomatic of the rabies 

virus or were injured. An exception may be when the animals were captured and drugged for handling 

purposes close to or during hunting/trapping seasons, at which times they may be euthanized to avoid 

concerns about hunters or trappers consuming raccoons that contain drug residues (see Section 2.2.1). 

APHIS-WS will conduct post-field trial ORV monitoring to evaluate program efficacy by collecting 

blood and tooth samples for determining rabies VNA levels and bait uptake (when appropriate) in 

raccoons and striped skunks. Serum samples are collected from unique (previously uncaptured and 

unsampled) raccoons and striped skunks captured. Post ONRAB® bait distribution monitoring and 

surveillance activities in the current action state (West Virginia) would not contribute further to any 

adverse impacts to the raccoon population. As discussed above, total lethal removal of raccoons (for all 

ORV programs, including the ONRAB® field trial) will remain at less than 1% of the total population in 

West Virginia. 

Effects of Monitoring and Surveillance on Striped Skunk Populations

Although easily recognized by their black and white fur, the striped skunk may be most readily 

recognized by the odiferous smell of its musk. They are common throughout the U.S. and Canada 

(Rosette 1987). Striped skunks are primarily nocturnal and do not have a true hibernation period, 

although during extremely cold weather they may become temporarily dormant. The striped skunk is an 
42

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

omnivore, feeding heavily on insects such as grasshoppers, crickets, beetles, bees, and wasps (Godin 

1982). The striped skunk’s diet also includes small mammals, the eggs of ground-nesting birds, and 

amphibians. Striped skunks are typically non-aggressive, and will attempt to flee when approached by 

humans (Rosatte 1987). However, when provoked, skunks will give a warning and assume a defensive 

posture prior to discharging their foul-smelling musk. This musk consists of sulfur-alcohol compounds 

known as butylmercaptan (Godin 1982). 

The striped skunk may use abandoned burrows of other animals as a home. They may also dig their own 

burrow, or use a protected place, such as a hollow log, crevice, or the space beneath a building. 

Adult skunks begin breeding in late February. Yearling females (born in the preceding year) mate in late 

March. Gestation usually lasts 7-10 weeks, and there is usually only 1 litter annually. Litters commonly 

consist of 4-6 young. The home range of the striped skunk is usually not consistent. It appears to vary in 

relation to life history requirements such as winter denning, feeding activities, dispersal and parturition 

(Rosatte 1987). Reported home ranges of striped skunks average between 2.2 and 4.9 km2

 (0.85-1.9 

mi2

) in rural areas of Minnesota and Illinois (Rosatte 1987). During the breeding season, males may 

travel larger areas in search of females. Skunk densities vary widely according to season, food sources, 

and geographic area. Densities have been reported to range from 1 skunk per 77acres to 1 per 10 acres 

(Rosatte 1987). 

No population estimates are available for striped skunks in West Virginia. Striped skunks can be found in 

a variety of habitats across West Virginia. To analyze impacts of ORV field trial activities on striped 

skunk populations in West Virginia, the best available information will be used. There are over 13 

million acres of rural land in WV (USDA 2009b), with approximately 4 million acres of farmland (USDA 

2009b). Using the assumption that 50% of the rural lands throughout the state have sufficient habitat to 

support striped skunks, skunks are found only in rural habitat, and skunk densities average 1 skunk per 77 

acres (lowest estimate available), a conservative statewide striped skunk population could be estimated at 

approximately 84,400 skunks. Considering skunks inhabit urban areas as well as rural, an estimate of 

84,400 is likely very low (R. Rogers, WV Dept. of Natural Resources, pers. comm. 2011). 

APHIS-WS and cooperating state or local agencies expect to live-trap or lethally remove less than 1 

percent of the lowest estimated number of striped skunks for monitoring and surveillance purposes for the 

ORV ONRAB® field trial. The majority of striped skunks captured for monitoring and surveillance 

purposes would be released at the site of capture once they have fully recovered from anesthesia. 

Individual skunks may be lethally removed and tested for rabies if they are demonstrating strange 

behavior symptomatic for the rabies virus or if they are injured. An exception may be when the animals 

are captured and drugged for handling purposes close to or during the trapping season, at which time they 

may be euthanized to avoid concerns for hunters or trappers consuming skunks that contain drug residues 

(see Section 2.2.1). 

Based upon the above information, WS’ limited lethal take or striped skunks would have no adverse 

impacts on overall populations of this species in West Virginia. 
43

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

Effects on Other Species not Targets for Purposes of ORV Field Trials, but which may be 

Considered Targets for Monitoring and Surveillance

Although the ORV ONRAB® field trials specifically targets raccoons and striped skunks, several other 

species may be treated as targets for monitoring and surveillance. These species will be referred to as 

non-ORV targets for purposes of this EA. The methods proposed for use in monitoring and surveillance 

activities would have no significant adverse effects on non-ORV target species. Species that are 

considered targets for monitoring and surveillance, but are not targets for the ORV ONRAB® field trial 

will include all known rabies reservoir species including red foxes, grey foxes, coyotes, spotted skunks 

(Spilogale putoris), bobcats (Lynx rufus), groundhogs (Marmota monax), feral dogs (Canis familiaris), 

and feral cats (Felis domesticus). Additionally, several small mammal species may be targets for 

monitoring and surveillance including Eastern chipmunk (Tamias striatus), Eastern gray squirrel (Sciurus 

carolinensis), red squirrel (Tamiasciurus hudsonicus), Southern flying squirrel (Galucomys volans), 

short-tailed shrew (Blarina brevicauda), deer mouse (Peromyscus maniculatus), white-footed mouse 

(Peromyscus leucopus), Southern red-backed vole (Clethrionomys gapperi), meadow vole (Microtus 

pennsylvanicus), and pine vole (Microtus pinetorum). Occasionally samples may be collected for 

serology from some mammal species that are incidentally captured during ORV monitoring and 

surveillance activities, but not specifically targeted by the ORV ONRAB field trials. They may be 

opportunistically sampled to determine the potential effectiveness of ONRAB® as many of these species 

have a propensity for contracting, harboring, and spreading the rabies virus. Non-ORV target animals 

captured in cage traps would normally be released unharmed unless the animal appears sick or injured. 

Therefore, monitoring and surveillance should have little or no effect on non-ORV target populations. 

4.1.1.2 Alternative 2: Proposed Action (the Preferred Alternative) 

Effects of the ONRAB® Vaccine on Target Species (Raccoons and Striped Skunks)

In 2011, APHIS-WS distributed 79,027 ONRAB® baits in West Virginia during the first field trial to 

determine the safety and immunogenicity of the ONRAB® vaccine in the U.S. Initial results from this 

trial are encouraging and warrant further study. As discussed in Section 1.1.3, a seroconversion rate of 

49% was observed in raccoons sampled during post-ORV monitoring and surveillance activities. This 

represents the highest population RVNA level WS has observed after the first ORV baiting of a vaccine 

naïve area (USDA 2012b). 

Swabs were collected from 125 target and nontarget individuals live-trapped on days 1-6 post ORV 

distribution to determine ONRAB® presence in the oral cavity and samples were shipped to the Animal 

Health Diagnostic Center, Cornell University for analysis. Individual raccoons captured on days 2, 3, and 

4 and an opossum captured on day 4 had qPCR values <35, which are considered strong positives 

(Knowles et al. 2009). An additional nine raccoons and four opossums with >35 qPCR values <40 were 

captured on day 1-4. No ONRAB® was detected on days 5-6 (USDA 2012b). 

Diverse fauna, including target and nontarget species, were sampled for histopathological analysis during 

the pre and post-ONRAB® periods. Tissue samples were collected and shipped to MD Anderson Cancer 

Center (Houston, Texas, USA) for analysis (USDA 2012b). These results were not available at the time 

of this EA, but will be included in any future environmental analysis for the ORV program. 
44

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

WS, NWRC captive histopathologic studies of species common to the West Virginia field trial area, 

including: cottontail rabbit (Sylvilagus floridamus), opossum (Didelphis virginiana), fox squirrel (Scuirus 

niger), and Eastern wild turkey (Meleagris gallopavo silvestri), evaluated for 10x dose of ONRAB® 

showed no effects in comparison to a control group for these species. The eastern woodrat (Neotoma 

florindana) is also in the process of being evaluated. A 10x dose was evaluated given that animals could 

consume more than one bait. 

As expected, there was no evidence of HAd5 antibodies in the 416 animals sampled during the pre-ORV 

sampling period. Seven of the 296 (2.4%) samples evaluated post-ORV demonstrated HAd5 virus 

neutralizing antibodies (VNA). This included 6 raccoons and 1 striped skunk. Low seroconversion may 

be expected for a human adapted virus. Monitoring for anamnestic responses will be incorporated into 

evaluation of baiting with ONRAB® in the proposed field trial (USDA 2012b). 

As with Alternative 1, no adverse effects would be expected with Alternative 2. ONRAB® field trial 

programs conducted in both the U.S. and Canada, as well as research conducted on the ONRAB® vaccine 

have demonstrated its safety and effectiveness in target species populations. Expanding the APHIS-WS 

ONRAB® field trial beyond WV into NH, NY, OH, and VT is not expected to result in any additional 

adverse effects to target species. 

Effects of Monitoring and Surveillance on Raccoon Populations

As with the effects of monitoring and surveillance described above for Alternative 1, Alternative 2 is also 

expected to have negligible adverse risks or impacts to raccoon populations. As discussed above, APHISWS and cooperating state and local agencies expect to lethally remove less than 1% of the lowest number 

of raccoons in all ORV program states, including any raccoons that may be lethally removed during 

ONRAB® field trials. The current V-RG ORV program conducts raccoon monitoring and surveillance 

activities in 17 eastern states. To date, lethal removal has accounted for less than 0.03% - 0.19% of the 

lowest estimated raccoon population annually (USDA 2011c, 2009, 2008, 2007, 2005, 2004, 2004b, 

2003) for all ORV programs. APHIS-WS rabies management program’s lethal removal of far less than 

1% of raccoons did not reduce statewide or regional densities of raccoons. As a result of the review of 

possible impacts to raccoons, the potential for cumulative impacts continues to be negligible. Therefore, 

the implementation of Alternative 2 would continue to have no adverse impact to raccoon densities in the 

involved states. In the absence of ORV program, including the proposed field trial, it is highly likely that 

substantially greater numbers of raccoons would succumb to the invariably fatal rabies virus than are 

removed during monitoring and surveillance activities. 

Effects of Monitoring and Surveillance on Striped Skunk Populations

The effects of the proposed alternative would be similar to those with the current program. Although 

striped skunk population estimates were not available for the states involved in the proposed field trial at 

the time of this publication, the best available information was used to estimate statewide populations. 

There are approximately 4 million, 26 million, 22 million, and 5 million of rural acres in NH, NY, OH, 

and VT, respectively (USDA 2009b). Using the assumption that 50% of rural lands throughout the states 

have sufficient habitat to support striped skunks, skunks are found only in rural habitat, and skunk 
45

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

densities average 1 skunk per 77 acres, conservative statewide striped skunk populations can be estimated 

at over 25,900 for NH, 169,200 for NY, 139,700 for OH, and 32,900 for VT. 

The states of NH, NY, OH, and VT all report that their respective striped skunk populations are secure 

and stable (NHGF 2012, NYDEC 2012a, ODNR 2010, K. Royar, pers. comm., 2006 in USDA 2006). As 

discussed above, APHIS-WS and cooperating state and local agencies expect to lethally remove less than 

1% of the total striped skunk population in any of the involved states. 

Based on the above information, implementation of Alternative 2 would have no adverse impacts on 

overall striped skunk populations. 

Effects on Other Species not Targets for Purposes of ORV Field Trials, but which may be 

Considered Targets for Monitoring and Surveillance

As discussed above, non-ORV target animals captured in cage traps would normally be released 

unharmed unless the animal appears sick or injured. Therefore, monitoring and surveillance activities that 

would occur with the implementation of Alternative 2 should have little or no effect on non-ORV target 

populations. 

4.1.1.3 Alternative 3: No ORV Field Trials 

Effects of the ORV ONRAB® Vaccine on Target Species (Raccoons and Striped Skunks)

Under this alternative, there would be no impact on target striped skunk or raccoon populations from 

ORV field trials. However, in the absence of a safe and immunogenic rabies virus vaccine for skunks, it is 

likely that more skunks will die from rabies with potentially greater short-term population impacts. 

Further, without a safe and efficacious rabies virus vaccine for wildlife, rabies epizootics may be expected 

to occur that would likely result in short-term die-offs of target species over broader geographic areas. 

ORV programs utilizing the V-RG vaccine would be expected to continue, however, as discussed in 

Section 1.3, studies have indicated that V-RG does not produce sufficient levels of population immunity 

in skunks in the wild at the current dose (Slate et al. 2005) and V-RG may be less effective in skunks than 

other species (Tolsen at al. 1987). Rabies virus containment and elimination in the U.S. will likely 

remain elusive until an oral vaccine is licensed that is immunogenic in all terrestrial rabies reservoir 

species (Slate et al. 2005). 

Effects of Monitoring and Surveillance on Target Species (Raccoons and Striped Skunks)

Under this alternative there would be no monitoring and surveillance activities to support an ORV 

ONRAB® field trial distribution, therefore there would be no effect to striped skunk or raccoon 

populations. However, as stated above, it is likely that raccoons and striped skunks will continue to die as 

a result of rabies virus infection.
46

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

Effects on Other Species not Targets for Purposes of ORV Field Trials, but which may be 

Considered Targets for Monitoring and Surveillance

Under this alternative there would be no ONRAB® field trial monitoring and surveillance activities and 

therefore, there would be no effect on these species as a result. However, it is highly likely in the absence 

of ORV programs, including the proposed field trial, that many more animals will die from rabies than 

would have been affected by monitoring and surveillance efforts proposed by the action alternatives. 

4.1.2 Potential for Adverse Effects on Nontarget Wildlife Species, including Threatened or 

Endangered Species 

4.1.2.1 Alternative 1: Current Action (the No Action Alternative) 

Effects of the ONRAB® Vaccine on Nontarget Wildlife including Threatened or Endangered 

Species

A primary concern of the ONRAB® vaccine is that it might cause disease in nontarget animals that 

consume or contact vaccine in the baits. 

At least 17 species have been included in the safety studies on ONRAB® (Knowles et al. 2009) from the 

following taxonomic groups: 

 Order Carnivora 

Family Canidae [red fox (Vulpes vuples), domestic dog (Canis familiaris)] 

Family Felidae [domestic cat (Felis domesticus)] 

Family Mustelidae [striped skunk (Mephitis mephitis)] 

Family Procyonidae [raccoon (Procyon lotor)] 

 Order Rodentia

Family Sciuridae [grey squirrel (Sciurus carolinensis), groundhog (Marmota monax)] 

Family Muridae [cotton rat (Sigmodon hispidus), meadow vole (Mictrotus 

pennsylvanicus), nude mouse (Mus Musculus), deer mouse (Peromyscus leucopus)] 

 Order Lagomorpha

Family Leporidae [European rabbit (Oryctologus cuniculus)] 

 Order Artiodactyla

Family Bovidae [cow (Bos Taurus), sheep (Ovis aries)] 

 Order Suina
47

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

Family Suidae [pig (Sus domesticus)] 

 Order Perissodactyla

Family Equidae [horse (Equus ferus)] 

 Order Galliformes

Family Phasianidae [chicken (Gallus domesticus)] 

No adverse reactions in the animals studied were found following oral inoculation of the experimental 

vaccine, while in most cases antibodies against the rabies viral protein were detected on day 28 postexposure (CFIA 2008, 2010). Test animals were found to be clinically healthy after vaccination with 

ONRAB®, however viral nucleic acids were detected in some tissues or feces of some vaccinated 

animals, suggesting that ONRAB® was replicating or persisting in these hosts for a few days to a couple 

of weeks post-vaccination. Replication of adenovirus in immunocompromised animals such as nude mice 

and SCID mice did not appear to result in adverse reactions (CFIA 2008, 2010). 

Overdosage of ONRAB® in amounts four to five times greater than the dose found in the vaccine baits 

resulted in no adverse effects in experiments involving skunks and raccoons (Artemis 2010). Therefore, 

even if domestic animals or other nontarget wildlife receive multiple doses of vaccine by consuming 

multiple baits, no adverse effects would be expected to occur. 

Knowles et al. (2009) confirmed in studies involving meadow voles, deer mice, grey squirrels, rabbits, 

and groundhogs that lung was the only tissue that tested positive four days post-vaccination (in one 

groundhog and one squirrel), while the remaining tissues sampled tested negative for vaccine virus. The 

distribution and consumption of baits is expected to have no adverse effect on any species. The 

distribution and consumption by mammals is more likely to have a positive effect on mammals because a 

successful program will reduce the risk of mammals contracting and dying from rabies. 

As stated in section 4.1.1.2, adenoviruses are extremely host specific. Except under exceptional 

laboratory conditions a human adenovirus will not replicate in anything other than human cells (A. 

Beresford, Artemis Technologies Inc., pers. comm., 2011). With few exceptions, the human adenovirus 

serotypes, are generally not pathogenic to animals, and animal adenoviruses are only pathogenic within 

the species of origin (Taylor 1977). The limited host range of human adenovirus reduces the risk of 

spread in target and nontarget wildlife or domestic animals. The risk of release of this experimental 

rabies vaccine is expected not to be greater than that for other licensed rabies vaccines (e.g. ERA, V-RG), 

and this vaccine is actually considered to have less potential for adverse consequences (CFIA 2008, 

2010). Therefore non-target species exposed to the ONRAB® vaccine virus would not be expected to 

support active replication of the virus. 

T&E Species ONRAB® Effects 

Although no T&E species were specifically tested for safety of ONRAB® baits, safety studies involving 

ONRAB® on other species representing 11 unique taxonomic families listed above indicate that no 
48

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

species will be affected by the baits (Knowles et al. 2009, Randrianarison-Jewtoukoff and Perricaudet 

1995, Artemis 2010). 

Reports of rabies among carnivores other than primary reservoir host species are rare but, other 

carnivorous mammals, including T&E species or closely related species, can be a source of rabies 

exposure to humans and domestic animals. A total of 2,851 cases of rabies among other carnivorous 

mammals of at least 17 different species were reported from 1960 through 2000. This total represents 

1.5% of the 185,014 wildlife cases reported during the same time period. A total of 45 otters (Lontra 

canadensis), 40 badgers (Taxidea taxus), 31 wolves (Canis lupus), 29 ringtails (Bassariscus astutus), 23 

domestic ferrets (Mustela putoris), 12 coatis (Nasua narica), 11 mink (Mustela vison), 11 weasels 

(Mustella spp.), 8 fisher (Martes pennanti), 4 puma (Puma concolor), 4 bears (Ursus spp.), and 1 ocelot 

(Leopardus pardalis) tested positive for the rabies virus (Krebs et al., 2003). Rabies among some other 

carnivorous mammals has been regarded as a threat to the survival of certain rare or endangered species 

(MacDonald, 1993). An epizootic of rabies in Alaska was credited with decimating an entire pack of 

wolves in one instance (Chapman 1978), and on several occasions a substantial number of wolves 

wearing radio-collars as part of long-term ecological studies have died of rabies (Ritter 1991; Theberge et 

al., 1994; Kat et al., 1995). Conversely, control of rabies in raccoons, foxes, and coyotes may have a 

potential indirect beneficial effect of preventing unnecessary die-offs of T&E and other sensitive species 

from rabies. 

As discussed, the distribution of ORV baits will not have an adverse effect on these species. It is 

expected that the vaccination of animals, the primary target species, and potentially the T&E species, 

could have a beneficial effect on T&E mammals, especially the carnivores and ungulates that are more 

apt to be in contact with infected animals, but not be killed by them. Mammals succumb to the rabies 

virus if exposed, unless they are vaccinated. The chance of a T&E mammal species being exposed in 

ORV treatment areas is much less than in non-treatment areas. No federally listed species occurring in 

West Virginia would be expected to consume or contact the ONRAB® vaccine; therefore the ORV field 

trials will have no effect on any listed species (see Appendix C for species list). Additionally, APHISWS has obtained and reviewed the list of WV State-listed T&E species and Special Concern species, as 

well as the USDA-Forest Service Regional Forester Sensitive Species (see Appendices D and E for 

species information) and has determined, for the reasons described above, that the proposed program will 

not adversely affect any of the species listed in WV. 

Effects of capture/removal methods (used in monitoring and surveillance activities) on nontarget 

species, including threatened or endangered species

The methods proposed for use in ONRAB® field trial monitoring and surveillance areas would have no 

significant adverse effects on nontarget species. Nontarget animals captured in cage traps would 

normally be released unharmed unless the animal appeared injured or sick. Therefore, monitoring and 

surveillance should have no effect on nontarget species populations. Analysis of nontarget take resulting 

from other APHIS-WS ORV programs can be found in USDA 2010.
49

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

T&E Species Monitoring and Surveillance Effects 

Special efforts are made to avoid jeopardizing T&E species through biological evaluations of the potential 

effects and the establishment of special restrictions or mitigation measures. Mitigation measures and 

SOPs to avoid T&E effects are described in section 3.3 of this EA. 

APHIS-WS reviewed lists of federal and state T& E species (Appendices C and D), as well as Regional 

Forester Sensitive Species (Appendix E) to determine if any species might be affected. ORV programs or 

the methods used in capture/removal of target species during monitoring and surveillance activities would 

have no effect on any listed fish, invertebrate, or plant species, as described below. 

Federally Listed T&E Species (USFWS 2012): 

The current list of species designated as threatened and endangered in West Virginia, as determined by 

the USFWS, was obtained and reviewed during the development of this EA. Consultation with the 

USFWS under Section 7 of the ESA concerning potential impacts of APHIS WS’ programmatic activities 

on T&E species was conducted as part of the development of APHIS WS’ programmatic FEIS (USDA 

1997). Methods that will be used in this proposed action were considered as a part of this consultation. 

WS obtained a BO from the USFWS addressing WS’ programmatic activities. For full context of the BO, 

see Appendix F of WS’ programmatic FEIS (USDA 1997). 

Striped skunks and raccoons are the primary targeted species in surveillance and monitoring with other 

species such as red foxes, gray foxes, coyotes, spotted skunks, bobcats, groundhogs, feral dogs, and feral 

cats being secondarily targeted to determine the prevalence of rabies in these species and the effectiveness 

of the ORV Program. Additionally, several small mammal species may targets for monitoring and 

surveillance including Eastern chipmunk (Tamias striatus), Eastern gray squirrel (Sciurus carolinensis), 

red squirrel (Tamiasciurus hudsonicus), Southern flying squirrel (Galucomys volans), short-tailed shrew 

(Blarina brevicauda), deer mouse (Peromyscus maniculatus), white-footed mouse (Peromyscus 

leucopus), Southern red-backed vole (Clethrionomys gapperi), meadow vole (Microtus pennsylvanicus), 

and pine vole (Microtus pinetorum). Cage traps are used to capture/take these species and have the 

potential to take T&E species. Species on the federal T&E list that could be taken under the proposed 

action with cage traps are mammals, birds, reptiles, and amphibians, mostly similar in size and weight to 

the target species. These are discussed below. The use of firearms is highly target-specific and would 

have no effect on T&E species. 

After review of program activities and methods used during monitoring and surveillance activities 

associated with the proposed ORV field trials, APHIS WS has determined that the proposed field trial 

activities in West Virginia would not adversely affect the gray bat (Myotis grisescens), Indiana bat 

(Myotis sodalist), Virginia big-eared bat (Plecotus townsendii virginianus), eastern cougar (felis concolor 

cougar), pink mucket (Lampsilis abrupt), tubercled blossom (Epioblasma torulosa torulosa), running 

buffalo clover (Trifolium stoloniferum), and small whorled pogonia (Isotria medeoloides). This 

determination is based on the conclusions made by the USFWS during the 1992 consultation on APHIS 

WS’ programmatic activities and subsequent BO (USDA 1997). The gray wolf (Canus lupus) was 

addressed in the 1992 BO issued by the USFWS and is listed in West Virginia but is not currently known 
50

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

to occur in the State. APHIS WS would abide by all reasonable and prudent measures identified in the 

BO for the gray wolf when conducting ORV activities. 

West Virginia Northern Flying Squirrel (Glaucomys sabrinus fuscus).  The West Virginia northern 

flying squirrel was recently re-listed on March 25, 2011. This squirrel could potentially be taken in cage 

traps, mostly being attracted to the different baits used or from curiosity. If APHIS-WS needed to 

conduct surveillance in an area where this species was present, APHIS-WS Specialists would implement 

measures to minimize the potential for take. Cage traps would be baited with unattractive baits. If a 

squirrel was inadvertently captured in a cage trap, it would be immediately released unharmed to avoid 

lethal take and reported to the appropriate wildlife agency. The USFWS issued a BO (USDA 1997, 

Appendix F) stating that the above mentioned species is not likely to be adversely affected by the APHISWS program. Additionally, ORV monitoring and surveillance activities would not occur in northern 

flying squirrel suitable or occupied habitat, typically high elevation spruce-hardwood forests, therefore 

proposed activities under Alternative 1 will have no effect on this species. 

Additional T&E species in West Virginia include the clubshell (Pleurobema clava), fanshell (Cyprogenia 

stegaria), northern riffleshell (Eppioblasma torulosa rangiana), flat-spired three-toothed snail (Triodopsis 

platysayoides), James spinymussel (Pleurobema collina), American burying beetle (Nicrophorus 

americanus), pink ring (Obovaria retusa), Madison Cave isopod (Antrolana lira), Northeastern bulrush 

(Scripus ancistrochaetus), harperella (Ptilimnium nodosum), shale barren rock-cress (Arabis serotina), 

and Virginia spirea (Spiraea virginiana). After review of the proposed activities under this alternative, 

APHIS WS has determined that the APHIS WS’ ORV field trial activities in West Virginia would have 

no effect on these T&E species or critical habitat not included in the 1992 BO as none of these have the 

potential to be captured in cage traps used during monitoring and surveillance activities, nor will there be 

any ground disturbance which could affect plant species. 

Currently, no federally listed T&E birds or reptiles occur in West Virginia. APHIS-WS has taken a few 

larger amphibians, mainly bullfrogs. It is possible that APHIS –WS could take toads and larger frogs as 

nontarget species during ORV operations in cage traps. Only 1 amphibian, the Cheat Mountain 

salamander (Plethodon nettinig), is federally listed as T&E species. APHIS-WS believes that it will have 

no effect on this species, because no cheat mountain salamanders are known or believed to occur within 

the field trial area (USFWS 2011). 

As discussed, the distribution of ORV baits will not have an adverse effect on amphibians, even though 

some could potentially be eaten by a few species. Rabies is a mammalian disease. Amphibians cannot be 

infected with rabies nor can they be vaccinated against the disease, even if they consume ORV baits. 

State Listed Species (WVDNR 2012) and Regional Forester Sensitive Species (USDA 2012): 

APHIS-WS is also concerned with the take of state-listed sensitive species and Regional Forester 

Sensitive Species (RFSS) (Appendices D and E). On average, APHIS-WS lethally takes approximately 

13 nontarget animals during all ORV program monitoring and surveillance activities annually (USDA 

2010). This includes take from 17 states that participate in ORV monitoring and surveillance. It is 

therefore expected that the take resulting from the proposed field trials in WV would be much less. The 

majority of nontarget captures will be released at the site of capture unharmed. Additionally APHIS-WS 
51

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

will consult with WVDNR and the USFS and provide them information on any listed species taken 

during ORV monitoring and surveillance, but believes that the proposed program is not likely to 

adversely impact any state-listed sensitive species or RFSS. As discussed above for federal T&E species 

impacts, APHIS-WS believes that the consumption of ORV baits would have no effect on state listed 

species or RFSS, but the overall effect of the program would be beneficial if the prevalence of rabies is 

reduced.

The majority of the state listed sensitive species and RFSS (Appendices D and E) will be unaffected by 

the APHIS-WS Program. This includes species too small to be held by cage traps including the golden 

mouse (Ochrotomys nuttalli) and eastern harvest mouse (Reithrodontomys humulis). Conversely, four 

species, in addition to the West Virginia northern flying squirrel discussed above, have the potential to be 

taken during ORV monitoring and surveillance activities and are discussed below. 

Eastern Spotted Skunk (Spilogale putoris). This species is state-listed as a sensitive species in 

Alabama, Maryland, and West Virginia. This species is taken as a target or nontarget infrequently (only 2 

taken from 2001-2007) due to its rarity in most areas where APHIS-WS has been conducting ORV 

surveillance. However, it is attracted to baits often used in cage traps. APHIS-WS personnel will check 

cage traps frequently and keep them in areas where animals captured are not exposed to the elements. 

This species, along with the other skunks, frequently contract rabies and, therefore, are monitored and 

taken as targets. However, APHIS-WS activities will not have a negative effect on their populations in 

West Virginia. Also, an indirect beneficial effect would be a reduced risk of the species suffering further 

declines because of a rabies epizootic. 

Southern Bog Lemming (Synaptomys cooperi) and Southern Rock Vole (Microtus chrotorrhinus 

carolinensis). Lemmings and voles may be large enough to be captured in small-wire mesh or enclosed 

traps used for monitoring smaller predators. These species only have a slight chance of being taken, even 

in cage traps, because the small rodents could exit the traps through gaps in the door. The primary 

concern with these species is exposure to the elements such as excessive sun/heat as this could result in 

lethal take. However, APHIS-WS would check traps frequently in these species’ occupied habitat so that 

any individuals captured could be released unharmed. APHIS-WS will not likely take these species, but a 

very slight potential exists. 

Allegheny Woodrat (Neotoma magister). This rat is large enough to be captured in cage traps, however 

they have only a slight chance of being taken even in cage traps because they could exit the traps through 

gaps in the door or wire-mesh. The primary concern with this species is exposure to the elements such as 

excessive heat/sun as this could result in a lethal take. However, APHIS-WS would check traps 

frequently in this species’ occupied habitat so that any individuals captured could be released unharmed. 

Appalachian Cottontail (Sylvilagus obscurus). Cottontails would not likely be attracted to or consume 

ORV baits. Although unlikely, this species could conceivably be captured in cage traps. If cage traps are 

used in their ranges, they will be located such to minimize exposure and checked frequently enough to 

release them alive. Therefore, WS will have minimal potential to take these species and will have 

virtually no impacts on their populations. 
52

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

4.1.2.2 Alternative 2: Proposed Action (the Preferred Alternative) 

Effects of the ONRAB® Vaccine on Nontarget Wildlife including Threatened or Endangered 

Species

Small mammals (primarily Peromyscus sp. and Microtus sp.) were collected for tissue sampling from 

major organs during the 2011 West Virginia ONRAB® field trial. These samples were supplemented 

with live trapped nontarget captures to assure a diverse representation of faunal samples for 

histopathological investigation. Larger mammals and birds were donated by WVDNR or collected by 

live trapping or shooting. Histopathological samples from nontarget species were also collected 

immediately following distribution of the ONRAB® vaccine. Tissue samples were collected and shipped 

to MD Anderson Cancer Center (Houston, TX) for analysis. These results were not available at the time 

of this EA, but will be included in any future environmental analysis for the ORV program. 

WS, NWRC captive histopathologic studies of species common to the West Virginia field trial area, 

including: cottontail rabbit (Sylvilagus floridamus), opossum (Didelphis virginiana), fox squirrel (Sciurus 

niger), and Eastern wild turkey (Meleagris gallopavo silvestri), evaluated for 10x dose of ONRAB® 

showed no effects in comparison to control groups for these species. The eastern wood rat (Neotoma 

floridana) is also in the process of being evaluated. A 10x dose was evaluated given that animals could 

consume more than one bait. 

As discussed in Section 4.1.2.1, safety studies (Knowles et al. 2009) resulted in no adverse reactions in 

those animals studied (CFIA 2008, 2010). Additionally, overdosage experiments on raccoons and skunks 

resulted in no adverse effects (Artemis 2010). The EA (USDA 2011b) concluded that the program would 

not adversely affect any nontarget or species listed in WV. 

T&E Species ONRAB® Effects 

APHIS-WS has determined that the expansion of ONRAB® field trials will not result in any additional 

adverse effects to nontarget species, including T&E species, in the other states (NH, NY, OH, and VT) 

where the trials will be conducted. Further, the proposed program could have an indirect beneficial effect 

by reducing the chance that nontarget and T&E species are exposed to the rabies virus in the wild. 

Although no T&E species were specifically tested for safety of ONRAB® baits, safety studies involving 

ONRAB® on other species representing 11 unique taxonomic families listed above indicate that no 

species will be affected by the baits (Knowles et al. 2009, Randrianarison-Jewtoukoff and Perricaudet 

1995, Artemis 2010). 

Effects of capture/removal methods (used in monitoring and surveillance activities) on nontarget 

species, including threatened or endangered species

As discussed above in Section 4.1.2.1 for Alternative 1, the methods proposed for monitoring and 

surveillance for the proposed action will have no significant adverse effects on nontarget species. 

Nontarget animals captured in cage traps would normally be released unharmed unless the animal 

appeared sick or injured. Therefore, monitoring and surveillance should have no effect on nontarget 

species populations. 
53

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

T&E Species Monitoring and Surveillance Effects 

Special efforts are made to avoid jeopardizing T&E species through biological evaluations of the potential 

effects and the establishment of special restrictions or mitigation measures. Mitigation measures and 

SOPs to avoid T&E effects are described in section 3.3 of this EA. 

APHIS-WS reviewed lists of federal and state T& E species within the proposed expanded field trial 

area(Appendices C and D), as well as Regional Forester Sensitive Species (Appendix E) to determine if 

any species might be affected. ORV programs or the methods used in capture/removal of target species 

during monitoring and surveillance activities would have no effect on any listed fish, invertebrate, or 

plant species, as described below. 

Federally Listed T&E Species (USFWS 2012): 

The current lists of species designated as threatened and endangered in New Hampshire, New York, Ohio, 

Vermont, and West Virginia as determined by the USFWS were obtained and reviewed during the 

development of this EA. Consultation with the USFWS under Section 7 of the ESA concerning potential 

impacts of APHIS-WS’ programmatic activities on T&E species was conducted as part of the 

development of APHIS-WS’ programmatic FEIS (USDA 1997). 

Cage traps are used to capture/take these species and have the potential to take T&E species. Species on 

the federal T&E list that could be taken under the proposed action with cage traps are mammals, birds, 

reptiles, and amphibians, mostly similar in size and weight to the target species. These are discussed 

below. The use of firearms is highly target-specific and would have no effect on T&E species. 

After review of program activities and methods available for use during monitoring and surveillance 

activities associated with the proposed expanded ORV field trial, APHIS-WS has determined that the 

proposed expanded ORV field trial monitoring and surveillance activities in New Hampshire, New York, 

Ohio, Vermont, and West Virginia would not adversely affect the gray bat (Myotis grisescens), Indiana 

bat (Myotis sodalist), Virginia big-eared bat (Plecotus townsendii virginianus), orangefoot pimpleback 

(Plethobasis cooperianus), piping plover (Charadrius melodus), fat pocketbook (Potamilus capax), 

eastern cougar (Felis concolor), pink mucket (Lampsilus abrupt), tubercled blossom (Epioblasma 

torulosa torulosa), green sea turtle (Chelonia mydas), hawksbill sea turtle (Eretmochelys imbricate), 

Kemp’s Ridley sea turtle (Lepidochelys kempii), leatherback sea turtle (Dermochelys coriacea), 

loggerhead sea turtle (Caretta caretta), shortnose sturgeon (Acipenser brevirostrum), roseate tern (Sterna 

dougallii dougallii), running buffalo clover (Trifolium stoloniferum), small whorled pogonia (Isotria 

medeoloides), and northern wild monkshood (Aconitum noveboracense). This determination is based on 

conclusions made by the USFWS during the 1992 consultation on WS’ programmatic activities and 

subsequent BO . For full context of the BO, see Appendix F of WS’ programmatic FEIS (USDA 1997). 

The gray wolf (Canus lupus) was addressed in the 1992 BO issued by the USFWS and is listed in NH, 

NY, OH, VT, and WV, but is not currently known to occur in any of the proposed states. APHIS-WS 

would abide by all reasonable and prudent measures identified in the BO for the gray wolf when 

conducting ORV activities. 

Within the states proposed for the expanded field trial activities there are other listed reptile and 

amphibian species that were not addressed in the 1992 BO. These include the Cheat Mountain 
54

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

salamander (Plethodon nettinig), bog turtle (Clemmy muhlenbergii), and copperbelly water snake 

(Nerodia erythrogaster neglecta). APHIS-WS has determined that the proposed monitoring and 

surveillance activities will have no effect on these species as populations of these species are not known 

or believed to occur within the proposed field trial zone. 

West Virginia Northern Flying Sqiurrel (Glaucomys sabrinus fuscus). This species was previously 

analyzed in Section 4.1.2.1 for this document and effects would be the same under Alternative 2 as this 

species only occurs in WV among the states where proposed activities would occur and the same methods 

will be use in Alternative 2 as with Alternative 1. 

Canada Lynx (Lynx canadensis). This species was recently declared federally threatened in the states 

of New York, and Vermont (68 FR 40076-40101, July 3, 2003) in the ORV field trial area. The primary 

habitat for this species is boreal forest with an abundance of snowshoe hare (Lepus americanus). No 

breeding populations are known to exist in New York or Vermont. Since 1900, lynx in New York and 

Vermont have always existed solely as dispersers. 

WS wildlife biologists consulted on the Canada lynx with the USFWS in Regions 3 and 5 in March 2001. 

The USFWS (letter from L. Lewis, USFWS, Acting Assistant Regional Director to G. Larson, WS 

Eastern Regional Director, May 9, 2001) determined that, “Canada lynx are unlikely to be affected by 

using guard dogs, scare devices, oral rabies vaccine, and shooting”. This letter states that a “not likely to 

adversely affect” determination is appropriate for APHIS-WS operational programs. 

Based on a review of past capture records, APHIS-WS has determined there to be no risk to lynx from 

ORV programs, from rabies monitoring and surveillance (including capture and testing of target animals) 

or other current APHIS-WS rabies-related activities in these states (USDA 2000). This is mostly because 

APHIS-WS has not conducted monitoring activities within occupied lynx habitat. If APHIS-WS 

conducts surveillance and monitoring in lynx occupied area, WS will only use cage traps and will check 

them frequently. Bobcats have been captured in cage traps and the potential exists for a lynx to be taken. 

Therefore, APHIS-WS determined that the proposed action has the potential to take a lynx if APHIS-WS 

conducts ORV monitoring in their habitat, but otherwise will have no effect on this species. 

After review of program activities and methods used during monitoring and surveillance activities 

associated with the proposed ORV field trials, APHIS-WS has determined that the proposed expanded 

field trial activities in New Hampshire, New York, Ohio, Vermont, and West Virginia would not 

adversely affect the following additional species: American burying beetle (Nicrophorus americanus), 

Karner blue butterfly (Lycaeides melissa samuelis), Mitchell’s satyr butterfly (Neonympha mitchellii 

mitchellii), white catspaw (Epioblasma obliquata perobliqua), clubshell (Pleurobema clava), Hine’s 

emerald dragonfly (Somatochlora hineana), fanshell (Cyprogenia stegaria) Madison cave isopod 

(Antrolana lira), Scioto madtom (Noturus trautmani), winged mapleleaf (Quadrula fragosa), scaleshell 

mussel (Leptodea leptodon), cracking pearlymussel (Hemistena lata), purple cat’s paw (Epioblasma 

obliquata obliquata), northern riffleshell (Epioblasma torulosa rangians), ring pink (Obvara retusa), flatspired three-toothed snail (Triodopsis platysayoides), Chittenango ovate amber snail (Succinea 

chittenangoensis), James spineymussel (Pleurobema collina), northeastern beach tiger beetle (Cicindeia 

dorsalis dorsalis), dwarf wedgemussel (Alasmidonta heterodon ), finback whale (Balaenopter physalus), 

humpback whale (Megaptera novaeangliae), North Atlantic right whale (Eubalaena glacialis), seabeach 
55

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

amaranth (Amaranthus pumilus), Northeastern bulrush (Scirpus ancistrochaetus), American caffseed 

(Scwalbea americana), lakeside daisy (Hymenoxys herbacea), American hart’s-tongue fern (Asplenium 

scolopendrium), sandplain gerardia (Agalinis acuta), Houghton’s goldenrod (Solidago houghtonii), 

harperella (Ptilimnium nodosum), Jesup’s milk-vetch (Astragalus robbinsii var. jessupi), eastern prairie 

fringed orchid (Platanthera leucophaea ), swamp pink (Helonias bullata), shale barren rock cress 

(Arabias serotina), Leddy’s roseroot (Rhodiola integrifolia ssp. leedyi), Virginia spiraea Spiraea 

virginiana). After review of the proposed activities under this alternative, APHIS WS has determined 

that the APHIS WS’ ORV field trial activities in New Hampshire, New York, Ohio, Vermont, and West 

Virginia would have no effect on these T&E species and critical habitat not included in the 1992 BO as 

none of these have the potential to be captured in cage traps used during monitoring and surveillance 

activities or are not known to occur within the specific field trial zone boundaries, nor will there be any 

ground disturbance which could affect plant species. 

State Listed Species (NHFG 2012, ODNR 2012, NYDEC 2012b, VTFW 2012) and Regional Forester 

Sensitive Species (USDA 2012): 

APHIS-WS has the potential to take some state-listed T&E and sensitive species. If a state listed species 

or RFSS were inadvertently captured it would be immediately released to avoid lethal take and reported to 

the appropriate wildlife agency. APHIS-WS believes, though, that the state-listed species from the 

following groups will not be impacted, except potentially very minimally, and, therefore, will not be 

discussed further: bats, insectivores (moles/shrews), birds, reptiles, amphibians, invertebrates, and plants. 

APHIS-WS believes that if APHIS-WS does have any potential to impact species it would be from the 

following groups of mammals: the rodents, lagamorphs, and carnivores. In additional to those state-listed 

species analyzed in Section 4.1.2.1, several others occur within the proposed field trial states. The 

woodland jumping mouse (Napaeozapus insignis) is likely too small to be held by cage traps or other 

monitoring methods and will not be discussed further. As discussed, ORV is not expected to cause any 

adverse effects on any of the sensitive species occurring within the field trial zone (Knowles et al. 2009). 

It is expected that the vaccination of wild animals, including the primary target species and, potentially 

T&E species, could have a beneficial effect on T&E mammals, especially carnivores that are more likely 

to be in contact with infected animals. The chance of a T&E mammal species being exposed in an ORV 

treatment area is extremely low. However, APHIS-WS does have the potential to incidentally capture 

certain state-listed T&E and sensitive species during monitoring and surveillance. The following species 

have the potential to be taken during ORV monitoring and surveillance activities and are discussed in 

detail below. 

Southern Red-Backed Vole (Clethrionomys gapperi). The southern red-backed vole is a state-listed 

species of concern in Ohio. Voles may be large enough to be captured in small-wire mesh or enclosed 

traps used for monitoring smaller predators. These species only have a slight chance of being taken, even 

in cage traps, because the small rodents could exit the traps through gaps in the door. The primary 

concern with these species is exposure to the elements such as excessive sun/heat as this could result in 

lethal take. However, APHIS-WS would check traps frequently in these species’ occupied habitat so that 

any individuals captured could be released unharmed. APHIS-WS activities will not likely take these 

species, but a very slight potential exists. 

New England Cottontail (Sylvilagus transitionalis) and Snowshoe Hare (Lepus americanus). The 
56

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

New England cottontail is state-listed as a species of special concern in New York and the snowshoe hare 

is state-listed as an endangered species in Ohio. These species could be taken in cage traps, leghold traps, 

or snares. If cage traps are used in their ranges, they will be located such to minimize exposure and 

checked frequently enough to release them alive. Leghold traps will be equipped with pan-tension 

devices to preclude capture. Snares will be elevated off the ground high enough to minimize potential 

exposure especially for cottontails or not set in areas where they would likely be taken. Therefore, 

proposed activities in Alternative 2 will have minimal potential to take these species and will have 

virtually no impacts on their populations. 

American Marten (Martes Americana). This species is state-listed as endangered in Vermont. It is 

conceivable that this species could consume ORV baits intended for other target species. Although not 

specifically tested for safety in this species, safety studies on other nontarget species (Knowles et al. 

2009) indicate that martens would not be adversely affected if they were to consume ORV baits. If a 

marten were inadvertently captured in a trap set for the target species, it would be released unharmed to 

avoid lethal take and reported to the appropriate state agency to complement their population monitoring 

data for this state-listed species. An indirect beneficial effect of rabies management would be a reduced 

risk of the species suffering further declines due to a rabies epizootic. Therefore, the proposed action 

should have no significant impact on this species. 

Bobcat (Lynx rufus). The bobcat is state-listed in Ohio. While bobcats are not likely to be attracted to 

lures used for raccoons and other predators, they potentially could be. Additionally, they may investigate 

new things in their environment. Typically, cage traps are used to capture ORV target species and should 

a bobcat be captured it would be released promptly. Traps will be placed in areas, as possible, to reduce 

the risk of the negative effects of exposure. It should be noted that bobcats may be targeted during 

surveillance, primarily in states where they are not listed. However, even so, the APHIS-WS ORV 

program will have no adverse effects on their population. 

Black Bear (Ursus americanus). Black bears are state-listed in Ohio. Although unlikely, the potential 

does exist for cage traps to capture black bear cubs. Traps are checked frequently and if a black bear 

were captured it would be release unharmed. The APHIS-WS ORV program will not adversely impact 

this species because take, if it occurs, would be exceedingly minimal. It should be noted that the black 

bear population in the eastern United States is expanding and growing, with several states now having 

more frequent damage problems associated with the increase.

American Badger (Taxidea taxus). This large mustelid is listed as a species of concern in Ohio, the 

eastern most portion of their range. This species could be taken during ORV monitoring and surveillance 

activities, however it is very unlikely that a badger will be captured in a cage trap. APHIS-WS will check 

traps frequently to release any captured badgers unharmed. Additionally, as possible, traps will be placed 

in locations to minimize exposure. APHIS-WS believes that few, if any, badgers will be taken in Ohio 

where they are listed and therefore potential impacts to badgers would be minimal to none. 

Ermine (Mustela ermine). This small weasel is an Ohio state-listed species of concern. Ermine could be 

taken in cage traps. Cage traps placed in their range will be checked frequently and placed in areas that 

limit exposure to minimize the potential for lethal take. APHIS-WS expects to not have more than a 

minimal effect, if any, on their populations.
57

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

4.1.2.3 Alternative 3: No ORV Field Trials 

Effects of the ONRAB® Vaccine on Nontarget Wildlife including Threatened or Endangered 

Species

Under the no ORV field trial alternative, there would be no potential for APHIS-WS assistance to result 

in adverse impacts on nontarget wildlife because of ORV field trials. 

Effects of capture/removal methods (used in monitoring and surveillance activities) on nontarget 

species, including threatened or endangered species

Under the no action alternative, the potential for APHIS-WS assistance to result in adverse impacts on 

nontarget wildlife would be zero because no capture/removal activities would occur. 

4.1.3 Potential for Adverse Effects on People, Pets, and Livestock that are Exposed to or 

Consume the Vaccine Laden Baits 

4.1.3.1 Alternative 1: Current Action (the No Action Alternative) 

Potential to Cause Rabies in Humans

The nature of the recombinant virus used as the ONRAB® vaccine is such that it cannot cause rabies. 

This is because the ONRAB® vaccine only carries the gene for producing the outer coating of the rabies 

virus (i.e., rabies virus glycoprotein) and not those portions of the virus that could result in replication of 

the rabies virus which would have to happen for the disease to occur. Implementation of ORV programs 

would reduce the risk of humans contracting rabies by reducing the chance of encountering rabid animals 

that have been infected by rabid raccoons, striped skunks, foxes, or coyotes. 

Potential for the Human Adenovirus Type 5 (Ad5) to Cause Disease in Humans

The ONRAB® vaccine employs a human adenovirus type 5 vector into which has been inserted a DNA 

copy of the ERA® virus glycoprotein gene. Adenoviruses belonging to the family Adneviridae are 

nonenveloped DNA viruses, and are commonly found in mammals, including humans (RandrianarisonJewtoukoff and Perricaudet 1995). This live human adenovirus-vectored rabies vaccine virus could cause 

infection in humans accidentally breaking open the bait packages, if the person is not already immune 

(CFIA 2008, 2010). In man, adenovirus infections are ubiquitous and are normally without significant or 

severe clinical symptoms. Usually, only the appearance of specific antibodies and seroconversion are 

indicative of an infection (Horowitz 1990 in Ranrianarison-Jewtoukoff and Perricaudet 1995). 

Nevertheless, some adenovirus serotypes can be the causative agents of mild or severe respiratory disease 

(Ranrianarison-Jewtoukoff and Perricaudet 1995). Specifically, Ad5 is a virus normally associated with 

mild respiratory symptoms endemic among preschool children (Orstavik and Wiger 1989 in Knowles et 

al. 2009). Vectors based on Ad5 have been extensively investigated for use in human gene therapy 

(Douglas 2007 in Knowles et al 2009) and thus, from a human health perspective, Ad5 is relatively 

innocuous although a single death has been documented in a clinical trial (Raper et al. 2003 in Knowles et 

al. 2009). 
58

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

Adenovirses are distributed worldwide and infections with human adenovirus type 5 do not result in 

serious disease (Rowe et al. 1995, Andiman and Miller 1982, Charlton et al. 1992, Russell 1998 in 

Rosatte et al. 2009). Ad5 is endemic in those parts of the world that have been studied and is associated 

with mild respiratory symptoms. By age one, 80% of children in the New Orleans area had acquired 

antibodies to adenovirus, with the percentage slightly lower in New York and Seattle. Antibodies against 

Ad5 was the third most common antibody detected (Foy 1997). Pre-existing antibodies to Ad5 or 

previous exposure to Ad5 will enable a rapid response to any subsequent exposure. 

In studies conducted on sera collected from adults, virus neutralizing antibody to Ad5 was detected in 

37% to 85% of the samples tested (Nwanegbo et al. 2004). This study reported 37% of sampled adults in 

the U.S. had neutralizing antibody to Ad5 virus. The percentage in the samples tested from Gambia and 

South Africa was much higher with approximately 85% to 80% detection rates respectively. The 37% 

seropositivity in the U.S. samples is lower than expected based on the information presented by Evans 

and Kaslow (1997). Other studies conducted in Europe indicated that 55% to 70% of samples from 

children >12 years old were seropositive for Ad5 antibody (Potter and Shedden 1963 and D’Aambrosio 

et. al. 1982). A study conducted in 2005 reported Ad5 seropositivity rates of 50% in the U.S., 82% in 

Haiti, 93% in Botswana, 93% in Zambia, and 88% in South Africa (Sumida et al. 2005). Most recently 

Cheng et al. (2005) reported the rate of Ad5 antibody occurrence in their North American test subjects as 

37.5%. Results from a previous study confirmed 55% of subjects had Ad5 antibody indicative of 

previous natural Ad5 infection. It is generally accepted that the majority of adults in North America will 

have been exposed to Ad5 during childhood. 

Human adenoviruses are currently being utilized in vaccine development due to their genetic stability and 

ability to be grown to high titers in a variety of cell types (Prevec et al. 1990 in Rosatte et al. 2009), and 

they are being considered to serve as vectors for human vaccination and gene therapy (Bonnekoh et al. 

1998, Molinier-Frenkel et al. 2000, Flotte 2004 in Rosatte et al. 2009). The prevalence of Ad5 antibody 

in the population has been suggested as one of the factors in the lack of efficacy of an Ad5 based human 

immunodeficiency virus (HIV) vaccine in clinical studies and has stimulated research into the use of less 

common adenovirus serotypes as a more suitable vector for use in human vaccine and gene therapy (A. 

Beresford, Artemis Technologies, Inc., pers.comm. 2011). 

While infection of people with human adenovirus type 5, more frequently children under five years old, is 

not generally associated with serious illness, it is noted, that adenoviruses are among the many pathogens 

and opportunistic agents that cause serious infection in congenitally immunocompromised persons, in 

patients undergoing immunosuppressive treatment for organ and tissue transplants and for cancers, and in 

HIV infected patients. In addition, adenovirus infection is observed to be more severe in children than 

adults. Therefore ONRAB® could present health hazards to humans, especially children or adults with 

immunocomprised status, given that ONRAB® is a live virus with replication potential (CFIA 2008, 

2010). Although infection with Ad5 is more frequent than other adenovirus types in children up to 5 

years of age, it is not generally associated with serious illness. In most cases, infection is limited to the 

upper respiratory tract with or without fever (Artemis 2010). Retrospective sampling studies of antibody 

titers to Ad5 show that, depending on the geographic region, from 50% to almost 100% of the population 

over the age of 5 years have been infected with Ad5 (Fox et al. 1969, van der Veen 1963, Vihma 1969 in 

Artemis 2010). The widespread immunity in humans over the age of 5 for related human type 5 
59

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

adenoviruses would make person-to-person spread of infection unlikely, even if significant contact with a 

bait’s blister pack contents was to occur (CFIA 2008, 2010). 

Human adenovirus 5 is widespread in the human population (Foy and Grayson 1976 in Charlton et al. 

1992), suggesting that few, if any, unforeseen consequences of human exposures to AdRG1 would occur 

(Charlton et al. 1992). Rosatte et al. (2009) discussed that there are no perceived environmental or public 

health impacts of distributing ONRAB® in Ontario, or elsewhere, because the vaccine has been 

extensively safety tested and it has been shown that there are very few human or companion animal 

contacts with the vaccine and no adverse reactions noted. Furthermore, adenovirus replication is highly 

species specific to the extent that developing an animal model of human infection has proven difficult. 

These properties suggest the Ad5 should be a safe viral vector for applications where widespread 

environmental release is conducted but experimental data are required to substantiate this position 

(Knowles et al. 2009). 

Over 100 million V-RG baits have been disbursed since APHIS-WS ORV program inception in 1995, yet 

only 1,464 people reported contacting or potentially contacting a bait (i.e., picking up bait, finding a bait 

in yard, or removing bait or sachet from pet’s mouth, feces, or vomit - any type of contact with a bait is 

also defined throughout the document as an “exposure”). This equates to one human exposure per 68,521 

baits distributed (0.0015% contact cases) (USDA 2011c). In addition, exposure cases were generally 

insignificant as most involved finding an intact bait. Very few cases involved touching a broken bait, 

sachet, or liquid vaccine. Furthermore, of the 0.0015% of contact cases reported since APHIS-WS ORV 

program inception in 1995, only two known adverse reactions have occurred (USDA 2011c, 2010; CDC 

2009). 

Recent V-RG bait exposure information collected during an ORV project completed in western 

Pennsylvania (August-September, 2003) revealed that out of 1,710,399 baits distributed over 

approximately 25,189 km2

, 190 humans or pets were exposed to a bait. This equates to one exposure per 

9,002 baits disbursed or 0.011% of distributed baits being found by pets or people. In at least 69 of the 

190 potential contact cases, the household pet (dog or cat) found the bait; however, the bait and sachet or 

sachet alone was normally still intact (at least 91% of cases). Of the six cases in which the sachet was 

ruptured, no reports were submitted regarding the development of an adverse reaction (i.e., lesions) 

(USDA 2004). This ORV project involved hand baiting in several urban areas such as Allegheny County, 

and aerial baiting of the rural areas. Therefore, pets and other domestic animals were more likely to find 

the baits and are the primary source for potential and human exposure to ORV baits. Most ORV baiting 

locations occur over rural or undeveloped lands where human exposure cases can be expected to be much 

lower. 

Hazards to public safety are not expected. The above information shows there is a minute potential for 

unusual circumstances to result in short-term adverse health effects from exposure to the human 

adenovirus type 5 in the ONRAB® vaccine. However, the overall risk of such effects appears to be 

minimal based on the extremely low rate of reported occurrences in ORV programs. 

Potential to Cause Cancer (Oncogenicity)

Adenoviruses are divided into three different subgroups based on their oncogenic potential. Subgroup A 
60

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

(adenovirus types 12, 18, and 31) is highly oncogenic, subgroup B (types 3, 3, and 16) are weakly 

oncogenic, and subgroup C (types 2, 5, and 6) are non-oncogenic (Fujinaga et al. 1979). The adenovirus 

used in the production of ONRAB® is type 5. 

Adenoviruses, like many DNA viruses, are known as tumor viruses because of their ability to induce 

tumors in experimental animals or transform cells in culture (Graham 1984 in Artemis 2010). There are a 

number of reasons for believing that adenoviruses are unlikely to be oncogenic in humans. First, no 

naturally occurring tumors in any animal have been shown to be caused by members of the adenovirus 

family in spite of the fact that adenoviruses are ubiquitous. In particular, an extensive survey of human 

tumors failed to find any evidence for virus specific sequences related to any of the three major groups of 

human adenoviruses (Green et al. 1979 in Artemis 2010). Second, even under the best experimental 

conditions, human adenoviruses are not highly effective at inducing tumors or transforming cells in 

culture. Third, in cell culture assays, adenoviruses generally replicate in, and lyse, cells from their normal 

host. Although human cells transformed by human adenoviruses exist, they have been generated only 

with considerable difficulty by DNA-mediated transformation techniques, using noninfectious viral DNA 

fragments (Graham et al. 1977 and Byrd et al. 1982 in Artemis 2010). 

Some Ad viruses (Ad 4, 7, 11, 21, 37) have a potential to be oncogenic or pathogenic, especially in 

infants and immunodeficient subjects. Because some Ad (e.g. Ad 12) can induce tumors in experimental 

animals, a search for human cancers induced by Ad was conducted. No convincing evidence of Ad 

involvement in human tumors has ever been reported (Randrianarison-Jeewtoukoff and Perricaudet 

(1995). 

Potential for Adverse Effects on Pet Dogs or Other Domestic Animals that Might Consume the 

Baits

Knowles at al. (2009) discussed results from ONRAB® in a variety of target and nontarget species. 

Several nontarget species included the following domestic livestock and companion animals: cows, 

horses, pigs, sheep, chickens, dogs, and cats. Although, histopathological findings included conditions 

related primarily to pulmonary congestion in 11 of the test subjects, no such results were found in the 

livestock and companion animals tested. This study concluded that upon examination of any gross 

pathological consequences of ONRAB®, the possible long-term consequences of virus in these species, 

and the possibility of environmental contamination as a result of vaccine excretion, all data indicate very 

low recovery of ONRAB® from tissues, feces, and oral samples of animals given a relatively high dose 

of vaccine. 

Overdosage of ONRAB® in amounts four to five times greater than the dose found in the vaccine baits 

resulted in no adverse effects in experiments involving skunks and raccoons (Artemis 2010). Therefore, 

even if domestic animals or other nontarget wildlife receive multiple doses of vaccine by consuming 

multiple baits, no adverse effects would be expected to occur. 

In APHIS-WS’ previously established ORV programs involving the V-RG vaccine, incidents involving 

dogs or cats finding and ingesting baits have been relatively limited. USDA (2011c) documented that of 

the more than 100 million baits distributed during the APHIS-WS program between 1995 and 2008 only 

1,327 instances have been reported where a pet or other domestic animal had contact with a bait. This 
61

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

equates to 1 domestic exposure per 75,596 baits disbursed or 0.001 % contact cases. In addition, USDA 

(2011c) documented that 261 incidents were reported in which pets came into contact with a bait in 2008; 

however, there were no reports of pets or other domestic animals experiencing any type of adverse 

reaction, other than 8 dogs who experienced vomiting or diarrhea after ingesting a number of baits. The 

dogs involved in the adverse reactions have reportedly not experienced any substantive or long term 

adverse effects. Domestic animals that bite into and ingest a bait of either V-RG or ONRAB® are most 

likely to be immunized against rabies or receive a boost from a previous vaccination. USDA (2011c) also 

documented the number of baits distributed in those states conducting ORV programs and the number of 

people who reported contact or potential contact with a bait by their pet or other domestic animal (i.e., 

carrying bait in mouth, chewing bait, vomiting sachet). In 2008, 261 incidents were reported in which 

pets came into contact with a bait. The number of documented exposures equates to 0.002% of the 11.5 

million baits distributed in 2008 or one domestic animal exposure per 44,091 baits distributed (USDA 

2011c). 

In 2011, following APHIS-WS ONRAB® field trial in WV, there were zero reports of pets or livestock 

contacting either intact baits or vaccine. Adverse effect to pets or other domestic animals that are exposed 

to or consume the vaccine laden bait are expected to be negligible. 

4.1.3.2 Alternative 2: Proposed Action (the Preferred Alternative) 

Potential for Adverse Effects on People that Become Exposed to the Vaccine or Baits

The expanded ONRAB® field trial sites include portions of NH, NY, OH, VT, and WV. Table 4-1 

shows the number of baits distributed in those states since program inception using the current V-RG 

vaccine and the number of human contacts4

 during the corresponding time period (from USDA 2011c). 

Table 4-1. Previous human/V-RG bait exposures in expanded field trial states. 

 NH NY OH VT WV 

Year ORV activities implemented 

in state 

2001 1998 1997 1997 2001 

Total V-RG baits dropped since 

program inception 

231,130 13,369,780 11,880,381 555,433 11,416,672 

Total V-RG bait contacts since 

program inception4

4 443 304 112 95 

Percent of baits dropped resulting 

in human contact 

0.002% 0.003% 0.003% 0.01% 0.001% 

Number of baits distributed per 

contact 

57,783 30,180 39,080 8,720 151,754 

Of the approximately 79,000 ONRAB® baits distributed in WV during 2011, there were zero calls or 

reports of human exposures to either intact baits or liquid vaccine. The baits did contain a warning label 

and were marked with a toll-free number that would put callers in direct contact with public health 

officials. To improve the surveillance for bait and vaccine contacts, a communication campaign was 

cooperatively implemented by WS specifically for the 2011 ONRAB® field trial. This campaign focused 

                                                           

4

 “Exposures” for purposes of this document include all reported calls whether baits were actually touched or not. For instance,

callers may have noticed baits in their yards or on roads, but it does not necessarily mean that they touched or moved the baits. In 

other situations, people may have picked up a bait with gloves and threw it into the woods or garbage. 
62

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

on raising public awareness of the field trial, enhancing public understanding of ORV and the associated 

risk of contact with baits and vaccine, and to increase reporting of potential vaccine exposures. 

WS further enhanced communication efforts through the preparation and distribution of a national press 

release about the 2011 field trial. Four media (television and newspaper) interviews were conducted at a 

media event in WV and at a county level meeting, where a detailed presentation on the ONRAB® field 

trial was given to county officials and to the public. WS also collaborated with multiple state, university, 

federal, and international partners to develop a list of talking points to assist in the coordination of 

information presented to the public, facilitate data collection on potential bait and vaccine exposures, and 

to ensure safety concerns were adequately addressed by all cooperating agencies. APHIS-WS will 

implement similar outreach efforts for the proposed expanded field trials to minimize the potential for 

human-bait exposures (see Section 3.3 for detailed SOPs employed by APHIS-WS to reduce negative 

effects of the ORV program). 

The province of Quebec has been distributing ONRAB® vaccine baits since 2007. Between 2007 and 

2009, despite the distribution of almost 2 million ONRAB® baits, there were only 16 reports of human 

exposures4

 (Mainguy and Canac-Marquis 2010). In 2010 just over 1 million baits were distributed with 

no human contacts reported (OMNR 2011). In all of these cases, no medical follow-up was required 

(Mainguy and Canac-Marquis 2010). Additionally, although hand distribution of baits occurred in and 

around the city of Montreal, there were zero reports of human contacts from this urban area. This may be 

due to several factors. First, the ONRAB® vaccine baits differ from the previously used V-RG baits in 

both color and scent. The ONRAB® bait matrix is a khaki green color which may aid in camouflaging 

the baits better in most habitats than the V-RG bait. The ONRAB® bait contains a sweet scent rather 

than a fish scent which may reduce the incidents of baits being found by domestic cats. Second, the 

province of Quebec employs a very targeted hand bating approach which avoids high profile areas and 

concentrates baits in target species desirable habitat thereby reducing the potential that a bait will be 

found by a human (pers. comm. Canac-Marquis 2011). Baits are concentrated along rivers and in parks. 

By adopting a similar approach, APHIS-WS will reduce the potential for human contacts in and around 

urban centers. 

During the 2007 Quebec ONRAB® baiting, a company producing green peas found two vaccine baits in 

their production line. The baits were intact and the CFIA considered that this event did not have any 

impact on the products. Again, in 2008, two ONRAB® baits were found by the same producer in a green 

bean production line. This time the vaccine packet was broken and it was considered by CFIA that there 

was a chance that the vaccine liquid could have been in contact with the vegetables. In this case, the 

contaminated portion of the production was considered by CFIA to not be acceptable for human 

consumption. A second incident occurred in 2008 in which an intact packet was found by a romaine 

lettuce producer in the middle of the leaves (Mainguy and Canac-Marquis 2010). 

In order to avoid such incidents, the Quebec Ministry of Natural Resources and Wildlife (QMNR) 

changed subsequent aerial distribution techniques and patterns in certain landscapes which has allowed 

them to completely avoid low level cultural fields or to use hand distribution of baits in farming areas 

where aerial time-off is more than 65%. As a result of these changes, no incidents have been reported 

since 2008 (Mainguy and Canac-Marquis 2010). 
63

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

Northern Vermont and Southern Quebec share several similarities in terms of human population density 

and land cover and use. The Estrie and Monteregie Regions of southeastern Quebec (areas receiving 

ONRAB® bait distribution) have population densities of 30.4/km2 (78.7/mi2

) and 129.7/km2 (335.9/mi2) 

(ISQ 2012) respectively, while the northern VT counties within the proposed ONRAB® field trial have 

an average population density of 33.2/km2

 (86/mi2) (USDC 2012a). Land use and cover in northern VT is 

an array of deciduous, mixed forest, pasture/hay, and cultivated to mixed forest and coniferous at higher 

elevations (Bailey 1995, USDC 2012b). Similarly, southern Quebec features mixed deciduous broadleaf 

forest, cropland, and mosaic lands (mix of cropland and forest) (NRCA 2012). These factors could be 

expected to result in similar rates of bait contacts using similar baiting strategies. 

The province of Ontario has been distributing ONRAB® baits since 2006. As in the U.S., baits 

distributed in Canada are marked with a toll-free number that the public can call should they see or 

contact a bait. If there was a public health or animal health concern as a result of these reports, 

arrangements are immediately made for the caller to make contact with a medical doctor or veterinarian, 

or the local Medical Officer of Health or a Canadian Food Inspection Agency (CFIA) veterinarian, if 

necessary. People that had found intact bait(s) were generally asked to place the baits in a nearby wooded 

area. Between 2006 and 2011 over 3.9 million ONRAB® baits have been distributed in Ontario. There 

were a total of 64 calls received in which a caller reported finding or contacting a bait. This equates to 

approximately 1 call for every 65,140 baits distributed or 15 calls for every million baits distributed. The 

total number of calls received reporting a possible contact with the vaccine by handling a punctured bait 

or removing a bait from a dog’s mouth or dog chewing a bait was 15. The rate of possible contact with 

vaccine equates to 1 contact for every 260,560 baits distributed. There were no reports of adverse effects 

to humans from any of the reported contacts (OMNR 2011, 2010, 2009, 2008, 2007). The OMNR did 

report that distribution of baits in urban areas, particularly the Niagara region, led to a disproportionate 

number of reports stemming from that area and that higher human population densities increase the 

likelihood of a bait being found (OMNR bait contact summary unpublished). Although APHIS-WS is 

proposing to distribute ONRAB® baits in urban areas (including Cincinnati, OH), methods that will be 

used to mitigate the potential for human contacts are addressed in SOP Section 3.3. 

As with the current program, hazards to public safety are not expected, but are factored into operations 

and communications planning. Using current baiting practices, the rate of encounters with V-RG baits 

(those used in APHIS-WS national ORV program) is 1 human encounter for every 68,521 baits 

distributed (USDA 2011c). It is likely that this rate may be lower with the use of ONRAB® baits as 

discussed above. The overall risk of such effects appears to be minimal based on the extremely low rate 

of reported occurrences in ORV programs. 

Potential for Adverse Effects on Pet Dogs or Other Animals that Might Consume the Baits

Section 4.1.3.1 of this EA concluded that ONRAB® field trials have only a negligible risk of adversely 

affecting pets or other domestic animals that are exposed to or consume the vaccine laden bait. The 

OMNR has distributed ONRAB® baits in Ontario since 2006. Of the more than 3.9 million baits 

distributed in Ontario between 2006 and 2011, there have been only 25 reports of dogs finding or 

consuming bait (OMNR 2011, 2010, 2009, 2008). Of these 25 reports, there were 2 adverse reactions in 

dogs involving vomiting. APHIS-WS expects that the expansion of ONRAB® field trial locations will 

continue to pose only a negligible risk of adverse effects to pets and other domestic animals. 
64

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

4.1.3.3 Alternative 3: No ORV Field Trials 

Potential to Cause Rabies in Humans

The no ORV field trials alternative would likely result in greater risk of human exposure to rabies than the 

proposed action. Without field trials to address the immunogenicity of new vaccines, current vaccines 

may not be successful in stopping or preventing the spread of the raccoon, grey fox, and coyote rabies 

virus variants. As discussed in Section 1.1.3, the current vaccines available do not produce sufficient 

levels of population immunity in all species. Therefore, an absence of new field trials could be expected 

to result in increased risk of human rabies cases because of expanding epizootics. 

Potential for Adverse Effects on Pet Dogs or Other Domestic Animals that Might Consume the 

Baits

Under the no ORV field trials alternative, the potential for APHIS-WS activities to result in adverse 

impacts on domestic pets or other domestic animals would be zero. However, in the absence of field 

trials to determine new efficacious vaccines, failure to stop or prevent the spread of rabies would result in 

adverse effects on domestic animals by increasing their likelihood of exposure to rabid wild animals. 

4.1.4 Potential for the Recombined ONRAB® Virus to “Revert to Virulence” or Recombine with 

other Viruses and Result in a Virus that Could Cause Disease in Humans or Animals 

4.1.4.1 Alternative 1: Current Action (the No Action Alternative) 

Potential for the Recombined ONRAB® Virus to “Revert to Virulence” and Result in a Virus that 

could Cause Disease in Humans or Animals

The concern here is whether the ONRAB® recombinant virus is genetically stable so that it would not 

become virulent (i.e., capable of causing disease) after it replicates (or reproduces) in animals that eat 

ORV baits containing the ONRAB® vaccine and perhaps be transmitted to other animals. 

An important concern from the standpoint of safety is that of genetic stability, since predictions of the 

vaccine behavior rely heavily on the knowledge of the genetic makeup of the recombinant. In order for a 

recombinant vaccine to be useful it should not undergo substantive mutation during production of the 

vaccine by passage or upon administration to the target species (Lutze-Wallace et al. 1995a). LutzeWallace et al. (1995a) examined AdRG1 (the precursor to AdRG1.3) for genetic stability upon 20 

passages5

 in a permissive6 human cell line. The results from this study indicated that the product obtained 

after 20 passages expressed authentic rabies glycoprotein. Since there is little evidence in the literature 

for the replication of Ad5 in animal species, the primary concern with ONRAB® is the maintenance of 

the rabies glycoprotein gene (Knowles et al. 2009). The data obtained from the Lutze-Wallace et al. study 

                                                           

5

 This means the AdRG1 was inoculated into one group of cells from which material containing the virus was obtained later and 

injected into a second group of cells, and then material obtained from the second group was injected into a third group, etc., until 

twenty such passages had been conducted. 

6

 A permissive cell is a cell that supports replication of a virus. 
65

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

suggests that the AdRG1 recombinant live viral vaccine underwent no major mutations and indicate that 

the genetically engineered vaccine virus is highly genetically stable. 

In another study, Lutze-Wallace et al. (1995b) examined the genetic stability of AdRG1 upon passage 

through orally vaccinated skunks. Vaccine virus, recovered from vaccinated skunks, was propagated on 

permissive cells. Passage of oral swab, rectal swab, and fecal suspensions produced 111 samples which 

were positive for AdRG1. Of these 111 isolates examined, three mutants comprising two forms of the 

vaccine virus were found, an insertion mutant (one case) and a deletion mutant (two cases). All three 

mutants were isolated from animals receiving the same lot of vaccine. The exact origin of these two 

mutant forms of the vaccine virus AdRG1 is not known. It may be possible that these mutants were 

present in the vaccine lot administered to the animals; however passages of 99 isolated plaques of the 

vaccine virus lot in question yielded no detectable mutants. Mutants were also not detected when vaccine 

virus was diluted to 20 plaque forming units (pfu) (150 samples) and subsequently passaged on 

permissive cells. Another possible explanation for the appearance of these mutants is through limited 

replication of the virus in the recipient animal (Lutze-Wallace et al. 1995b) 

Recently, Knowles et al. (2009b) conducted both in vitro7

 and in vivo8 passages with ONRAB®. The 

results from this study indicated that the titer of the ONRAB® virus, harvested from 20 in vitro passages, 

was maintained at a fairly constant level. From the 20th passage, 67 virus clones were recovered for 

molecular characterization and in all cases the size of the resulting amplicon9

 matched what was expected, 

indicating no substantial alteration in sequence over this region. The in vitro genetic stability of the 

ONRAB® construct was established by demonstrating that 67 independent viral clones, recovered after 

20 passages in cell culture, exhibited no sequence variation over the transgene region. This is in accord 

with the high genetic stability reported previously for the AdRG1 recombinant (Lutze-Wallace et al. 1995 

a). If mutations within the transgene region had emerged in even a small proportion of viruses of the 

stock population, the approach used by Knowles et al. (2009b) would have allowed for their 

identification. For the in vivo passages a total of five sequential passages were performed using 5 groups 

of 5 cotton rats. During the in vivo passages, none of the animals exhibited any clinical symptoms 

throughout the course of the experiment. For each series of cotton rats, lung homogenates yielded virus 

titers between 104 and 105 TCID50/ml after the first and second passages. Following the third passage (in 

four of the series) and the second passage (in one series), virus titers dropped to levels insufficient for 

continued passaging. 

The experiments demonstrated that the ability of the ONRAB® virus to cause disease does not increase 

by repeated animal passage, thus “reversion to virulence” is unlikely. Further alleviating the concern 

about this issue is the evidence that the virus does not transmit readily to other animals from animals that 

have consumed ORV baits as evidenced by Charelton et al. (1992). This noted that foxes that had been 

vaccinated with AdRG1 shed adenovirus from oral fluids and feces for a very brief period (2 days) after 

vaccination and most skunks only excreted virus 1-3 days post-vaccination; however, 1 out of 8 skunks 

may have virus in oral fluids at 10 days post-vaccination (Charelton et al. 1992). The short period of 

fecal excretion after oral vaccination suggests that there is little or no replication of AdRG1 in the 

                                                           

7

 Meaning outside of a living body. 

8

 Meaning within a living body. 

9

 A piece of DNA formed as the product of natural or artificial amplification events.
66

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

intestine, and that there would be minimal or no inter-animal transmission when AdRG1 is used in the 

field. 

Potential for the ONRAB® Vaccine to Recombine with Other Viruses in the Wild to Form New 

Viruses that could Cause Disease in Humans or Animals

The concern here is whether the ONRAB® vaccine in the ORV baits might encounter other viruses in 

animals, exchange genetic material with them during replication, and result in new viruses that could 

cause serious diseases in humans or animals. 

According to Artemis (2010), regarding the potential for ONRAB® to recombine with naturally occurring 

adenoviruses, the end product of ONRAB® recombining with wild human adenovirus type 5 would be 

human adenovirus type 5. Thus this vaccine is extremely safe in terms of recombination potential. 

The potential for in vivo recombination of the adenovirus-vectored recombinant vaccine with field and 

other viruses is unknown, but is considered small (CFIA 2008, 2010). For intergenic recombination to 

occur, two related viruses would have to infect the same cell. The likelihood of co-infection of individual 

cells would be predicted to be a rare event because the proposed vaccine has a single viral component and 

the vaccine virus does not lead to infection in the target species or other wildlife species that are likely to 

consume the baits. Therefore, occurrence of recombination in vivo is not expected (CFIA 2008, 2010). 

In practice, opportunities for co-infection between different adenovirus species are already present in 

large animal veterinary medicine and farming practices, where natural or intentional adenovirus infections 

may occur simultaneously in both humans and other animals. Under such circumstances, both humans 

and other animals may have two different natural adenovirus infections with an opportunity for cross-over 

infections. Recombination between adenoviruses infecting different species is perhaps more likely in 

existing settings of human/animal co-habitation at high population densities, rather than in the lower 

population density, wildlife situations. Should recombination occur, it is unlikely that such an event 

would yield a viable, transmissible virus, with enhanced pathogenicity for wildlife, domestic animals, or 

humans (CDC 2011b). 

A concern regarding the release of recombinant vaccines is their ability to remain viable in the 

environment for prolonged periods; however, a recombinant vaccine must also have a suitable shelf-life 

and retain its infectivity long enough in the field to successfully immunize target species (Kalicharran et 

al. 1992). Persistence and stability of the ONRAB® virus outside of an organism is highly dependent on 

ambient temperatures and local environmental conditions. Kalicharran et al. found that at ambient 

temperatures up to 24-25o

C (75-77oF), the half-life of Ad5RG1 (the predecessor of AdRG1.3) would be 

several weeks. Additionally, several feces samples from experimentally-vaccinated foxes and skunks 

were screened but none had a reasonably high titer of infectious virus. Of note, bacteria and fungi were 

removed from the tested feces samples by filtration, whereas whole feces would contain large numbers of 

viable microorganisms which could inactivate the viruses contained therein (Kalicharran et al. 1992). 

Once a virus is outside of the blister pack and exposed to microbiological and/or enzymatic activity in the 

environment, it will degrade more rapidly than it would inside the protective blister pack (A. Beresford, 

Artemis Technologies Inc., 2011, pers. comm.). 
67

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

4.1.4.2 Alternative 2: Proposed Action (the Preferred Alternative) 

Potential for the Recombined V-RG Virus to “Revert to Virulence” and Result in a Virus that 

could Cause Disease in Humans or Animals

A similar impact, as with Alternative 1, is expected with regard to expanding APHIS-WS’ ONRAB® 

field trial into New Hampshire, New York, Ohio, Vermont, and West Virginia. Therefore, APHIS-WS 

has determined that adverse effects regarding this potential issue would be minimal. 

Potential for the ONRAB® Vaccine to Recombine with Other Viruses in the Wild to Form New 

Viruses that could Cause Disease in Humans or Animals

A similar impact, as with Alternative 1, is expected with regard to the proposed action. Therefore, 

APHIS-WS has determined no effect regarding this potential issue. 

4.1.4.3 Alternative 3: No ORV Field Trials 

Under the no ORV field trials alternative ONRAB® ORV baits would not be distributed, therefore the 

potential of the vaccine to revert to virulence or recombine would not be a concern here. 

4.1.5 Potential for Aerially Dropped Baits to Strike and injure People, or Domestic Animals 

4.1.5.1 Alternative 1: Current Action (the No Action Alternative) 

ORV baits would be distributed from aircraft at an average density of 75 baits per km2

 (194 baits per mi2). 

This density is sparse enough to predict that the chance of a person being struck and harmed by falling 

bait is extremely remote. For example, if 100 persons were standing outdoors in a square mile of area in 

which ORV baits were being dropped, and each person occupies about 2 square feet of space at the time 

that baits were dropped, the chance of being struck would be 1 in 139,000 (200 ft2

 total space occupied by 

persons divided by 27.8 million ft2

 per mi2). The negligible risk of being struck is further supported by 

the fact that out of more than 100 million baits distributed in the U.S. by APHIS-WS during other ORV 

programs between 1995 and 2008, only 11 incidents have been reported in which a person claimed to 

have been struck by a falling bait (0.00001% chance of being struck by a bait or 1 strike per 9.1 million 

baits dropped) (USDA 2011c). None of the reports since APHIS-WS’ ORV program inception have 

resulted in any injury or harm to the individuals involved. In addition, trained aircrews avoid dropping 

baits into cities, towns, and other areas with human dwellings, or if humans are observed below. In areas 

with higher human density, ground placement of baits is normally used. These techniques used by 

APHIS-WS’ current ORV programs would also be employed during the ONRAB® field trials. 

Of the 11.5 million V-RG baits that were distributed by APHIS-WS in other ORV programs in 2008, 

there were no reports received in which a person claimed to have been struck by falling bait. No reports 

of injury were received during the 2008 APHIS-WS ORV program (USDA 2011c). In 2008, no cases 

were documented involving falling baits striking or injuring domestic animals. Additionally, in 2008, no 

reports were received regarding baits striking property (USDA 2011c). The potential for falling baits to 

strike or injure people or domestic animals continues to be insignificant. Impacts of the program on this 

issue are expected to remain negligible. The potential for baits to strike people or animals is further 

mitigated by the fact that bait disbursal crews avoid dropping baits into cities, towns, and other areas with 
68

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

human dwellings, or if humans are observed below. Hand placement or dropping of baits from slower 

moving helicopters to allow for more precise control over the areas on which the baits are dropped would 

primarily be used in urban parks or suburban situations, which would further reduce the risk of being 

struck. 

4.1.5.2 Alternative 2: Proposed Action (the Preferred Alternative) 

Under the proposed program baits will be distributed at common densities of 75 baits/km2 (194 baits/mi2

) 

or 150 baits/km2 (388 baits/mi2). A similar impact, as with Alternative 1, is expected with regard to 

implementation of the proposed action. Although APHIS-WS is proposing to distribute ONRAB® over a 

wider geographic region (portions of NH, NY, OH, VT, and WV), the analysis for Alternative 1 indicates 

that APHIS-WS’ current ORV program, which included bait distribution over 16 eastern states and Texas 

in 2008 (USDA 2011c), has resulted in minimal potential for adverse effects regarding this issue. 

Therefore, APHIS-WS has determined that adverse effects resulting from the proposed program regarding 

this potential issue would be minimal. 

4.1.5.3 Alternative 3; No ORV Field Trials 

Under the no ORV field trials alternative, the potential for APHIS-WS actions to result in this risk would 

be zero because no APHIS-WS ORV trials would occur. 

4.1.6 Humaneness of Methods Used to Collect Wild Animal Specimens Critical for Timely 

Program Evaluation 

4.1.6.1 Alternative 1: Current Action (the No Action Alternative) 

Some people would view methods employed to capture and/or kill skunks and raccoons, as well as other 

wild animals for monitoring and surveillance or local depopulation purposes, as inhumane. Humaneness, 

as it relates to the killing or capturing of wildlife, is an important but complex concept that can be 

interpreted in a variety of ways. Humaneness is a person's perception of harm or pain inflicted on an 

animal, and people may perceive the humaneness of an action differently. 

However, humaneness as it relates to the natural world through natural mortality versus man-induced 

mortality must be brought into perspective. DeVos and Smith (1995) explain the characteristics of natural 

mortality in wildlife populations. There seems to be an increasing public perception that, left alone by 

humans, animal populations will experience few premature deaths and live to an old age without harm, 

pain, or suffering. It should be recognized that wildlife populations reproduce at far greater rates than 

would be necessary to replace deaths if all lived to old age. To counterbalance this high reproduction, it 

is natural for most individuals of most species to die young, often before reaching breeding age. Natural 

mortality in wildlife populations includes predation, malnutrition, disease, inclement weather, and 

accidents. These “natural” deaths are often greater in frequency than human-caused deaths through 

regulated hunting, trapping, and wildlife damage management operations. From the standpoint of the 

animal, these natural mortality factors also may cause more suffering by wildlife, as perceived by 

humans, than human-induced mortality. Under given habitat conditions, most wildlife populations 

fluctuate around a rather specific density, sometimes called the carrying capacity. Populations that 

overshoot this density via reproduction become very sensitive to various sources of mortality, and death 
69

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

rates increase. Conversely, as populations drop, mortality rates decline (DeVos and Smith 1995). Thus, 

human-induced mortality, which often involves much less suffering of individual animals, invariably 

lessens mortality from other sources. For example, it would seem that an animal taken in a leg-hold trap 

or by a snare, would certainly suffer less than if it died from rabies. 

APHIS-WS has made modifications to management devices through research and development which 

have increased selectivity toward the species being targeted. Research is continuing with the goal of 

bringing new findings and products into practical use. Until such time as new findings and products are 

found to be practical, some animal suffering will occur during lethal collection of animal specimens if 

monitoring and program effectiveness objectives are to be met. 

4.1.6.2 Alternative 2: Proposed Action (the Preferred Alternative) 

As with Alternative 1, a similar impact is expected with regard to the implementation of the proposed 

program. 

4.1.6.3 Alternative 3: No ORV Field Trials 

Under the no action alternative, APHIS-WS would not assist in collecting wild animal specimens for 

ORV monitoring programs. Failure of a successful ORV field trial would likely result in an increased, 

but varying, proportion of the skunk and other wild mammal species populations succumbing to rabies 

when exposed to the various specific strains. The symptoms of rabies include insomnia, anxiety, 

confusion, slight or partial paralysis, excitation, hallucinations, agitation, hypersalivation, difficulty 

swallowing, and hydrophobia (fear of water) (CDC 2011). Some persons might argue that dying from 

rabies, which can take several days once symptoms appear, results in more animal suffering than being 

captured or killed through monitoring and surveillance activities. In any event, it is almost certain that 

much larger numbers of animals would succumb to rabies without effective ORV programs than would 

experience stress and suffering from being captured or killed by monitoring activities. The number of 

animals dying of rabies could increase dramatically as epizootics of specific strains spread across larger 

areas of the U.S. With this in mind, it would appear that, on balance, the implementation of successful 

ORV programs that include animal collections for monitoring results in less animal suffering than taking 

no action. 

4.2 CUMULATIVE IMPACTS 

Cumulative impacts, as defined by the Council on Environmental Quality (CEQ) (40 CFR 1508.7), are 

impacts to the environment that result from incremental impact of the action when added to other past, 

present, and reasonably foreseeable future actions, regardless of what agency (federal or non-federal) or 

person undertakes such actions. Cumulative impacts may result from individually minor, but collectively 

significant, actions taking place or time. 

No significant cumulative environmental impacts are expected from either the Proposed Action or 

Current Action. Under the No ORV Field Trials Alternative, APHIS-WS would have no impact on the 

issues evaluated; however implementation of this alternative might indirectly lead to increased human 

exposures and domestic and wild animal rabies cases across much of the U.S. As discussed in Chapter 4, 

APHIS-WS and cooperating state and local agencies expect to continue to live-trap or lethally remove 
70

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

less than one percent of the lowest estimated number of the target species combined for monitoring and 

surveillance purposes or implementation of contingency plans involving lethal population reduction in all 

of APHIS-WS’ ORV programs, including the AgRG1.3 field trial. 

Additionally, as discussed in Chapter 4, the potential for adverse effects resulting from the recombination 

of ONRAB® with other adenoviruses is negligible. It is unlikely that an exchange of genetic material 

with wild-type virus would occur in the field. Even if it did occur, the event would not be expected to 

generate a more virulent virus than the already present wild-type virus (USDA 2011a). Broadening the 

distribution of ONRAB® will not alter this potential. 

Although some persons will likely remain opposed to the use of recombinant vaccines or the use of 

human adenovirus type 5 as a component of ORV, and some will remain opposed to the lethal removal of 

raccoons, skunks, and other wild animals for monitoring purposes, the analysis in this EA indicates that 

ORV use and such lethal removals will not result in significant risk of cumulative adverse impacts on the 

quality of the human environment. 

4.3 SUMMARY OF IMPACTS OF ALTERNATIVES FOR EACH ISSUE 

Table 4-2 presents a comparison of the alternatives and environmental consequences (impacts) on each of 

the issues identified for detailed analysis: 

Table 4-2. Issues/Impacts/Alternatives - Comparison

Alternative 3: No ORV field 

trials

Alternative 1: Current Action 

(the no action alternative) 

Alternative 2: Proposed Action 

(the preferred alternative) 

Alternative 3: No ORV field 

trials 

Potential for adverse effects on 

target wildlife species 

populations.

 Effects of the ONRAB® 

vaccine on target species. 

No probable risk of adverse 

effects.

No probable risk of adverse 

effects.

No risk.

 Effects of monitoring and 

surveillance on target 

species. 

Very low impact. Very low impact. (Similar to Alt. 

1)

No impact.

 Effects of monitoring and 

surveillance on other 

species not targets for 

purposes of ORV, but 

which may be considered 

targets for monitoring and 

surveillance 

Low impact Low impact. (Similar to Alt. 1) No impact

Potential for adverse effects on 

nontarget wildlife species, 

including threatened or 

endangered species.

 Effects of the ONRAB® 

vaccine on nontarget 

wildlife including 

threatened and endangered 

species. 

No adverse effect on T&E 

species. No probable risk of 

adverse effects on other nontarget 

species. 

No adverse effect on T&E 

species. No probable risk of 

adverse effects on other nontarget 

species.

No effect. 

 Effects of capture/removal 

methods (used in 

monitoring and surveillance 

activities) on nontarget 

species, including 

threatened and endangered 

species. 

No effect on T&E species; Very 

low risk of adverse effects on 

other nontarget species. 

No effect on T&E species; Very 

low risk of adverse effects on 

other nontarget species.

No effect. 

Potential for adverse effects on 
71

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

people, pets, and livestock that 

are exposed to or consume the 

vaccine laden baits. 

 Potential to cause rabies in 

humans. 

No probable risk. No probable risk. No risk. 

 Potential for the human 

adenovirus type 5 (Ad5) to 

cause disease in humans. 

Possible but risk is low; risk of 

significant adverse effects on 

individuals that experience Ad5 

infections is also low. 

Possible but risk is low; risk of 

significant adverse effects on 

individuals that experience Ad5 

infections is also low. 

No risk. 

 Potential to cause cancer 

(oncogenicity) 

No probable risk. No probable risk. No risk. 

 Potential for adverse effects 

on pet dogs or other 

domestic animals that might 

consume the bait. 

Low risk; Possible benefit from 

improving immunity to rabies. 

Low risk; Possible benefit from 

improving immunity to rabies.

No risk 

Potential for the recombined 

ONRAB® virus to “revert to 

virulence” or recombine with 

other viruses and result in a virus 

that could cause disease in 

humans or animals. 

 Potential for the 

recombined ONRAB® 

virus to “revert to 

virulence” and result in a 

virus that could cause 

disease in humans or 

animals 

Very low risk. Very low risk. No risk. 

 Potential for the ONRAB® 

virus to recombine with 

other viruses in the wild to 

form new viruses that could 

cause disease 

Very low risk Very low risk No risk. 

Potential for aerially dropped 

baits to strike and injure people 

or domestic animals. 

Low risk. Low risk. No risk. 

Humaneness of methods used to 

collect wild animal specimens 

critical for timely program 

evaluation. 

Capture and handling of skunks 

would be viewed by some 

persons as inhumane, but many 

animals saved from suffering and 

death due to rabies. 

Capture and handling of skunks 

would be viewed by some 

persons as inhumane, but many 

animals saved from suffering and 

death due to rabies. 

Probably less impact on this issue 

than Alt. 2; more animals likely 

to die of rabies if lack of federal 

action reduces effectiveness of 

ORV programs. 
A-1 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

APPENDIX A

LIST OF PREPARERS AND REVIEWERS/AGENCIES CONSULTED 

LIST OF PREPARERS: 

Beth Kabert, Wildlife Biologist - Environmental Coordinator, USDA, APHIS-WS, Pittstown, NJ – 

writer/editor 

Richard Chipman, Acting National Rabies Program Coordinator, USDA, APHIS-WS, Concord, NH – 

Writer/editor 

Dennis Slate, National Rabies Program Coordinator, USDA, APHIS-WS, Concord, NH – 

writer/editor 

David Ede, Forest Planner and Environmental Coordinator, USFS, Monongahela National Forest, 

Elkins, WV - writer/editor 

Robert Hale, IT Specialist-Rabies Planner, USDA, APHIS-WS, Reynoldsburg, OH – prepared maps 

LIST OF REVIEWERS/AGENCIES CONSULTED: 

In addition to the reviewers listed above, the following federal and state agencies and persons were 

consulted on various aspects of the information and analysis in this EA: 

Lauren Axley, Attorney Advisor, Office of the General Council, USDA, Washington, D.C. 

Dr. Charles Rupprecht, Chief, Rabies Section, CDC, Atlanta, GA 

Chris Croson, State Director, USDA, APHIS-WS, Elkins, WV 

Parker Hall, State Director, USDA, APHIS-WS, Concord, NH 

Martin Lowney, State Director, USDA, APHIS-WS, Castleton, NY 

Andy Montiney, State Director, USDA, APHIS-WS, Reynoldsburg, OH 

Clyde Thompson, Forest Supervisor, USFS, Monongahela National Forest, Elkins, WV 

Andrew Beresford, President, Artemis Technologies, Inc., Guelph, Ontario, Canada 

Dennis Donovan, Rabies Research and Development Coordinator, Ontario Ministry of Natural Resources, 

Peterborough, Ontario, Canada 

Mark Ellingwood, Wildlife Programs Administrator, NH Fish and Game Department, Wildlife Division 

Richard Rogers, District Wildlife Biologist – Furbearer Program Coordinator, West Virginia Division of 

Natural Resources, Romney, WV 

Julien Mainguy, Biologist, Quebec Ministry of Natural Resources and Wildlife, Quebec, Quebec, Canada 
A-2 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

Pierre Canac-Marquis, Quebec Ministry of Natural Resources and Wildlife, Quebec, Quebec, Canada 

Jordona Kirby, Rabies Field Coordinator, USDA, APHIS-WS, Knoxville, TN 

Travis Daugherty, Ranger, U.S. Army Corp of Engineers, Huntington District, Hinton, WV 
B-1 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

APPENDIX B 

LITERATURE CITED

Agriculture Canada. 1989. Guidelines for the regulation of veterinary biologics produced by 

biotechnology. Nepean, Ontario: Veterinary Biologics and Biotechnology Section, Animal Health 

Division, Cat. No. A62-43/1989E. 

Andersen, D.E., O.J. Rongstad, and W.R. Mytton. 1989. Response of nesting red-tailed hawks to 

helicopter overflights. Condor 91:296-299. 

Andiman, W. and G. Miller. 1982. Persistent infection with adenovirus type 5 and 6 in lymphoid cells 

from humans and woolly monkey. J. Wild. Dis.: 145: 83-88. 

ANG (Air National Guard). 1997a. Final Environmental Impact Statement for the Colorado Airspace 

Initiative. Air National Guard, National Guard Bureau; 3500 Fletchet Avenue, Andrews AFB, MD 

20762-5157. Vol. I, Vol. II. 

ANG (Air National Guard). 1997b. Final Biological Assessment for the Colorado Airspace Initiative 

with emphasis on the American Peregrine Falcon; Air National Guard Readiness Center, 

Environmental Planning Branch; 3500 Fetchet Avenue; Andrews AFB, MD 20762-5157. 83 pp. 

Artemis Technologies, Inc., 2010. Information for the environmental assessment of rabies vaccine, live 

adenovirus vector, (AdRG1.3) for the immunization against rabies of striped skunks in Ontario. 51 

Watson Road South, Guelph, Ontario, N1L 1E3. 

Artemis Technologies, Inc., 2009. 2009 AdRg1.3 Baits Field Stability Trial 09-01. Unpublished. 51 

Watson Road South, Guelph, Ontario, N1L 1E3. 

Artois, M., F. Cliquet, J. Barrat, and C.L. Schumacher. 1997. Effectiveness of SAG1 oral vaccine for the 

long-term protection of red foxes (Vulpes vulpes) against rabies. Vet. Rec. 140:57-59. 

Artois, M., E. Masson, J. Barrat, and M.F.A. Aubert. 1993. Efficacy of three oral rabies vaccine-baits in 

the red fox: a comparison. Vet. Microb. 38:167-172. 

Bacon, P.J. 1985. Population dynamics of rabies in wildlife. New York: Academic Press 

Baer G.M. 1988. Oral rabies vaccination: an overview. Rev. Infect. Dis. 10:S644-8. 

Bailey, R.G. 1995. Description of the ecoregions of the United States. (1st ed. 1980). Misc. Publ. No. 

1391 (rev.) Washington, DC: USDA Forest Service. 108 pp. 

Balser, D.S. 1964. Management of predator populations with antifertility agents. J. Wildl. Manage. 

28(2):352-358. 

Bingham, J., C. L. Schumacher, F.W.G. Hill, and A. Aubert. 1999. Efficacy of SAG2 oral rabies vaccine 

in two species of jackal (Canis adustus and Canis mesomelas). Vaccine. 17:551-558. 

Bingham, J., C.L. Schumacher, M.F.A.Aubert, F.W.G. Hill, and A. Aubert. 1997. Innocuity studies of 

SAG2 oral rabies vaccine in various Zimbabwean wild non-target species. Vaccine. 15: 937-943. 
B-2 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

Blancou, J., M.P. Kieny, R. Lathe, J.P. Lecocq. P.P Patoret, and J.P. Soulebot. 1986. Oral vaccination of 

the fox against rabies using a live recombinant vaccinia virus. Nature.; 322: 373-375. 

Blanton, J.D., D. Palmer, K.A. Christian, C.E. Rupprecht. 2011. Rabies surveillance in the United States 

during 2010. J. Amer. Vet. Med. Assoc. 239: 773-783. 

Bonnekoh, B., B. Greenhalgh, S. Chen, A. Block, S. Rich, T. Krieg, S. Woo, and D. Roop. 1998. Ex vivo 

and in vivo adenovirus-mediated gene therapy strategies induce a systemic anit-tumor immune 

defence in the B16 melanoma model. J. of Inves. Derm. 110:867-871. 

Bradley, M.P. 1995. Immunocontraceptive vaccines for control of fertility in the European Red Fox. 

T.J. Kreeger, tech. coord. Contraception in Wildlife Management. USDA Technical Bulletin No. 

1853, U.S. Department of Agriculture, Washington, D.C. pp 195-203. 

Brochier, B., J. Blancou, I. Thomas, B Languet, M. Artois, and M.P. Keirny. 1989. Use of recombinant 

vaccinia-rabies glycoprotein virus for oral vaccination of wildlife against rabies: innocuity to several 

non-target bait consuming species. J. Wild. Dis.; 25:540-547. 

Byrd P, Brown KW, Gallimore PH. Malignant transformation of human embryo retinoblasts by cloned 

adenovirus 12 DNA. Nature. 1982 Jul 1;298(5869):69-71. 

CDC(Centers for Disease Control and Prevention). 2011. Rabies prevention and control. Information 

obtained from website: http://www.cdc.gov/ncidod/dvrd/rabies

CDC (Centers for Disease Control and Prevention), Lovelace Respiratory Research Institute, Mayo 

Clinic, and Wildlife Disease Association). 2011b. Proposed U.S. field trial of a recombinant human 

adenovirus – rabies vaccine (ONRAB®): recommendations of a national working group to the U.S. 

Department of Agriculture, August 2011. CDC, 1600 Clifton Road, Atlanta, Georgia, 30333. 14pp. 

CDC (Centers for Disease Control and Prevention). 2009. Human vaccinia infection after contact with a 

raccoon rabies vaccine bait – Pennsylvania, 2009. CDC – Morbidity and Mortality Weekly Report. 

Information obtained from website: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5843a2.htm

CDC (Centers for Disease Control and Prevention). 1999. Mass Treatment of humans who drank 

unpasteurized milk from rabid cows - Massachusetts, 1996-1998. CDC - Morbidity and Mortality 

Weekly Report. 48(11); 228-229. 

CFIA (Canadian Food Inspection Agency), Canadian Centre for Veterinary Biologics (CCVB). 2010. 

Environmental Assessment – Rabies vaccine, live adenovirus vector (AdRG1.3 baits) For field use in 

vaccination campaigns by the Ontario Ministry of Natural Resources. CCVB File No. 

900VV/R5.0/A22., 59 Camelot Drive, Ottawa, Ontario, K1A 0Y9. 

CFIA (Canadian Food Inspection Agency), Canadian Centre for Veterinary Biologics (CCVB). 2008. 

Environmental Assessment – Rabies vaccine, live adenovirus vector (AdRG1.3 baits) For field use in 

field trials by le Ministère des resources naturelles et de la faune du Québec. CCVB File No. 

900VV/R5.0/A22, 2 Contellation Crescent, Ottawa, Ontario, K1A 0Y9. 

Chapman, R.C. 1978. Rabies: Decimation of a wolf pack in arctic Alaska. Science. 201: 365-367. 
B-3 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

Charleton, K.M., M. Artois, L. Prevec, J.B. Campbell, G.A. Casey, A.I. Wandeler, and J. Armstrong. 

1992. Oral rabies vaccination of skunks and foxes with a recombinant human adenovirus vaccine. 

Arch. Virol.; 123:169-179. 

Cheng, C., J.G. gall, M. Nason, C.R. King, R.A. Kroup, M. Roederer, M.J. McElrath, C.A. Morgan, G. 

Churchyard, L.R. Baden, A.C. Duerr, M.C. Keefer, B.S. Graham, G.J. Nabel. 2010. Differential 

specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural 

infections or immunization. J. Virol. 84:630-638. 

Clark, W.R. and E.K. Fritzell. 1992. A review of population dynamics of furbearers. In: McCullough, 

D.R., R.H. Barrett, Eds. Wildlife 2001: populations. London, England: Elsevier: 899-910. 

Connolly, G. E., and W. M. Longhurst. 1975. The effects of control on coyote populations. Div. of 

Agric. Sci., Univ. of California Davis. Bull. 1872. 37pp. 

Conomy, J.T., J.A. Collazo, J.A. Dubovsy, W.J. Fleming. 1998. Dabbling duck behavior and aircraft 

activity in coastal North Carolina. J. Wildl. Manage. 62(3):1127-1134. 

Davidson, W.R., V.F. Nettles, L.E. Hayes, E.W. Howerth, and C.D. Couvillion. 1992. Diseases diagnosed 

in gray foxes (Urocyon cinereoargenteus) from the southeastern United States. Journal of Wildlife 

Diseases. 28(1):28-33. 

Debbie, J.G. 1991. Rabies control of terrestrial wildlife by population reduction. Pages 477-484 in, ed. 

G.M. Baer, The natural history of rabies. CRC Press, Boston, MA. 

Delaney, D.K, T.G Grubb, P. Beier, L.L. Pater, and M.H. Reiser. 1999. Effects of helicopter noise on 

Mexican Spotted Owls. J. Wildl. Management. 63:60-76. 

DeVos, Jr., J.C. and J.L. Smith. 1995. Natural mortality in wildlife populations. Proactive Strategies 

Committee Report #1. Proactive Strategies Project of the International Association of Fish and 

Wildlife Agencies and Arizona Game and Fish Department. 

Douglas, J.T. 2007. Adenoviral vectors for gene therapy. Mol. Bioltechnol. 36:71-80. 

Ellis, D.H. 1981. Responses of raptorial birds to low-level jet aircraft and sonic booms. Results of the 

1980-81 Joint U.S. Air Force-U.S. Fish and Wildl. Service Study. Institute for Raptor Studies, 

Oracle, AZ. 59 pp. 

Evans, R.H. 1982. Canine distemper: Diagnosis and treatment. In Wildlife Rehabilitation. Vol. 1. 

Exposition Press, Smithtown, New York. Pp. 127-137. 

Fancy, S.G. 1982. Reaction of bison to aerial surveys in interior Alaska. Canadian Field Naturalist. 

96:91. 

Farry, S.C., S.E. Henke, A.M. Anderson, and G.M. Fearneyhough. 1998a. Responses of captive and freeranging coyotes to simulated oral rabies vaccine abits. J. Wildl. Dis.; 34(1): 13-22. 

Farry, S.C., S.E. Henke, S.L. Beasom, and G.M. Fearneyhough. 1998b. Efficacy of bait distributional 
B-4 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

strategies to deliver canine rabies vaccines to coyotes in southern Texas. J. Wildl. Dis.; 34(1): 23-32. 

Fehlner-Gardiner, C., R. Rudd, D. Donovan, D. Slate, L. Kempf, and J. Badcock. 2012. Comparison of 

ONRAB® and Raboral V-RG® oral rabies vaccine field performance in raccoons and striped skunks 

in New Brunswick, Canada, and Maine, U.S.A. Journal of Wildlife Diseases 48: 157-167. 

Fekadu, M.S., L. Nesby, J.H. Shaddock, C.L. Schumacher, S.B. Linhart, and D.W. Sanderlin. 1996. 

Immunogenicity, efficacy, and safety of an oral rabies vaccine (SAG2) in dogs. Vaccine. 14: 465-468. 

Flotte, T.R. 2004. Immune responses to recombinant adeno-associated virus vectors: Putting preclinincal 

findings into perspective. Human Gene Therapty. 15:716. 

Flamand, A., P. Coulon, F. Laray, and C. Tuffereau. 1993. Avirulent mutants of rabies virus and their 

use as live vaccine. Trends in Microbiology 1(8):317-320. 

Follman, E.H., D.G. Ritter, and G.M. Baer. 1996. Evaluation of the safety of two attenuated oral rabies 

vaccines, SAG1 and SAG2 in six arctic mammals. Vaccine 14: 270-273. 

Fox, J.P., C.D. Brandt, F.E. Wassermann, et al. 1969. The Virus Watch Program: a continuing 

surveillance of viral infections in metropolitan New York families. VI. Observationos of adenovirus 

infections: virus excretion patterns, antibody reponse, efficiency of surveillance, patterns of infection 

and relation to illness. Am. J. Epidemiol. 89:25-50. 

Foy, HM. Adenoviruses. In: Evans A, Kaslow R, eds. Viral Infections in Humans: epidemiology and 

control. 4th ed. New York: Plenum; 1997:119-38. 

Foy, H.M. and J.Z. Grayson. 1976. Adenoviruses. In: Evans AS (ed) Viral infections of humans. 

Epidemiology and control. Plenum, New York. Pp 53-69. 

Fujinaga, K., Y. Sawada, and K. Sekikawa. 1979. Three different classes of human adenovirus 

transforming DNA sequences: highly oncogenic subgroup A, weakly oncogenic subgroup B, and 

subgroup C specific transforming DNA sequences. Virology. 93: 578-581. 

Gaede, T. 1992. Bat rabies in Denmark 1985-1990. In: Bogel, K., Meslin, F.X., Kaplan, M., eds. 

Wildlife rabies control. Royal Tunbridge Wells, Kent, UK: Wells medical: 76-78. 

Godin, A.J. 1982. Striped and Hooded Skunks, Pp 674-687 in J.A. Chapman and G.A. Feldhamer, Eds., 

Wild Mammals of North America: biology, management, and economics. Johns Hoplikns Univ. 

Press, Blatimore, MD. 1147pp. 

Graham, F. L. and L. Prevec. 1992. Adenovirus-based expression vectors and recombinant vaccines. In: 

Ellis, R.W., editor. Vaccines: new approaches to immunological problems. Boston: ButterworthHeinemann. P. 369-390. 

Graham, F.L (1984) The Adenovinues (Ginsberg, H.S., ed.), pp. 339-398, Plenum Press, New York 

Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA 

from human adenovirus type 5. J Gen Virol. 1977 Jul;36(1):59-74. 
B-5 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

Green M, Wold WS, Mackey JK, Rigden P. Analysis of human tonsil and cancer DNAs and RNAs for 

DNA sequences of group C (serotypes 1, 2, 5, and 6) human adenoviruses. 

Proc Natl Acad Sci U S A. 1979 Dec;76(12):6606-10. 

Guerra, M.A., A.T. Curns, C.E. Rupprecht, C.A. Hanlon, J.W. Krebs, J.E. Childs. 2003. Skunks and 

raccoon rabies in the eastern United States: temporal and spatial analysis. Emerg. Inf. Dis. 9: 1143-

1151. 

Guynn, D.C. 1997. Contraception in wildlife management: reality or illusion. T.J. Kreeger, tech. coord. 

Contraception in Wildlife Management. USDA Technical Bulletin No. 1853, U.S. Department of 

Agriculture, Washington, D.C. pp 241-246. 

Hable, C.P., A N. Hamir, D. E. Snyder, R. Joyner, J. French, V. Nettles, C. Hanlon, and C. E. Rupprecht. 

1992. Prerequisites for oral immunization of free-ranging raccoons (Procyon lotor) with a 

recombinant rabies virus vaccine: Study site ecology and bait system development. J. Wildl. Dis.; 

28(1): 64-79. 

Hadidian, J., S.R. Jenkins, D.H. Johnston, P.J. Savarie, V.F. Nettles, D. Manski, and G.M. Baer. 1989. 

Acceptance of simulated oral rabies vaccine baits by urban raccoons. J. Wildl. Dis. 25(1):1-9. 

Hanlon, C.A, M. Niezgoda, P. Morrill, and C.E. Rupprecht. 2002. Oral efficacy of an attenuated rabies 

virus vaccine in skunks and raccoons. J. Wild. Dis. 38(2): 420-427. 

Hanlon, C.A., J.E. Childs, V.F. Nettles. 1999. Rabies in wildlife - Article III, Special Series - 

Recommendations of a national working group on prevention and control of rabies in the United 

States. J. Amer. Vet. Med. Assoc. 215(11):1612-1620. 

Hanlon, C.A. and C.E. Rupprecht. 1997. Considerations for immunocontraception among free-ranging 

carnivores: The rabies paradigm. Contraception in Wildlife Management. USDA Technical Bulletin 

No. 1853, U.S. Department of Agriculture, Washington, D.C. pp 185-194. 

Hanlon, C.L., D.E. Hayes, A.N. Hamir, D.E. Snyder, S. Jenkins, C.P. Hable,and C.E. Rupprecht. 1989. 

Proposed field evaluation of a rabies recombinant vaccine for raccoons (Procyon lotor): Site 

selection, target species characteristics, and placebo baiting trials. J. Wildl. Dis. 25(4): 555-567. 

Hoff, G.L., S.J. Proctor, and L. P. Stallings. 1974. Epizootic of canine distemper virus infection amoung 

urban raccoons and gray foxes. J. Wild. Dis. 10:423-428. 

Horowitz, M.S., 1990. Adenoviruses. In: Fields, B.N., Knipe, D.M., et al. (eds). Virology, 2nd ed. New 

York: raven Press. 1723-1741. 

ISQ (Quebec Institute of Statistics). 2011. Quebec 2006 population census. Retrieved on 12 January 

2012 from: http://www.stat.gouv.qc.ca/regions/index_2006_an.htm

Kalicharran, K.K., V. S. Springthorpe, and S.A. Sattar. 1992. Studies on the stability of a human 

adenovirus-rabies recombinant vaccine. Can. J. Vet. Res. 56:28-33. 

Kat, P. W., K.A. Alexander, J.S. Smith, and L. Munson. 1995. Rabies and African wild dogs in Kenya. 
B-6 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

Proceedings of the Royal Society of London Biological Sciences 262: 229-233. 

Kemere, P., M.K. Liddel, P. Evangelou, D. Slate, and S. Osmek. 2001. Economic analysis of a large 

scale oral vaccination program to control raccoon rabies. Proc. Human conflicts with wildlife: 

economic considerations symposium. Fort Collins, CO. 

Kennelly, J.J., and K.A. Converse. 1997. An underutilized procedure for evaluating the merits of 

induced sterility. T.J. Kreeger, tech. coord. Contraception in Wildlife Management. USDA Technical 

Bulletin No. 1853, U.S. Department of Agriculture, Washington, D.C. pp 21-28. 

Knowles, M.K., S.A. Nadin-Davis, M. Sheen, R. Rosatte, R. Mueller, and A. Beresford. 2009. Safety 

studies on an adenovirus recombinant vaccine for rabies (AdRG1.3 ONRAB®) in target and nontarget species. Vaccine; 27: 6619-6626. 

Knowles, M.K., D. Roberts, S. Craig, M. Sheen. 2009b. In vitro and in vivo genetic studies of a human 

adenovirus type 5 recombinant rabies glycoprotein vaccine (ONRAB). Vaccine. 27:2662-2668. 

Krausman, P.R., M.C. Wallace, C.L. hayes, and D.W. DeYoung. 1998. Effects of jet aircraft on mountain 

sheep. J. Wildl. Manage. 62:1246-1254. 

Krausman, P.R., B.D. Leopold, and D.L Scarbrough. 1986. Desert mule deer response to aircraft. Wildl. 

Soc. Bull. 14:68-70. 

Krausman, P.R. and J.J. Hervert. 1983. Mountian sheep responses to aerial surveys. Wildl. Soc. Bull. 

11:372-375. 

Krebs, J.W., S.M. Williams, J.S. Smith, C.E. Rupprecht, and J.E. Childs. 2003. Rabies among 

infrequently reported mammalian carnivores in the United States, 1960-2000. J. Wildl. Dis. 

39(2):253-261. 

Krebs, J.W., A.M. Mondul, C.E. Rupprecht, J.E. Childs. 2001. Rabies surveillance in the United States 

during 2000. J. Am. Vet. Med. Assoc. 219: 1687-1689 

Krebs, J.W., C.E. Rupprecht, and J.E. Childs. 2000. Rabies surveillance in the United States during 

1999. J. Amer. Vet. Med. Assoc. 217:1799-1811. 

Krebs, J.W., T.W. Strine, J.S. Smith, C.E. Rupprecht, J.E. Childs. 1995. Rabies surveillance in the United 

States during 1994. J. Am. Vet. Med. Assoc. 207: 1562-1575 

Kushlan, J.A. 1979. Effects of helicopter censuses on wading bird colonies. J. Wildl. Manage. 43:756-

760. 

Lafay F., J. Benejean, C. Tuffereau, A. Flamand, and P. Coulon. 1994. Vaccination against rabies: 

construction and characterization of SAG2, a double avirulent derivative of SADBern. Vaccine. 

12:317-320. 

Lawson, K.F., H. Chiu, S.J. Crosgrey, M. matson, G.A. Casey, and J.B. Campbell. 1997. Duration of 

immunity in foxes vaccinated orally with ERA vaccine in a bait. Can. J. Vet. Res. 61:39-42. 
B-7 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

Lawson, K.F., D.H. Johnston, J.M. Patterson, R. Hertler, J.B. Campbell, and A.J. Rhodes. 1989. 

Immunization of foxes by the intestinal route using an inactivated rabies vaccine. Can. J. Vet. Res. 

53:56-61. 

Linhart, S.B., J. Wlodkowski, V. Neetles, T. harbin, L. Motes-Kreimeyer, and M. Mackowaik. 1997. A 

modified bait for delivering V-RG rabies vaccine to wildlife. Rabies Am. Conf.; No. 8: (“Rabies in 

the Americas Conference, November 2-6, 1997, Kingston, Ontario, Canada”; MacInnes, Charles D. 

[convener], editor). Abstract only; proceedings available on internet at 

http://www.gis.queensu.ca/RReporter/mnr.html. 

Linhart, S.B., F.S. Blom, R.M. Engeman, H.L. Hill, T. Hon, D.I. Hall, and J.H. Shaddock. 1994. A field 

evaluation of baits for delivering oral rabies vaccines to raccoons (Procyon lotor). J. Wildl. Dis. 

30(2):185-194. 

Linhart, S.B., H.H. Brusman, and D.S. Balser. 1968. Field evaluation of an antifertility agent, Stilbestrol, 

for inhibiting coyote reproduction. Transactions of the 33rd North American Wildlife Conference, 

Vol. 33:316-327. 

Lutze-Wallace, C., T. Sapp, M. Sidhu, A. Wandler. 1995a. In vitro assessments of the genetic stability of 

a live recombinant human adenovirus vaccine against rabies. Can. J. Vet. Res. 59:157-160. 

Lutze-Wallace, C., A. Wandler, L. Prevec, M. Sidhu, T. Sapp, and J. Armstrong. 1995b. Characterization 

of a human adenovirus 5: rabies glycoprotein recombinant vaccine reisolated from orally vaccinated 

skunks. Biologics. 23:271-277. 

MacDonald, D.W. 1993. Rabies and wildlife: A conservation problem? Onderstepoort Journal of 

Veterinary Research 60: 351-355. 

MacInnes, C. D. 1998. Rabies, in M. Novak, J.A. Baker, M.E. Obbard, B. Mallock, eds, Wild Furbearer 

management and Conservation in North America. Ontario Trappers Association/Ontario Ministry of 

Natural Resources, Toronto, Ontario, Canada, pp. 910-929. 

Maheshwari, G., R. Jannat, L. McComick, D. Hsu. 2004. Thermal inactivation of adenovirus type 5. J. 

Vir. Methods. 118: 141-145. 

Masson, E., F. Cliquet, M. Aubert, J. Barrat, A. Aubert, M. Artois, C.L. Schumacher. 1996. Safety study 

of the SAG2 rabies virus mutant in several non-target species with a view to its future use for the 

immunization of foxes in Europe. Vaccine. 14: 1506-1510. 

Mainguy, J. and P. Canac-Marquis. 2010. Use of the ONRAB® rabies vaccine, live adenovirus vector 

(AdRG1.3), in the province of Quebec in 2007-2009: data from field experiments. Quebec Ministry 

of Natural Resources and Wildlife, 880 Chemin Sainte-Foy, RC 120-C, Quebec, QC G1S-4X4. 

Meltzer, M.I. 1996. Assessing the costs and benefits of an oral vaccine for raccoon rabies: a possible 

model. Emerging Infectious Diseases 2(4):343-349. 

Miller, L.A. 1997. Delivery of immunocontraceptive vaccines for wildlife management. T.J. Kreeger, 
B-8 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

tech. coord. Contraception in Wildlife Management. USDA Technical Bulletin No. 1853, U.S. 

Department of Agriculture, Washington, D.C. pp 49-58. 

Moliner-Frenkel, V., C. Le Boulaire, F. Le Gal, H. Gahert-Segard, T. Tursz, J. Guillet, and F. Farace. 

2000. Longitudinal follow-up of cellular and humoral immunity induced by recombinant adenovirusmediated gene therapy in cancer patients. Human Gene Therapy. 11:1911-1920. 

Noah, D.L., M.G. Smith, J.C. Gotthardt., J.W. Krebs, D.Green, and J.E. Childs. 1995. Mass human 

exposure to rabies in New Hampshire: Exposures, Treatment, and cost. Public Health Briefs, 

National Center for Infectious Diseases, 1600 Clifton Rd. Mailstop G-13, Atlanta, GA 30333. 3 pp. 

NRCA (Natural Resources Canada). 2012. The atlas of Canada. Retrieved on 12 January 2012 from: 

http://atlas.nrcan.gc.ca/site/english/maps/environment/forest/forestcanada/landcover

Nwanegbo, E., E. Vardas., W. Gao, H Whittle, H. Sun, D. Rowe, P. Robbins, and A. Gambotto. 2004. 

Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of the 

Gambia, South Africa, and the United States. Clinical and Diagnostic Laboratory Immunology. 11: 

351-357. 

NYDEC (New York Department of Environmental Conservation). 2012a. Striped skunk factsheet. 

Retrieved on 1 February, 2012 from: http://www.dec.ny.gov/animals/9353.html

NYDEC (New York Department of Environmental Conservation). 2012b. List of Endangered, 

Threatened, and Special Concern Fish & Wildlife Species in New York State. Information retrieved 

on February 7, 2012 from website: http://www.dec.ny.gov/animals/7494.html

ODNR (Ohio Department of Natural Resources), Division of Wildlife. 2012. Endangered, Threatened, 

and Species of Concern lists. Information retrieved on February 7, 2012 from website: 

http://www.dnr.state.oh.us/Home/ExperienceWildlifeSubHomePage/Endangeredthreatenedspeciespla

ceholder/resourcesmgtplansendangered/tabid/6005/Default.aspx

ODNR (Ohio Department of Natural Resources), Division of Wildlife. 2010. 2009-2010 Wildlife 

population status report. Retrieved on 1 February, 2012 from: 

http://www.dnr.state.oh.us/Home/wild_resourcessubhomepage/ResearchandSurveys/WildlifePopulati

onStatusLandingPage/tabid/19230/Default.aspx

ODNR (Ohio Department of Natural Resources), Division of Wildlife. 2009. Fur harvest in Ohio, 1994-

1995 through 2005-2006. Publication 178. Retrieved on June 10, 2009 from 

http://www.ohiodnr.com/wildlife/dow/regulations/trapping.aspx

OMNR (Ontario Ministry of Natural Resources), Wildlife Research and Development Section. 2011. 

Wildlife Rabies Control Program annual report 2010-2011. 2140 East Bank Drive, Peterborough, ON 

K9J 7B8. 

OMNR (Ontario Ministry of Natural Resources), Wildlife Research and Development Section. 2010. 

Wildlife Rabies Control Program annual report 2009-2010. 2140 East Bank Drive, Peterborough, ON 

K9J 7B8. 
B-9 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

OMNR (Ontario Ministry of Natural Resources), Wildlife Research and Development Section. 2009. 

Wildlife Rabies Control Program annual report 2008-2009. 2140 East Bank Drive, Peterborough, ON 

K9J 7B8. 

OMNR (Ontario Ministry of Natural Resources), Wildlife Research and Development Section. 2008. 

Wildlife Rabies Control Program annual report 2007-2008. 2140 East Bank Drive, Peterborough, ON 

K9J 7B8. 

OMNR (Ontario Ministry of Natural Resources), Wildlife Research and Development Section. 2007. 

Wildlife Rabies Control Program annual report 2006-2007. 2140 East Bank Drive, Peterborough, ON 

K9J 7B8. 

Orstavik, I. and D. Wiger. 1989. Adenovirus. In: G. Haukins, L.R. Haaheim, J.R. Pattison, editors. A 

practical guide to clinical virology. Rexdale. John Wiley and Sons. p. 83-87. 

Pastoret, P.-P., B. Brochier, J. Blancou, M. Artois, M. Aubert, M.-P. Kieny, J.-P. Lecocq, B. Languet, G. 

Chappuis, and P. Desmettre. 1992. Development and deliberate release of a vaccinia rabies 

recombinant virus for the oral vaccination of foxes against rabies. In: Binns, M.M.; Smith, G. L., eds. 

Recombinant Poxviruses. Boca Raton: CRC Press; p. 163-206. 

Pastorette P.P., B. Brochier. B. Languet, I. Thomas, A. Paquot, and B. Bauduin. 1988. First field trial of 

fox vaccination against rabies using vaccine-rabies recombinant virus. Vet. Rec.; 123:481-483. 

PGC (Pennsylvania Game Commission), Bureau of Wildlife Management. 2009a. Annual wildlife 

management reports: Furbearer population and harvest monitoring. Retrieved on May 7, 2009 from 

http://www.pgc.state.pa.us/pgc/cwp/browse.asp?a=491&bc=0&c=69956&pgcNav=|

Prevec, L., J.B. Campbell, B.S. Chrisite, L. Belbeck, and F.L. Graham. 1990. A recombinant human 

adenovirus vaccine against rabies. J. Infect. Dis.; 161:27-30. 

Pybus, M.J. 1988. Rabies and rabies control in striped skunks (Mephitis mephitis) in three prairie regions 

of western North America. J. Wildl. Dis. 24:434-449. 

Ranrianarison-Jewtoukoff, V. and M. Perricaudet. 1995. Recombinant adenoviruses as vaccine. 

Biologicals; 23:145-157. 

Rapper, S.E., N. Chirmule, F.S. Lee, N.A. Wivel, A. Bagg, G.P. Gao, et al. 2003. Fatal systemic 

inflammatory response syndrome in a ornithine transcarbamylase deficient patient following 

adenovirus gene transfer. Mol. Gen., 80:148-158. 

Ricketts, T.H., E. Dinerstein, D.M. Olson, C.J. Loucks, W. Eichbaum, D. DellaSala, K. Kavanagh, P. 

Hedao, P.T. Hurley, K.M. Carney, R. Abell, and S. Waters. 1999. Terrestrial ecoregions of North 

America: A conservation assessment. World Wildl. Fund – U.S. and Canada. Island Press. 

Washington, D.C. 485 pp. 

Riley, S.J., J. Hadidian, and D. Manski. 1998. Population density, survival and rabies in raccoons in an 

urban national park. Canadian J. of Zoology, 76:1153-1164[;lk 
B-10 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

Ritter, D.G. 1991. Rabies in Alaskan furbearers: A review. In Proceedings of the sixth northern furbearer 

conference. Alaska Department of Fish and Game, Fairbanks, Alaska, pp. 26-34. 

Rosatte, R.C., D. Donovan, J.C. Davies, L. Brown, M. Allen, V. von Zuben, P. Bachmann, K. Sobey, A. 

Silver, K. Bennett, T. Buchanan, L. Bruce, M. Gibson, M. Purvis, A. Beresford, A. Beath, and C. 

Fehlner-Gardiner. 2011. High-density baiting with ONRAB® rabies vaccine baits to control arcticvariant rabies in striped skunks in Ontario, Canada. J. Wildl. Dis.; 47(2): 450-465. 

Rosatte, R. C., D. Donovan, J.C. Davies, M. Allan, P. Bachmann, B. Stevenson, K. Sobey, L. Brown, A. 

Silver, K. Bennett, T. Buchanan, L. Bruce, M. Gibson, A. Beresford, A. Beath, C. Fehler-Gardiner, 

and K. Lawson. 2009. Aerial distribution of ONRAB® baits as a tactic to control rabies in raccoons, 

and striped skunks in Ontario, Canada. J. Wildl. Dis.; 45(2): 363-374. 

Rosatte, R.C., C.D. MacInnes, R.T. Williams, and O. Williams. 1997. A proactive prevention strategy 

for raccoon rabies in Ontario, Canada. Wildl. Soc. Bull.; 25(1):110-116. 

Rosatte, R.C. 1987. Skunks. Pp 599-613 in M. Novak, J.A. Baker, M.E. Obbard, B. Mallock, eds., Wild 

Furbearer Management and Conservation in North America. Ministry of Natural Resources, Ontario, 

Canada 1150pp. 

Roscoe, D.E. 1993. Epizootiology of canine distemper in New Jersey raccoons. Journal of Wildlife 

Diseases. 29(3):390-395 

Rowe, W.P., R. Huebner, J. Hartley, T. Ward, and R. Parrot. 1955. Studies of the adenoidal-pharyngealconjuctival (APC) group of viruses. American Journal of Hygiene 61: 197-218. 

Rupprecht, C.E. and J.S. Smith. 1994. Raccoon rabies: the re-emergence of an eipozootic in a densely 

populated area. Seminars in Virology (5):155-264. 

Rupprecht, C.E., J.S. Sahddock, D.W. Sanderlin, C.A. Hanlon, M. Niezgoda, and C.L. Chumacher. 1998. 

Oral vaccination of dogs. Israel Journal of veterinary Medicine. 53: 127-131. 

Rupprecht, C.E., B. Dietzschold, J. B. Campbell, K. M. Charlton, and H. Koprowski. 1992c. 

Consideration of inactivated rabies vaccines as oral immunogens of wild carnivores. J. Wild. Dis. 

28(4):629-635. 

Rupprecht, C.E., K.M/. Charlton, M. Artois, G.A. Casey, W.A. Webster, J.B. Campbell, K.F. Lawson, 

and L.G. Schneider. 1990. Ineffectiveness and comparative pathogenicity of attenuated rabies virus 

vaccine in striped skunk (Mephitis mephitis). Journal of Wildlife Diseases. 26: 99-102. 

Rupprecht, C.E., B. Dietzchold, J.H. Cox, and L.G. Schiender. 1989. Oral vaccination of raccoons 

(Procyon lotor) with attenuated (SAD-B19) rabies virus vaccine. J of Wildlife Diseases. 25: 548-554. 

Rupprecht, C.E., A.N. Hamir, D.H. Johnson, and H. Koprowski. 1988. Efficacy of a vaccinia-rabies 

glycoprotein recombinant virus vaccine in raccoons (Procyon lotor). Rev. Infect. Dis.; 10:5803-5809. 

Russell, W.C. 1998. Adenoviruses. In Toply and Wilson’s Microbiology and microbial infections, 9th

edition, L. Collier, A. Barows and M. Sussman (eds.). Edward Arnold, London, England, pp 281-290. 
B-11 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

Sanderson, G. C. 1987. Raccoon, in M. Novak, J.A. Baker, M.E. Obbard, B. Mallock, eds, Wild 

Furbearer management and Conservation in North America. Ontario Trappers Association/Ontario 

Ministry of Natural Resources, Toronto, Ontario, Canada, pp.486-499. 

Slate, D., C.E. Rupprecht, J.A. Rooney, D. Donovan, D.H. Lein, R.B. Chipman. 2005. Status of oral 

rabies vaccination in wild carnivores in the United States. Virus Research. 111: 68-76. 

Steelman, H.G., S.E. Henke, and G.M. Moore. 2000. Bait delivery for oral rabies vaccine to gray foxes. 

J. Wildl. Dis.; 36(4): 744-751. 

Steelman, H.G., S.E. Henke, G.M. Morre. 1998. Gray fox response to baits and attractants for rabies 

vaccination. J. Wildl. Dis.; 34(4): 764-770. 

Sumida, S.M., D.M. Truitt, A.A.C. Lemckert, R. Vogels, J.H.H.V. Custers, M.M. Addo, S. Lockman, T. 

Peter, F.W. Peyerl, M.G. Kishko, S.S. Jackson, D.A. Gorgone, M.A. Lifton, M. Essex, B.D. Walker, 

J. Goudsmit, M.J.E. Havenga, and D. H. Barouch. 2005. Neutralizing antibodies to adenovirus 

serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J. Imm. 174: 

7179-7185. 

Taylor PE. Adenoviruses: Diagnosis of infections. In: Kurstak E, Kurstak C, eds. Comparative diagnosis 

of viral disease. New York : Academic press, 1977:86-170. 

Therberge, J.B., G.J. Forbes, I.K. Barker, and T. Bollinger.1994. Rabies in wolves of the Great Lakes 

region. Journal of Wildlife Diseases 27: 337-339. 

Thomas, I., B. Brochier, B. Languet, J. Blancou, D. Peharpre, and M.P. Kieny. 1990. Primary 

multiplication site of the vaccine-rabies glycoprotein recombinant virus administered to foxes by the 

oral route. J. Gen. Virol.; 71:37-42. 

Thompson, J.A. and P.J. Fleming. 1994. Evaluation of the efficacy of 1080 poisoning of red foxes using 

visitation to non-toxic baits as an index of fox abundance. Wildl. Res. 21:27-39. 

Tolson, N.D., K.M. Charlton, R.B. Stewart, J.B. Campbell, T.J. Wiktor. 1987. Immune response in 

skunks to a vaccinia virus recombinant expressing the rabies virus glycoprotein. Can. J. Vet. Res. 51: 

363-366. 

USDA (U.S. Department of Agriculture), Forest Service (FS). 2012. Regional Forester Sensitive Species 

Lists (Region 9). April 15, 2008. USDA, FS, 626 East Wisconsin Ave., Milwaulkee, WI 53202. 

USDA (U.S. Department of Agriculture), Animal and Plant Health Inspection Service (APHIS), Wildlife 

Services. 2012b. ONRAB® (Human adenovirus serotype 5) oral rabies vaccine field trial report, 

West Virginia 2011. USDA, APHIS, Wildlife Services, National Rabies Management Program. 59 

Chenell Dr., Suite 2, Concord, NH 03301. 

USDA (U.S. Department of Agriculture), Animal and Plant Health Inspection Service (APHIS), Center 

for Veterinary Biologics. 2011a. Risk assessment for field testing rabies vaccine, live adenovirus 

vector. USDA-APHIS-CVB. 
B-12 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

USDA (U.S. Department of Agriculture), Animal and Plant health Inspection Service (APHIS), Wildlife 

Services. 2011b. Environmental Assessment (EA) and decision/finding of no significant impact 

(FONSI) – Field trial of an experimental rabies vaccine, human adenovirus type 5 vector in West 

Virginia. USDA, APHIS, Wildlife Services. 4700 River Road, Unit 87, Riverdale, MD 20737-1234. 

USDA (U.S. Department of Agriculture), Animal and Plant Health Inspection Service (APHIS), Wildlife 

Services. 2011c. Monitoring Report-Calendar Year 2008-for Environmental Assessment – Oral 

vaccination to control specific rabies virus variants in raccoons, gray foxes, and coyotes in the United 

States. USDA, APHIS, Wildlife Services, 140-C Locust Grove Rd, Pittstown, NJ, 08867. 26p. 

USDA (U.S. Department of Agriculture), Forest Service (FS). 2011d. Land areas report – as of September 

30, 2011. Retrieved from: http://www.fs.fed.us/land/staff/lar/LAR2011/lar2011index.html

USDA (U.S. Department of Agriculture), Animal and Plant Health Inspection Service (APHIS), Wildlife 

Services. 2010. Environmental Assessment (EA) and decision/finding of no significant impact 

(FONSI) - Oral vaccination to control specific rabies virus variants in raccoons, gray foxes, and 

coyotes in the United States. USDA, APHIS, Wildlife Services, 4700 River Road, Unit 87, Riverdale, 

MD 20737-1234. 

USDA (U.S. Department of Agriculture), Animal and Plant Health Inspection Service (APHIS), Wildlife 

Services. 2009. Monitoring Report-Calendar Year 2007-for Environmental Assessment – Oral 

vaccination to control specific rabies virus variants in raccoons, gray foxes, and coyotes in the United 

States. USDA, APHIS, Wildlife Services, 140-C Locust Grove Rd, Pittstown, NJ, 08867. 23p. 

USDA (U.S. Department of Agriculture), Natural Resources Conservation Service. 2009b. Summary 

Report: 2007 Natural Resources Inventory. USDA, NRCS, Washington, D.C. and Center for Survey 

Statistics and Methodology, Iowa State University, Ames, Iowa. 123p. from: 

http://www.nrcs.usda.gov/technical/NRI/2007/2007_NRI_Summary.pdf

USDA (U.S. Department of Agriculture), Animal and Plant Health Inspection Service (APHIS), Wildlife 

Services. 2008. Monitoring Report-Calendar Year 2006-for Environmental Assessment – Oral 

vaccination to control specific rabies virus variants in raccoons, gray foxes, and coyotes in the United 

States. USDA, APHIS, Wildlife Services, 140-C Locust Grove Rd, Pittstown, NJ, 08867. 23p. 

USDA (U.S. Department of Agriculture), Animal and Plant Health Inspection Service (APHIS), Wildlife 

Services. 2007. Monitoring Report-Calendar Year 2005-for Environmental Assessments Concerning 

the Management of Rabies in the United States. USDA, APHIS, Wildlife Services, 6213-E Angus 

Drive, Raleigh, NC 27617. 

USDA (U.S. Department of Agriculture), Animal and Plant Health Inspection Service (APHIS), Wildlife 

Services. 2007b. Decision/finding of no significant impact (FONSI) for environmental assessment 

oral vaccination to control specific rabies virus variants in raccoons, gray foxes, and coyotes in the 

United States. USDA, APHIS, Wildlife Services, 4700 River Road, Unit 87, Riverdale, MD 20737-

1234. 
B-13 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

USDA (U.S. Department of Agriculture), Animal and Plant Health Inspection Service (APHIS), Wildlife 

Services. 2006. Environmental Assessment – Reducing mammal damage through an integrated 

wildlife damage management program in the state of Vermont. USDA, APHIS-WS, 617 Comstock 

Rd., Berlin, VT 05602. 

USDA (U.S. Department of Agriculture), Animal and Plant Health Inspection Service (APHIS), Wildlife 

Services. 2006b. Environmental assessment (EA) and decision/finding of no significant impact 

(FONSI) – Predator Damage Management in New Mexico. USDA, APHIS, Wildlife Services, New 

Mexico State Office, 8441 Washington NE, Albuquerque, NM 87113-1001. 

USDA (U.S. Department of Agriculture), Animal and Plant Health Inspection Service (APHIS), Wildlife 

Services. 2005. Monitoring Report-Calendar Year 2004-for Environmental Assessments Concerning 

the Management of Rabies in the United States. USDA, APHIS, Wildlife Services, 6213-E Angus 

Drive, Raleigh, NC 27617. 

USDA (U.S. Department of Agriculture), Animal and Plant Health Inspection Service (APHIS), Wildlife 

Services. 2005b. Environmental assessment (EA) and decision/finding of no significant impact 

(FONSI) – Predator damage management in Colorado. USDA, APHIS, Wildlife Services, Colorado 

State Office, 12345 West Alameda Parkway, Lakewood, Colorado, 80228. 

USDA (U.S. Department of Agriculture), Animal and Plant Health Inspection Service (APHIS), Wildlife 

Services. 2004. Monitoring Report-Calendar Year 2003-for Environmental Assessment – Oral 

vaccination to control specific rabies virus variants in raccoons, gray foxes, and coyotes in the United 

States. USDA, APHIS, Wildlife Services, 6213-E Angus Drive, Raleigh, NC 27617. 22p. 

USDA (U.S. Department of Agriculture), Animal and Plant Health Inspection Service (APHIS), Wildlife 

Services. 2004b. Monitoring Report-Calendar Year 2002-for Environmental Assessments Concerning 

the Management of Rabies in the United States. USDA, APHIS, Wildlife Services, 6213-E Angus 

Drive, Raleigh, NC 27617. 

USDA (U.S. Department of Agriculture), Animal and Plant Health Inspection Service (APHIS), Wildlife 

Services. 2004c. Supplemental environmental assessment (EA) and decision/finding of no significant 

impact (FONSI) – Oral vaccination to control specific rabies virus variants in raccoons, gray foxes, 

and coyotes in the United States. USDA, APHIS, Wildlife Services, 4700 River Road, Unit 87, 

Riverdale, MD 20737-1234. 

USDA (U.S. Department of Agriculture), Animal and Plant Health Inspection Service (APHIS), Wildlife 

Services. 2004c. Supplemental environmental assessment (EA) and decision/finding of no significant 

impact (FONSI) – Oral vaccination to control specific rabies virus variants in raccoons, gray foxes, 

and coyotes in the United States. USDA, APHIS, Wildlife Services, 4700 River Road, Unit 87, 

Riverdale, MD 20737-1234. 

USDA (U.S. Department of Agriculture), Animal and Plant Health Inspection Service (APHIS), Wildlife 

Services. 2003. Monitoring Report-Calendar Year 2001-for Environmental Assessments Concerning 

the Management of Rabies in the United States. USDA, APHIS, Wildlife Services, 6213-E Angus 

Drive, Raleigh, NC 27617. 
B-14 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

USDA (U.S. Department of Agriculture), Animal and Plant Health Inspection Service (APHIS), Wildlife 

Services. 2003b. Supplemental environmental assessment (EA) and decision/finding of no significant 

impact (FONSI) – Oral vaccination to control specific rabies virus variants in raccoons, gray foxes, 

and coyotes in the United States. USDA, APHIS, Wildlife Services, 4700 River Road, Unit 87, 

Riverdale, MD 20737-1234. 

USDA (U.S. Department of Agriculture), Animal and Plant Health Inspection Service (APHIS), Wildlife 

Services. 2002. Decision/finding of no significant impact (FONSI) for environmental assessment oral 

vaccination to control specific rabies virus variants in raccoons, gray foxes, and coyotes in the United 

States. USDA, APHIS, Wildlife Services, 4700 River Road, Unit 87, Riverdale, MD 20737-1234. 

USDA (U.S. Department of Agriculture), Animal and Plant Health Inspection Service (APHIS), Wildlife 

Services. 2001a. Environmental Assessment (EA) and decision/finding of no significant impact 

(FONSI) - Oral vaccination to control specific rabies virus variants in raccoons, gray foxes, and 

coyotes in the United States. USDA, APHIS, Wildlife Services, 4700 River Road, Unit 87, Riverdale, 

MD 20737-1234. 

USDA-APHIS-WS. 2001b. Wildlife Services Field Operations Manual for the Use of Immobilization and 

Euthanasia Drugs. 120pp 

USDA (U.S. Department of Agriculture), Animal and Plant Health Inspection Service (APHIS), Wildlife 

Services. 2000. Biological Assessment of potential Impacts on Lynx by the USDA, APHIS, Wildlife 

Services Program-Eastern Region. USDA, APHIS, Wildlife Services Eastern Regional Office, 920 

Main Campus Drive, Suite 200, Raleigh, NC 27606. October, 2000. 12pp. 

USDA (U.S. Department of Agriculture), Animal and Plant Health Inspection Service (APHIS), Animal 

Damage Control Program. 1997. Final Environmental Impact Statement - revised October 1997. 

USDA, APHIS, Wildlife Services Operational Support Staff, 4700 River Road, Unit 87, Riverdale, 

MD 20737-1234. 

USDA (U.S. Department of Agriculture), Animal and Plant Health Inspection Service (APHIS), 

Biotechnology, Biologics, and Environmental Protection (BBEP). 1995. EA and Finding of No 

Significant Impact – Proposed Issuance of a Conditional United States Veterinary Biological Product 

License to Rhone Merieux, Inc., for Rabies Vaccine, Live Vaccinia Vector. USDA, APHIS, BBEP, 

USDC (U.S. Department of Commerce), U.S. Census Bureau. 2012a. State and county quick facts. 

Retrieved on 12 January 2012 from: http://quickfacts.census.gov/qfd/states/50000.html

USDC (U.S. Department of Commerce), National Oceanic and Atmospheric Administration. 2012b. 

Coastal Services Center land cover analysis. Retrieved on 12 January 2012 from: 

http://www.csc.noaa.gov/crs/lca/northeast.html

USDC (U.S. Department of Commerce). U.S. Census Bureau. 2012c. Statistical abstract of the United 

States. Source: U.S. Census Bureau, 2000 Census of population and Housing, Population and 

housing Unit Counts PHC-3. Information retrieved on February 21, 2012 from 

http://www.census.gov/compendia/statab/

USDI (U.S. Department of the Interior), National Park Service (NPS). 1995. Report of effects of aircraft 
B-15 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

overflights on the National Park System. USDI-NPS D-1062, July, 1995. 

USFWS (U.S. Fish and Wildlife Service), Endangered Species Program. 2012. Species information. 

Retrieved on January 18, 2012 from http://www.fws.gov/endangered/

Van der Veen, J. 1963. Am. Rev. Respir. Dis. 88:167-180. 

VerCauteren, K.C. and S.E. Hygnstrom. 2002. Efficacy of hunting for managing a a suburban deer 

population in eastern Nebraska. P. 51-58 in R.I. Warren, editor, Proceeding of the first National 

Bowhunting Conference. Archery Manufacturers and Merchants Organization, Comfrey, MN. 

Vihma, L. 1969. Surveillance of acute viral respiratory diseases in children. Acta. Paediatr. Scand. Suppl. 

192: 1-52. 

VTFW (Vermont Fish and Wildlife Department). 2012. Endangered and Threatened Animals of Vermont, 

15 July, 2011. Information retrieved on February 7, 2012 from website: 

http://www.vtfishandwildlife.com/library/Reports_and_Documents/NonGame_and_Natural_Heritage

/Rare_Threatened_and_Endangered_Species%20%20---

%20lists/Endangered%20and%20Threatened%20Animals%20of%20Vermont.pdf

Wandeler, A.I. 1991. Oral immunization of wildlife. p. 485-505 in The natural history of rabies, 2nd ed., 

GM Baer, ed, CRC Press, Boca Raton, FL. 

Weisenberger, M.E., P.R. Krausman, M.C. Wallace, and O.E. Maughan. 1996. Effects of simulated jet 

aircraft noise on heart rate and behavior of desert ungulates. J. Wild. Manage. 60:52-61. 

White, C.M. and S.K. Sherrod. 1973. Advantages and disadvantages of the use of rotor-winged aircraft 

in raptor surveys. Raptor Research 7:97-104. 

White, C.M. and T.L. Thurow. 1985. Reproduction of ferruginous hawks exposed to controlled 

disturbance. Condor 87:14-22. 

WVDNR (West Virginia Department of Natural Resources). 2012. Rare, threatened ,and endangered 

animals. Information retrieved on February 14, 2012 from website: 

http://www.wvdnr.gov/Wildlife/documents/Animals2007.pdf

WVDNR (West Virginia Department of Natural Resources). 2010a. 2010-2011 Season, dates, and limits. 

Information retrieved on July 20, 2010 from www.wvdnr.gov/hunting/Regs1011/Season_dates.pdf

WVDNR (West Virginia Department of Natural Resources). 2010b. Furbearer Management Newsletter 

Fall/Winter 2009/2010. Information obtained from website: 

www.wvdnr.gov/hunting/PDFFiles?fur_news_fall09.pdf
C-1 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

APPENDIX C 

SPECIES LISTED AS THREATENED OR ENDANGERED 

UNDER THE ENDANGERED SPECIES ACT 

Information obtained from http://ecos.fws.gov/tess_public/StateListing.do?state=all on March 2012. 

Ohio – 29 listings 

Animals – 23 

Status Listing 

E Bat, Indiana (Myotis sodalist) 

E Beetle, American burying (Nicrophorus americanus) 

E Butterfly, Karner blue (Lycaeides melissa samuelis) 

E Butterfly, Mitchel’s satyr (Neonympha mitchellii mitchellii) 

E Catspaw, white (pearlymussel) (Epioblasma obliquata perobliqua) 

E Clubshell Entire Range; except where listed as Experimental Populations (Pleurobema 

clava) 

E Dragonfly, Hine’s emerald (Somatochlora hineana) 

E Fanshell (Cyprogenia stegaria) 

E Madtom, Scioto (Noturus trautmani) 

E Mapleleaf, winged Entire; except where listed as experimental populations (Quadrula 

fragosa) 

E Mucket, pink (pearlymussel) (Lampsilis abrupta) 

E Mussel, scaleshell (Leptodea leptodon) 

E Pearlymussel, cracking Entire Range; except where listed as Experimental Populations 

(Hemistena lata) 

E Pimpleback, orangefoot (pearlymussel) (Plethobasus cooperianus) 

E Plover, piping Great Lakes watershed (Charadrius melodus) 

T Plover, piping except Great Lakes watershed (Charadrius melodus) 

E Pocketbook, fat (Potamilus capax) 

E Puma (=cougar) eastern (Felis concolor cougar) 

E Purple cat’s paw (=purple cat’s paw pearlymussel) Entire Range; Except where listed as 

Experimental Populations (Epioblasma obliquata obliquata) 

E Riffleshell, northern (Epioblasma torulosa rangiana) 

E Ring pink (mussel) (Obovaria retusa) 

T Snake, copperbelly water Indiana north of 40 degrees north latitude, Michigan, Ohio 

(Nerodia erythrogaster neglecta) 

E Wolf, gray Lower 48 States, except MN, MT, ID, portions of eastern OR, eastern WA, 

north-central UT, and where EXPN. Mexico (canis lupus) 

Plants – 6 

Status Listing 

E Clover, running buffalo (Trifolium stoloniferum) 

T Daisy, lakeside (Hymenoxys herbacea) 
C-2 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

T Monkshood, northern wild (Aconitum noveboracense) 

T Orchid, eastern prairie fringed (Platanthera leucophaea) 

T Pogonia, small whorled (Isotria medeoloides) 

T Spirea, Virginia (Spirea virginiana) 

New Hampshire – 17 listings 

Animals – 14 

Status Listing 

E Beetle, American burying (Nicrophorus americanus) 

E Butterfly, Karner blue (Lycaeides melissa samuelis) 

T Lynx, Canada (Contiguous U.S. DPS) (Lynx canadensis) 

T Plover, piping except Great Lakes watershed (Charadrius melodus) 

E Puma (=cougar) eastern (Felis concolor cougar) 

T Sea turtle, green except where endangered (Chelonia mydas) 

E Sea turtle, hawksbill (Eretmochelys imbricate) 

E Sea turtle, leatherback (Dermochelys coriacae) 

T Sea turtle, loggerhead (Caretta caretta) 

E Tern, roseate northeast U.S. nesting pop. (Sterna dougallii dougallii) 

T Tiger bettle, Puritan (Cicindela puritan) 

E Wedgemussel, dwarf (Alasmidinta heterodon) 

E Whale, finback (balaenoptera physalus) 

E Wolf, gray U.S.A.: All of AL, Ar, CA, CO, CT, DE, FL, GA, KS, KY, LA, MA, MD, 

ME, MO, MS, NC, NE, NH, NJ, NV, NY, OK, PA, RI, SC, TN, VA, VT, and WV; those 

portions of AZ, NM, and TX not included in an experimental population; and portions of 

IA, IN, IL, ND, OH, OR, SD, UT, and WA. Mexico. (Canus lupus) 

Plants – 3 

Status Listing 

E Bulrush, Northeastern (Scirpus ancistrochaetus) 

E Milk-vetch, Jesop’s (Astragalus robbinsii var. jesupi) 

T Pogonia, small whorled (Isotria medeoloides) 

New York – 34 Listings 

Animals – 23 

Status Listing 

E Bat, Indiana (Myotis sodalist) 

E Beetle, American burying (Nicrophorus americanus) 

E Butterfly, Karner blue (Lycaeides melissa samuelis) 

E Clubshell Entire Range; Except where listed as Experimental Populations (Pleurobema 

clava) 

T Lynx, Canada (Contiguous U.S. DPS) (Lynx canadensis) 

T Plover, piping except Great Lakes watershed (Charadrius melodus) 
C-3 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

E Plover, piping Great Lakes watershed (Charadrius melodus) 

E Puma (=cougar) eastern (Felis concolor cougar) 

T Sea turtle, green except where endangered (Chelonia mydas) 

E Sea turtle, hawksbill (Eretmochelys imbricate) 

E Sea turtle, Kemp’s ridley (Lepidochelys coriacea) 

E Sea turtle, leatherback (Dermochelys coriacae) 

T Sea turtle, loggerhead (Caretta caretta) 

T Snail, Chittenango ovate amber (Succinea chittenangoensis) 

E Sturgeon, shortnose (Acipenser brevirostrum) 

E Tern, roseate northeast U.S. nesting pop. (Sterna dougallii dougallii) 

T Tiger bettle, northeastern beach (Cicindela dorsalis dorsalis) 

T Turtle, bog (=Muhlenberg) northern (Clemmys muhlenbergii) 

E Wedgemussel, dwarf (Alasmidinta heterodon) 

E Whale, finback (balaenoptera physalus) 

E Whale, humpback (Megaptera novaengliae) 

E Whale, North Atlantic Right (Eubalaena glacialis) 

E Wolf, gray Lower 48 States, except MN, MT, ID, portions of eastern OR, eastern WA, 

north-central UT, and where EXPN. Mexico. (Canus lupus) 

Plants – 11 

Status Listing 

T Amaranth, seabeach (Amaranthus pumilus) 

E Bulrush, Northeastern (Scirpus ancistrochaetus) 

E Chaffseed, American (Schwalbea Americana) 

T Fern, American hart’s tongue (Asplenium scolopendrium var.) 

E Gerardia sandplain (Agalinis acuta) 

T Goldenrod, Houghton’s (Solidago houghtonii) 

T Monkshood, northern wild (Aconitum noveboracense) 

T Orchid, eastern prairie fringed (Platanthera leucophaea) 

T Pink, swamp (Helonias bullata) 

T Pogonia, small whorled (Isotria medeoloides) 

T roseroot, Leddy’s (Rhodiola integrifolia ssp. leedyi) 

Vermont – 10 Listings 

Animals – 7 

Status Listing 

E Bat, Indiana (Myotis sodalist) 

E Beetle, American burying (Nicrophorus americanus) 

T Lynx, Canada (Contiguous U.S. DPS) (Lynx canadensis) 

E Puma (=cougar) eastern (Felis concolor cougar) 

E Wedgemussel, dwarf (Alasmidinta heterodon) 

T Tiger bettle, northeastern beach (Cicindela dorsalis dorsalis) 

E Wolf, gray Lower 48 States, except MN, MT, ID, portions of eastern OR, eastern WA, 

north-central UT, and where EXPN. Mexico. (Canus lupus) 
C-4 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

Plants – 3 

Status Listing 

E Bulrush, Northeastern (Scirpus ancistrochaetus) 

E Milk-vetch, Jesop’s (Astragalus robbinsii var. jesupi) 

T Pogonia, small whorled (Isotria medeoloides) 

West Virginia – 22 listings 

Animals – 17 

Status Listing 

E Bat, Indiana (Myotis sodalist) 

E Bat, gray (Myotis grisescens) 

E Bat, Virginia big-eared (Plecotus townsendii virginianus) 

E Beetle, American burying (Nicrophorus americanus) 

E Blossum, tubercled (pearlymussel) Entire Range; Except where listed as Experimental 

Populations (Epioblasma torulosa torulosa) 

E Clubshell Entire Range; except where listed as Experimental Populations (Pleurobema 

clava) 

E Fanshell (Cyprogenia stegaria) 

T Isopod, Madison Cave (Antrolana lira) 

E Mucket, pink (pearlymussel) (Lampsilis abrupta) 

E Puma (=cougar) eastern (Felis concolor cougar) 

E Riffleshell, northern (Epioblasma torulosa rangiana) 

E Ring pink (mussel) (Obovaria retusa) 

T Salamander, Cheat Mountain (Plethodon netting) 

T Snail, flat-spired three-toothed (Triodopsis platysayoides) 

E Spinymussel, James (Pleurobema collina) 

E Squirrel, Virginia northern flying (Glaucomys sabrinus fuscus) 

E Wolf, gray Lower 48 States, except MN, MT, iD, portions of eastern OR, eastern WA, 

north-central UT, and where EXPN. Mexico. (Canus lupus) 

Plants – 6 

Status Listing 

E Bulrush, Northeastern (Scriptus ancistrochaetus) 

E Clover, running buffalo (Trifolium stoloniferum) 

E Harperella (Ptilimnium nodosum) 

T Pogonia, small whorled (Isotria medeoloides) 

E Rock-cress, shale barren (Arabis serotina) 

T Spirea, Virginia (Spirea virginiana) 

E=Endangered, T=Threatened
D-1 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

APPENDIX D 

SUMMARY OF SPECIES LISTED AS THREATENED, ENDANGERED, OR SPECIAL STATUS 

UNDER STATE LAW IN STATES PROPOSED FOR APHIS-WS INVOLVEMENT IN 

CONTINUED OR EXPANDED ONRAB® FIELD TRIALS 

Number of State Listed Species by Category

(Species for which concerns about ORV programs might be raised are identified and shown in bold)

Information obtained from http://www.fws.gov/offices/statelinks.html on February 2012. 

State Mammals Birds Reptiles Amphibians Fish Invertebrates Plants 

New 

Hampshire 

4E, 1T 

Canada lynx, American 

marten, New England 

Cottontail, gray wolf 

8E, 7T 3E, 2T 1E 1T 9E, 2T 316E, 

81T 

New York 10E, 1T, 3SC 

Canada lynx, New England 

cottontail, gray wolf, 

Eastern puma 

10E, 

10T, 

19SC 

7E, 5T, 

6SC 

2E, 7SC 8E, 

11T, 

5SC 

16E, 8T, 18SC 331E, 

135T, 

11R 

Ohio 5E, 12SC 

bobcat, snowshoe hare, 

American black bear, 

ermine, American badger 

16E, 

11T, 

13 SC, 

31SI 

5E, 3T, 

11SC 

5E, 1T, 2SC 23E, 

13T, 

11SC 

71E, 28T, 

52SC, 11SI 

250E, 

152T, 

130P 

Vermont 6E, 1T 

Canada lynx, Eastern 

mountain lion, American 

marten 

8E, 1T 3E, 3T 1E 4E, 2T 8E, 6T 64E, 

93T 

West Virginia 6S1, 11S2, 5S3 

West Virginia northern 

flying squirrel, eastern 

spotted skunk, 

Appalachian cottontail 

28S1, 

15S2, 

15S3 

3S1, 9S2, 

6S3 

6S1, 7S2, 5S3 26S1, 

26S2, 

20S3 

173S1, 80S2, 

26S3 

267S1, 

136S2, 

27S3 

E=State Endangered; T=State Threatened; SC=Species of Concern; SI=Species of Interest; R=Rare; P=Potentially Threatened; 

S1, S2, and S3=WV designations for levels of concern. 

State T&E Protections under State Law

New Hampshire With respect to any endangered or threatened species, it is unlawful to: (a) Export 

any such species from this state; (b) Take any such species within this state; (c) 

Possess, process, sell, or offer for sale, deliver, carry, transport, or ship, by any 

means whatsoever, any such species; (d) Violate any rule adopted under this 

chapter pertaining to the conservation of such species of wildlife listed pursuant to 

RSA 212-A:6, IV 

New York Endangered and threatened categories have protections against “take”; “special 

concern” category has no special additional protection. 

Ohio Unlawful to “take” and endangered species of fish or wildlife; “take” not 

specifically defined; no exemptions or permits to allow for incidental take; no 

special protections for “threatened” or “special interest” species; APHIS-WS 

advised to just release any state listed species if captured or to report accidental 

mortality. 

Vermont Unlawful to “take” any endangered or threatened species without the issuance of a 

permit; “take” not specifically defined; state law includes all federally listed 

species as state listed. 

West Virginia Only lists federal T&E species as having protections; “Species of Concern” are 

listed, but have no legal status other than that are already federally listed. 
E-1 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

APPENDIX E 

REGIONAL FORESTER SENSITIVE SPECIES 

for the 

MONONGAHELA NATIONAL FOREST (USDA 2011) 

Mammals 

Southern Rock Vole Microtus chrotorrhinus carolinensis 

Eastern Small-footed Myotis Myotis leibii 

Little Brown Myotis Myotis lucifugus 

Northern Myotis Myotis septentrionalis 

Allegheny Woodrat Neotoma magister 

Tri-colored bat Perimyotis subflavus 

Long-tailed or Rock Shrew Sorex dispar 

Southern Water Shrew Sorex palustris punctulatus 

Eastern Spotted Skunk Spilogale putoris 

Southern Bog Lemming Synaptomys cooperi 

Birds 

Northern Goshawk Accipiter gentilis

Henslow’s Sparrow Ammodramus henslowii 

Long-eared Owl Asio otus 

Olive-sided Flycatcher Contopus cooperi 

American Peregrine Falcon Flaco peregrines anatum

Bald Eagle Haliaeetus leucocephalus

Migrant Loggerhead Shrike Lanius ludovicianus migrans 

Red-headed Woodpecker Melanerpes erythrocephalus 

Vesper Sparrow Pooecetes gramineus

Golden-winged Warbler Vermivora chrysoptera 

Reptiles 

Wood Turtle Glyptemys insculpta

Timber Rattlesnake Crotalus horridus 

Amphibians 

Green Salamander Aneides aeneus

Eastern Hellbender Cryptobrachus alleghaniensis

Mud Salamander Pseudotriton montanus 

Fish 

Redside Dace Clinostomus elongatus

Candy Darter Etheostoma osburni
E-2 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

Pearl Dace Margariscus margarita

New River Shiner Notropis scabriceps 

Cheat Minnow Pararhinichthys bowersi

Appalachia Darter Percina gymnocephala

Kanawha Minnow Phenacobious teretulus

Arachnids 

Dry Fork Valley Cave Pseudoscorpion Apochthonius paucispinosus 

Bivalves 

Elktoe Alasmindonta marginata 

Green Floater Lasmigona subviridis 

Crustaceans 

Cannulate Cave Isopod Caecidotea cannula 

Holsiger’s Cave Isopod Caecidotea holsingeri

A Cave Obligate Isopod Caecidotea simonini

A Cave Isopod Caecidotea sinuncus

Elk River Crayfish Cambarus elkensis

Greenbrier Cave Crayfish Cambarus nerterius

Culver’s Cave Amphipod Stygobromus culveri

Greenbrier Cave Amphipod Stygobromus emarginatus

Pocahontas Cave Amphipod Stygobromus nanus

Minute Cave Amphipod Stygobromus parvus 

Gastropods 

Organ Cavesnail Fontigens tartarea 

Insects 

Boreal Fan Moth Brachionycha borealis

Northern Metalmark Calephelis borealis

Appalachian Tiger Beetle Cicindela ancocisconensis

Northern Barrens Tiger Beetle Cicindela patruela

Cow Path Tiger Beetle Cicindela purpurea

Early Hairstreak Erora laeta

Columbine Duskywing Erynnis lucillius 

A Geometrid Moth Euchlaena milnei

Rapids Clubtail Gomphus quadricolor

Green-faced Clubtail Gomphus viridifrons

A Noctuid Moth Hadena ectypa

Cobweb Skipper Hesperia metea

Bronze Copper Lycaena hyllus

West Virginia White Pieris virginiensis

A Cave Beetle Pseudanophthalmus fuscus

Timber Ridge Cave Beetle Pseudanophthalmus hadenoecus
E-3 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

A Cave Beetle Pseudanophthalmus hypertrichosis

Dry Fork valley Cave Beetle Pseudanophthalmus montanus

Gandy Creek Cave Springtail Pseudosinella certa

A Springtail Pseudosinella gisini

Southern Grizzled Skipper Pyrgus wyandot

A Springtail Sinella agna

Diana Fritillary Speyeria Diana 

Invert-Other 

Hoffmaster’s Cave Planarian Macrocotyla hoffmasteri

A Cave Obligate Planarian Phagocata angusta

Greenbrier Valley Cave Millipede Pseudotremia fulgida

Germany Valley Cave Millipede Pseudotremia lusciosa

South Branch Valley Cave Millipede Pseudotremia princeps

Culver’s Planarium Sphalloplana culveri

Grand Caverns Blind Cave Millipede Zygonopus weyeriensis

Luray Caverns Blind Cave Millipede Zygonopus whitei
F-1 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

APPENDIX F 

ECOREGION DESIGNATIONS WITHIN THE STATES AFFECTED BY APHIS-WS 

CONTINUED OR EXPANDED INVOLVEMENT IN ONRAB® FIELD TRIALS 

Ecoregions are ecosystems of regional extent as defined by Bailey (1995). An “X” means the state 

contains the ecosystem/ecoregion described in the key below. The reader is referred to Bailey 

(1995) for more detailed descriptions of each ecoregion and the climate, soils, vegetation, and 

animal life that occur there. 

 212 M212 221 222 M221 231 232 234 255 313 M313 315 321 322 331 M331 411 

New 

Hampshire 

X X 

New York X X X X 

Ohio X X 

Vermont X X 

West 

Virginia 

X X 

Key to Ecoregion Designations (adapted from descriptions by Bailey 1995): 

Numbers in the 200 series are within the “humid temperate Domain”: 

212 Laurentian Mixed Forest Province – lower elevation areas (sea level to 2,400 ft.); flat to rolling hills in 

relief; moderately long and sever winters; average annual precipitation is moderate, ranging from 24 to 45 

in.; native vegetation types are transitional between spruce-fir coniferous boreal forest and broadleaf 

deciduous forest zones and are characterized by mixed stands of coniferous (mainly pine) species and a few 

deciduous species (mainly yellow birch, sugar maple, and American beech). 

M212 Adirondack-New England Mixed Forest Coniferous Forest-Alpine Meadow Province – mountainous region 

with elevations between 500 and 4,000 ft.; warm summers and sometimes cold winters; annual 

precipitation averages 35 in. and average annual snowfall is more than 100 in.; native vegetation types are 

transitional between boreal spruce-fir coniferous forest to the north and deciduous forest to the south; 

valleys contain hardwood forest (sugar maple, yellow birch, beech, hemlock); lower mountain slopes are 

characterized by mixed forest of spruce, fir, maple, beech, and birch; higher elevations are dominated by fir 

and spruce. 

221 Eastern Broadleaf Forest (oceanic) Province – diverse topography; elevations from 1,000 to 3,000 ft.; cold 

winters and warm summers; year-round precipitation averaging 35 to 60 in.; native vegetation 

characterized by temperate deciduous forest dominated by tall broadleaf trees that provide a dense, 

continuous canopy in summer and shed their leave in winter; dominant deciduous species include 

American beech, yellow-poplar, basswoods, sugar maple, buckeye, red oak, white oak, hemlock; includes 

areas of pine-oak forest (“Pine Barrens”). 

222 Eastern Broadleaf Forest (Continental) Province – flat to rolling to moderate relief; elevations from 80 to 

1,650 ft.; hot summers; precipitation varies from 20 to 50 in. mostly occurring during the growing season; 

native vegetation dominated by broadleaf deciduous forest with oak and hickory tree species more 

abundant than in other provinces; gradually turns to prairies towards the Midwest, forming a mosaic pattern 

with prairie. 
F-2 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

M221 Central Appalachian Broadleaf Forest-Coniferous Forest-Meadow province – low mountains at elevations 

ranging from 300 to 6,700 ft.; distinct summers and winters; average annual precipitation varies from 35 in. 

in the valleys to up to 80 in. on the highest peaks; native vegetation characterized by mixed oak-pine forest, 

dominated by white and black oak groups at lower levels; northeastern hardwood forest at mid elevation 

levels; and spruce-fir forest and meadows on the highest peaks. 
G-1 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

APPENDIX G 

STATUTES REGARDING RABIES MANAGEMENT 

States to be included in the expanded field trial area: 

New Hampshire

New Hampshire Department of Health and Human Services (New Hampshire Revised Statutes 

Annotated: Title X, Chapter 125, Section 125:9:II). The New Hampshire Department of Health and 

Human Services is authorized to make investigations and inquires concerning the causes of epidemics and 

other diseases, the sources of morbidity and mortality, and the effects of localities, employments, 

conditions, circumstances, and the environment on the public health. Investigations also include an 

extended rabies surveillance effort which shall be conducted with assistance from the New Hampshire 

Department of Agriculture, Markets, and Food; and New Hampshire Fish and Game Department. 

New Hampshire Department of Agriculture, Markets, and Food (New Hampshire Statutes 

Annotated: Title XL, Chapter 436-A, Section 436-A:1). The state veterinarian within the New 

Hampshire Department of Agriculture, Markets, and Food may authorize the application of vaccines and 

treatments for zoonotic disease to wildlife within the state through baiting and other methods. 

New Hampshire Department of Fish and Game (New Hampshire Statutes Annotated: Title XVIII, 

Chapter 206, Section 206:10:I). The New Hampshire Fish and Game Department is charged with 

protecting, propogating and preserving the fish, game, and wildlife resources of New Hampshire and 

protecting and conserving nongame birds of New Hampshire. 

New Hampshire Department of Fish and Game (New Hampshire Statutes Annotated: Title XVIII, 

Chapter 207, Section 207:8-c). The New Hampshire Department of Fish and Game requires that no 

person shall administer any drug, including but not limited to drugs used for fertility control, disease 

prevention or treatment, immobilization, or growth stimulation, to any mammal, bird, reptile, or 

amphibian under the jurisdiction of the Fish and Game Department without written authorization from the 

executive director or his or her designee. However, this shall not be construed to limit employees or 

agencies of the state or United States in the performance of their official duties related to public health, 

wildlife management, wildlife rehabilitation, or wildlife removal. 

New York

New York State Agriculture and Markets (New York Legislative Authorization Code: Chapter 69, 

Article 5, Section 73b). The New York State Department of Agriculture and Markets is authorized to 

establish a New York State Veterinary Diagnostic Laboratory (Cornell University works under this law 

during ORV program participation) which is authorized to respond to disease outbreaks in animals, 

establish diagnostic testing capabilities to establish heard health status and evaluation of disease 

programs; support disease surveillance and monitoring programs of domestic, zoo, and wild animals; 

supports veterinarians by analyzing and interpreting samples obtained from clinical cases; and evaluate, 

adjust, and improve New York’s ability to recognize diseases that impact animal populations. 

New York Legislative Authorization Code: Chapter 69, Article 5, Section 72). The New York State 

Department of Agriculture and Markets is authorized to investigate, suppress, or eradicate infectious or 

communicable disease affecting domestic animals or carried by domestic animals and affecting humans. 

Measures shall be taken to prevent such disease from being brought into the state or suppress or prevent 

the disease from spreading within the state. 
G-2 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

New York Department of Environmental Conservation (New York Legislative Authorization Code: 

Chapter 43-B, Article 11, Title 3, Section 11-0325 and 11-0525). The New York Department of 

Environmental Conservation is authorized to undertake fish or wildlife control measures to eliminate, 

reduce, or confine and disease which endangers the health and welfare of fish or wildlife populations. 

The New York Department of Environmental Conservation is directed to undertake through the use of 

professional trappers or by other means wildlife control measures when rabies is certified to exist in an 

area of the state in attempt to eliminate, reduce, or confine the disease. 

New York State Department of Health (New York Legislative Authorization Code: Chapter 45, 

Article 2, Section 201). The New York State Department of Health is directed to supervise the reporting 

and control of disease and promote education in the prevention and control of disease. 

Ohio

Ohio Department of Health (Ohio Administrative Code: Chapter 3701 – Zoonotic Diseases and 

Animal Bites). The Ohio Department of Health Rabies Program conducts rabies prevention activities to 

protect Ohio residents from the spread of wildlife rabies to people, pets, and other animals. Bat, raccoon, 

skunk, and other wild animal and domestic animal rabies cases are reviewed to determine any necessary 

control initiatives. 

Ohio Department of Natural Resources – Division of Wildlife (Ohio Administrative Code: Chapter 

1501:31). The Ohio Department of Natural Resources is “dedicated to conserving and improving fish and 

wildlife resources and their habitats, and promoting their use and appreciation by the public so that these 

resources continue to enhance the quality of life for all Ohioans.” 

Ohio Department of Agriculture (Ohio Administrative Code, Chapter 901). The Ohio Department of 

Agriculture’s mission is “to provide regulatory protection to producers, agribusinesses and the consuming 

public; to promote Ohio agricultural products in domestic and international markets; and to educate the 

citizens of Ohio about our agriculture industry.” 

Vermont

Vermont Department of Health (Vermont Statutes Annotated: Title 18, Chapter 1). The Vermont 

Department of Health is authorized to promote health and safety, and prevent disease. 

Vermont Agency of Agriculture, Food and Markets (Vermont Statutes Annotated: Title 6, Chapter 

102, §1152). The Vermont Agency of Agriculture, Food, and Markets may contract and cooperate with 

the USDA and other federal agencies or other states for the control and eradication of contagious diseases 

of animals. (Vermont Statutes Annotated: Title 6, Chapter 102; § 1151, “contagious disease” includes 

rabies). 

Vermont Department of Fish and Wildlife (Vermont Statutes Annotated: Title 10, Chapter 103). 

The Vermont Department of Fish and Wildlife is charged with conservation of fish, wildlife, and plants 

and their habitats for the people of Vermont. 

West Virginia

West Virginia Department of Agriculture (West Virginia Code of State Regulations: Section §19-9-

2A). The West Virginia Department of Agriculture is charged with prevention, suppression, control, and 

eradication of any communicable disease of animals or poultry. 
G-3 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

West Virginia Department of Health and Human Resources (West Virginia Code of State 

Regulations: Chapter 16, Section §16-2-11 (a)(1)(iii)). Chapter 16 of the West Virginia Department of 

Health and Human Resources authorizes the creation of a state public health system, including local 

boards of health, whose duties include “prevention and control of rabies.” 

West Virginia Division of Natural Resources (West Virginia Code of State Regulations: Section 

§20-2-1). The West Virginia Division of Natural Resources is charged with protecting the wildlife 

resources for the use and enjoyment of all the citizens in West Virginia 
H-1 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

APPENDIX H 

ONRAB® FIELD TRIAL STUDY PROTOCOLS 

Outline for Proposed ONRAB® Oral Rabies Vaccine Field Trial in Northeast Ohio in 2012

PRIMARY GOALS: Determine if ground/hand distribution of ONRAB® at 150 baits/km2

 would result in 

significantly higher sero-prevalence in an area that has often been subject to twice/year and high density baiting (150 

baits/km2

) with Raboral V-RG® and trap-vaccine-release. A primary focus will be on the ORV and TVR naïve 

juvenile cohort in 2012. Also, evaluate the risk of human contact with the ULTRALITE bait containing ONRAB® in 

this largely residential and commercial landscape. Raboral V-RG® ground/hand baited cells will be included in this 

field trial for comparative context. 

1) SITE LOCATION (Figure 1) 

 State: Ohio 

 Counties: portions of Cuyahoga, Geauga, Lake, Portage and Summit 

Towns: Aurora, Beachwood, Bedford, Bedford Heights, Bentleyville, Chagrin Falls, Boston Heights, Burton, 

Chardon, Cleveland, Cleveland Heights, Cleveland Metro Parks, Concord, East Cleveland, Eastlake, Euclid, 

Garfield Heights, Gates Mills, Glenwillow, Highland Heights, Highland Hills, Hudson, Hunting Valley, 

Independence, Kirkland, Kirkland Hills, Lyndhurst, Macedonia, Madison, Maple Heights, Mayfield, Mayfield 

Heights, Mentor, Mentor on the Lake, Middlefield, Moreland Hills, North Randall, Northfield, Northfield 

Center, Oakwood, Orange, Painesville, Pepper Pike, Perry, Reminderville, Richmond Heights, Sagamore Hills, 

Shaker Heights, Solon, South Euclid, South Russell, Twinsburg, University Heights, Valley View, Waite Hills, 

Warrensville Heights, Wickliffe, Willoughby, Willoughby Hills, Willowick, Woodmere 

2) RATIONALE FOR FIELD TRIAL SITE SELECTION 

 The area has been intensively managed since 2007 though contingency actions (high density baiting often 

at 150 baits/km2

, twice/year baiting frequency over much of the area, and TVR) because it continues to 

represent a high risk corridor for raccoon rabies to spread to the west 

 Selection was predicted partially on the need for improved ORV performance and the ability to evaluate 

high density hand baiting, a commonly used ORV tactic in urban-suburban settings 

 All Ohio field trial cells will be hand baited at 150 baits/km2 of the baitable habitat 

 Raccoons and skunks present 

 Raccoon rabies present east of existing area and detected in skunks within the ORV zone 

 Continued local support within state and county 

 WS infrastructure in place 

3) FIELD TRIAL PLOT SIZE 

 Total area: 3,016.66 km2

 [1,493.09 km2 (fixed wing baiting) and 1,523.57 km2 (ground and helicopter 

baiting )] 

 9 distance buffered 3 km2

 cells (1.7 x 1.7 km) for pre and post-ORV sampling 

4) BAITING CHARACTERISTICS 

 Total ONRAB® baits: 329,670 (150,660 fixed wing and 179,010 ground and helicopter) 

 Bait density: 75/150 baits/km2

 Total Raboral V-RG® baits: 12,516 (all distributed by hand) 
H-2 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

 Approximately 350 ONRAB® or Raboral V-RG® baits will be distributed by hand/3km2 sampling cell 

 Flight line spacing: 375/750 m 

 Off-time: 33% for fixed wing and an average of 23% for ground and helicopter using National Land Class 

Dataset used determine “baitable” habitat 

 Projected baiting dates: September 4 – 7, 2012 

 Baiting duration: 4 days, 3 planes, 1 helicopter and ground crews for hand-baiting 

5) BAIT-VACCINE CHARACTERISTICS 

 Each bait contains 1.8 ± 0.1ml of ONRAB® vaccine (titer of not < 109.5 cell culture infectious dose 50% 

[CCID50]/ml) 

 Bait matrix is comprised of partially hydrogenated vegetable shortening (34%), Microbond® wax (30%), 

stearine (12.5%), Icing sugar (20%), vegetable oil (1%), artificial marshmallow flavor (1%), artificial sweet 

flavor (1%), and a fat-soluble food dye (0.5%) 

 Bait matrix contains 100 mg of tetracycline hydrochloride as a biomarker 

 Each vaccine-bait weighs approximately 4g 

 The body of the blister pack is an elongated oval with dimensions of 30x14x10mm 

(1.81 x 0.55 x 0.39in) 

 Each bait contains a conspicuous advisory label with a toll free number in the event of a bait contact and 

potential vaccine exposure 

6) PRE-ORV SAMPLING (BASELINES) AND ACTIVITIES 

 Enhanced rabies surveillance has been in place since 2004, with no raccoon rabies variant cases detected in 

2012 (including spillover in skunks) 

 In late summer 2012, 150 raccoon-sized cage traps will be tended for 10 consecutive days within each of 

the 9 sampling cells (6 ONRAB® and 3 Raboral V-RG®) 

 Traps will be deployed at predetermined random roadside trapping locations based on past trapping trends 

to ensure adequate property access in this highly residential and commercial landscape 

 Target for juvenile captures is 40/3km2

 cell as young of the year represent the only ORV naïve cohort in the 

sample; maximize recaptures 

 Maximize skunk captures by additional targeted trapping where practical 

 From raccoons and skunks: collect pertinent biological, physical and spatial-temporal data; sera for rabies 

and human adenovirus serological analysis; first premolar teeth for age determination and biomarker 

analysis; mark and release at site of capture 

 Euthanize target species with unusual lesions or behaviors for analysis 

 Opportunistic sampling for additional target and nontarget species (e.g., roadkills or live animals) that 

display abnormal behavior or have lesions that should evaluated 

 Use various media outlets to advise the public when and where baiting will occur and precautions to be 

followed to reduce chance of vaccine exposure 

7) POST-ORV SAMPLING (TREATMENT EFFECTS) AND ACTIVITIES 

 Continue enhanced rabies surveillance 

 Continue opportunistic sampling for target and nontarget species (e.g., roadkills, hunter harvest) that 

display abnormal behavior or have lesions that should be evaluated 

 5 weeks post-ORV sample ≥100 raccoons and as many skunks as practical within each of the 9 sampling 

cells using the pre-ORV target species trapping protocol 
H-3 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

 Collect pertinent biological, physical and spatial-temporal data from raccoons and skunks as well as sera 

for rabies and human adenovirus analysis and first premolar teeth for age determination and biomarker 

analysis 

 Use acceptable algorithm with appropriate public health, agriculture and wildlife officials to ensure bait 

contacts are reported through a legible, toll-free phone number on each bait or other sources and addressed 

by the proper expertise 

8) SAMPLE ANALYSIS 

 Rabies virus titers to be determined by CDC 

 Human adenovirus titers determined by Dr. Dubovi, Cornell University 

 Opportunistic histopathological sample analysis to be finalized 

 Specific age determination and biomarker detection by Matson’s Laboratory, Milltown, Montana or other 

suitable facility 

9) REPORT FINDINGS 

 Expect results from analysis of field data by February 2013 

 Draft report by April 2013 

Figure 1. Locations of ONRAB® and Raboral V-RG® 3 km2

 sampling cell established for proposed field trial in 

northeast Ohio in the 2012. 
H-4 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

Outline for Proposed Replicate of ONRAB® Oral Rabies Vaccine Field Trial in Southeastern West Virginia in 

2012

PRIMARY GOALS: Determine if replication of the 2011West Virginia ONRAB® trial through a second annual ORV 

campaign at 75 baits/km2

 would result in significantly increased sero-prevalence in 2012. Compare ONRAB® to 

Raboral V-RG® sero-prevalence in 2012. Sero-prevalence would be derived from sampling cells in established 

Raboral V-RG® ORV zones in West Virginia since 2001 and Virginia since 2002 that have been baited annually at 

75 baits/km2

. 

1) SITE LOCATION (Figure 2) 

 States: West Virginia and Virginia 

 WV Counties: Fayette, Greenbrier, Mercer, Monroe, Pocahontas, Raleigh, Summers 

 WV Towns: Alderson, Fairlea, Falling Springs, Hinton, Lewisburg, Ronceverte 

 Virginia Counties: Russell, Scott, Washington 

2) RATIONALE FOR FIELD TRIAL SITE SELECTION 

 Site of first field trial with ONRAB® in 2011, which allows for replication to evaluate sero-prevalence after 

a second identical ONRAB® baiting in 2012 

 Ability to add two sampling cells in the adjacent historic Raboral V-RG® zone in West Virginia to 

facilitate a more formal comparison 

 In 2011, post-ORV sampling from the closest historic Raboral V-RG® area in Virginia was used for 

reference; due to rare high seroprevalence this area will also be formerly sampled pre and post-ORV with 

Raboral V-RG® in 2012 

 Raccoons and skunks present 

 Raccoon rabies present east of existing ORV zone 

 Continued local support within state and county 

 WS infrastructure in place 

3) FIELD TRIAL PLOT SIZE 

 Total area: 2,953.38 km2

 [2,920.71 km2 (fixed-wing baiting) and 32.67 km2 (ground baiting)] 

 6 distance buffered (4 ONRAB and 2 Raboral V-RG) 126.84 km2 cells (11.2 x 11.2 km) cells for pre and 

post-ORV sampling in West Virginia 

 2 Raboral V-RG distance buffered 126.84 km2

cells (11.2 x 11.2 km) for pre and post-ORV sampling in 

Virginia 

4) BAITING CHARACTERISTICS 

 Total baits in ONRAB® zone: 149,040 (146,943 fixed-wing and 2,097 ground) 

 Bait density: 75 baits/km2 (ONRAB® and Raboral V-RG®) 

 Approximately 14,000 ONRAB® or Raboral V-RG® baits/sampling cell 

 Flight line spacing: 750 m 

 Off-time: 27% for fixed wing and an average of 24% for ground using NLCD to determine “baitable” 

habitat 

 Projected baiting dates: September 9-11, 2012 

 Baiting duration: 1 day, 5 planes and ground crews for hand-baiting 
H-5 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

5) BAIT-VACCINE CHARACTERISTICS 

 Each bait contains 1.8 ± 0.1ml of ONRAB® vaccine (titer of not < 109.5 cell culture infectious dose 50% 

[CCID50]/ml) 

 Bait matrix is comprised of partially hydrogenated vegetable shortening (34%), Microbond® wax (30%), 

stearine (12.5%), Icing sugar (20%), vegetable oil (1%), artificial marshmallow flavor (1%), artificial sweet 

flavor (1%), and a fat-soluble food dye (0.5%) 

 Bait matrix contains 100 mg of tetracycline hydrochloride as a biomarker 

 Each vaccine-bait weighs approximately 4g 

 The body of the blister pack is an elongated oval with dimensions of 30 x 14 x 10mm (1.81 x 0.55 x 0.39in) 

 Each bait contains a conspicuous advisory label with a toll free number in the event of a bait contact and 

potential vaccine exposure 

6) PRE-ORV SAMPLING (BASELINES) 

 Enhanced rabies surveillance has been in place for > than 1 year 

 In late summer 2012, 150 raccoon-sized cage traps will be tended for 10 consecutive days within each of 

the 6 sampling cells (4 ONRAB® and 2 Raboral V-RG®) in West Virginia and the 2 Raboral V-RG® cells 

in Virginia 

 Traps will be deployed at predetermined random roadside trapping locations 

 Expect capture rate of ~100 raccoon/cell based on recent previous trapping efforts in area 

 Attempt to maximize skunk captures by additional targeted trapping if practical 

 From raccoons and skunks: collect pertinent biological, physical and spatial-temporal data; sera for rabies 

and human adenovirus serological analysis; first premolar teeth for age determination and biomarker 

analysis; mark and release at site of capture 

 Euthanize target species with unusual lesions or behaviors for analysis 

 Opportunistic sampling for additional target and nontarget species (e.g., roadkills or live animals) that 

display abnormal behavior or have lesions that should be evaluated 

 Use various media outlets to advise the public when and where baiting will occur and precautions to be 

followed to reduce chance of vaccine exposure 

7) POST-ORV SAMPLING (TREATMENT EFFECTS) 

 Continue enhanced rabies surveillance 

 Continue opportunistic sampling for target and nontarget species (e.g., roadkills, hunter harvest) that 

display abnormal behavior or have lesions that should be submitted for analysis 

 5 weeks post ORV sample for a target of ~100 raccoons and as many skunks as practical within each of the 

6 cells in West Virginia and the 2 cells in Virginia using the pre-ORV target species trapping protocol 

 Collect pertinent biological, physical and spatial-temporal data from raccoons and skunks as well as sera 

for rabies and human adenovirus analysis and first premolar teeth for age determination and biomarker 

analysis 

 Use acceptable algorithm with appropriate public health, agriculture and wildlife officials to ensure bait 

contacts are reported through a legible, toll-free phone number on each bait or other sources and addressed 

by the proper expertise 

8) SAMPLE ANALYSIS 

 Rabies virus titers to be determined by CDC 

 Human adenovirus titers determined by Dr. Dubovi, Cornell University 

 Opportunistic histopathological sample analysis to be finalized 
H-6 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

 Specific age determination and biomarker detection by Matson’s Laboratory, Milltown, Montana or other 

suitable facility 

9) REPORT FINDINGS 

 Expect results from analysis of field data by February 2013 

 Draft report by April 2013 

Figure 2. Location of the four ONRAB® field trial sampling cells in West Virginia, and the two Raboral V-RG®

sampling cells in West Virginia and Virginia. 
H-7 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

Outline for Proposed ONRAB® Oral Rabies Vaccine Field Trial in Northeastern New York, Northern 

Vermont and Northern New Hampshire in 2012

PRIMARY GOALS: Determine if ONRAB® baiting at 75 baits/km2

 over an area that has been baited at the same bait 

density with Raboral V-RG® since the late 1990’s would result in a significant increase in sero-prevalence in 2012. 

Determine the sero-prevalence of baiting an ORV naïve rural area in New York, Vermont and New Hampshire and 

evaluate these results in the context of the same baiting protocol used in rural West Virginia in 2011. 

1) SITE LOCATION (Figure 3) 

 States: New Hampshire, New York and Vermont 

 Counties: 

o New Hampshire: Coos, Grafton 

o New York: Clinton, Essex 

o Vermont: Franklin, Essex, Grand Isle, Orleans, Lamoille, Caledonia, Chittenden, Washington 

 Towns with some ground baiting: 

o New Hampshire: Colebrook, Lancaster 

o New York: Altona, Champlain, Chazy, Keeseville, Mooers, Plattsburgh, Rouses Point 

o Vermont: Burlington, Derby Center, Derby Line, Enosbugh, Jericho, Lyndonville, Milton, 

Newport, North Troy, Richford, St. Albans, St. Johnsbury, Swanton, Waterville 

2) RATIONALE FOR FIELD TRIAL SITE SELECTION 

 North American Rabies Management Plan collaboration in a high risk corridor for raccoon rabies to spread 

from the U.S. back into Quebec 

 Raccoons and skunks present 

 Raccoon rabies present in the U.S. but no cases in Quebec since July 2009 

 Local support within state and county and the Province of Quebec 

 WS infrastructure in place 

 Quebec will consider committing resources in 2013, to expand this ONRAB® ORV zone to increase the 

immune buffer to reduce the risk of raccoon rabies spreading into Montreal 

3) FIELD TRIAL PLOT SIZE 

 Total ONRAB ORV zone: 9,753.86 km2

 [ 9,405.35 km2 (fixed wing baiting) and 348.51 km2 (ground 

baiting)] 

 8 distance buffered 126.84 km2

cells (11.2 x 11.2 km) for pre and post-ORV sampling 

4) BAITING CHARACTERISTICS 

 Total ONRAB® baits: 600,480 (578,610 fixed wing and 21,870 ground) 

 Bait density: 75/150 baits/km2

 Approximately 14,000 ONRAB® baits/sampling cell 

 Flight line spacing: 375/750 meters 

 Overall Off-time: 29.45% average for fixed wing and 25% average for ground using NLCD to determine 

“baitable” habitat 

 Projected baiting dates: August 27 – 31, 2012 

 Baiting duration: 5 days, 5 planes and ground crews for hand-baiting 
H-8 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

5) BAIT-VACCINE CHARACTERISTICS 

 Each bait contains 1.8 ± 0.1ml of ONRAB® vaccine (titer of not < 109.5 cell culture infectious dose 50% 

[CCID50]/ml) 

 Bait matrix is comprised of partially hydrogenated vegetable shortening (34%), Microbond® wax (30%), 

stearine (12.5%), Icing sugar (20%), vegetable oil (1%), artificial marshmallow flavor (1%), artificial sweet 

flavor (1%), and a fat-soluble food dye (0.5%) 

 Bait matrix contains 100 mg of tetracycline hydrochloride as a biomarker 

 Each vaccine-bait weighs approximately 4g 

 The body of the blister pack is an elongated oval with dimensions of 30x14x10mm (1.81 x 0.55 x 0.39in) 

 Each bait contains a conspicuous advisory label with a toll free number in the event of a bait contact and 

potential vaccine exposure 

6) PRE-ORV SAMPLING (BASELINES) AND ACTIVITIES 

 Enhanced rabies surveillance has been in place for > than 1 year 

 In late summer 2012, 150 raccoon-sized cage traps will be tended for 10 consecutive days within each of 

the 8 sampling cells (4 ORV naïve cells and 4 cells historically baited at 75 baits/km2

) 

 Traps will be deployed at predetermined random roadside trapping locations 

 Expect capture rate of ~100 raccoon/cell based on recent previous trapping efforts in area 

 Attempt to maximize skunk captures by additional targeted trapping if practical 

 From raccoons and skunks: collect pertinent biological, physical and spatial-temporal data; sera for rabies 

and human adenovirus serological analysis; first premolar teeth for age determination and biomarker 

analysis; mark and release at site of capture 

 Euthanize target species with unusual lesions or behaviors for analysis 

 Opportunistic sampling for additional target and nontarget species (e.g., roadkills or live animals) that 

display abnormal behavior or have lesions that should be evaluated 

 Use various media outlets to advise the public when and where baiting will occur and precautions to be 

followed to reduce chance of vaccine exposure 

7) POST-ORV SAMPLING (TREATMENT EFFECTS) AND ACTIVITIES 

 Continue enhanced rabies surveillance 

 Continue opportunistic sampling for target and nontarget species (e.g., roadkills, hunter harvest) that 

display abnormal behavior or have lesions that should evaluated for pathological context 

 5 weeks post ORV sample ~100 raccoons and as many skunks as practical within each of the 8 sampling 

cells using the pre-ORV target species trapping protocol 

 Collect pertinent biological, physical and spatial-temporal data from raccoons and skunks as well as sera 

for rabies and human adenovirus analysis and first premolar teeth for age determination and biomarker 

analysis 

 Use acceptable algorithm with appropriate public health, agriculture and wildlife officials to ensure bait 

contacts are received through a legible, toll-free phone number on each bait or other sources are reported 

and addressed by the proper expertise (e.g., Vermont Rabies Hotline) 

8) SAMPLE ANALYSIS 

 Rabies virus titers to be determined by the New York State Rabies Laboratory at the Wadsworth Center 

 Human adenovirus titers determined by Dr. Dubovi, Cornell University 

 Opportunistic histopathological sample analysis to be finalized 
H-9 

___________________________________________________________________________________________________________________

Environmental Assessment-Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in 

New Hampshire, New York, Ohio, Vermont, and West Virginia

 Specific age determination and biomarker detection by Matson’s Laboratory, Milltown, Montana or other 

suitable facility 

9) REPORT FINDINGS 

 Expect results from analysis of field data by February 2013 

 Draft report by April 2013 

Figure 3. Baiting plan for the New Hampshire, New York and Vermont ONRAB® field trial in 2012, including eight 

sampling cells.